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Woord vooraf 
 
 
In de loop van de voorbije jaren heb ik vaak gemijmerd hoe een ideaal woord vooraf er 
zou kunnen uitzien. Het is meer dan zomaar een proloog of een dankwoord. Het zou 
eerder een metastabiele balans moeten zijn tussen het oproepen van de sfeer waarin ik 
vier jaar heb vertoefd, doorspekt met stilistische fijnzinnigheden en een portie 
karikaturale humor om de lezer niet te vervelen, en tussen een terechte dankzegging. 
Deze finale versie op papier krijgen bleek echter een werk van lange adem en is hetgeen 
u nu leest. Een kortverhaal waarin de beslommeringen en wederwaardigheden die mij 
te beurt zijn gevallen uit de doeken worden gedaan – vol herkenbare situaties, oneliners 
en een vleugje weemoedigheid – en waarin vele mensen een hoofd- of bijrol hebben 
gespeeld. 
Alvorens alles teveel verbloemd wordt, dien ik er wel de nadruk op te leggen dat de 
voorbije vier jaar bij wijlen een aaneenschakeling waren van frustratiemomenten, 
gevloek en eindeloos geploeter omdat ‘de beestjes’ niet wilden groeien of besloten om 
pas tegen de avond in gang te schieten. Uiteraard zijn er nog andere topbelevenissen – 
horresco referens – zoals ’s nachts met goede moed een staal nemen uit de reactor die 
blijkt overgeschuimd te zijn, zaterdagochtend katerig de warme kamer binnenwandelen 
en ontdekken dat je toch geen kolonies hebt of snel nog een groeiproef willen opzetten 
en vaststellen dat je geliefkoosde mediumfles weer gecontamineerd is met een 
schimmelbol… Misschien heb ik daarom wel vooraan dit proefschrift de woorden van 
Hannibal neergepend. Ofwel vind ik een weg, ofwel maak ik er een. Dat was zijn antwoord 
toen één van zijn generaals zei dat het onmogelijk was om de Alpen over te steken met 
olifanten. Welja, de vader der strategie achterna heb ik ook steeds een weg proberen 
vinden wanneer er zich verschillende obstakels op mijn pad bevonden.  
In tegenstelling tot Hannibal had ik twee andere generaals aan mijn zijde die met veel 
graagte de moeilijkst begaanbare paden wilden opzoeken en wiens visie en 
overredingskracht mij aanspoorden om de rug te rechten en door te gaan tijdens de 
donkerste uren van dit proefschrift. Daarom ben ik ook veel dank verschuldigd aan 
Marjan De Mey en Wim Soetaert omdat ze mij de mogelijkheid hebben gegeven om mij 
te vervolmaken in dit boeiende onderzoeksdomein in een ongedwongen setting. Ze 
zorgden ervoor dat InBio (en zeker de MEMO-groep!) op de kaart werden gezet en het 
ultieme voorwerp van afgunst waren van menig vakgroep. Waar anders werd gezellig 
ontbeten, gebarbecued of gepintelierd? Waar anders werd lief en leed gedeeld of 
geschaterlacht? Waar anders stond men schouder aan schouder om ons territorium af te 
bakenen in de koepuur? Ik zal er niet ver naast zitten als ik stel dat ons labo een van de 
fijnste plekken is om onderzoek te verrichten. Het is een dorp waar iedereen elkaar (te 
  
 
goed) kent en maandag staat te popelen om met een koffie in de hand elkaars geheugen 
op te frissen omtrent de doldwaze avonturen van afgelopen vrijdag… 
Het echte orgelpunt van vier jaar doctoreren was misschien wel het “zorgvuldig” 
samenstellen van het beruchte UDP-suiker team. Deze League of Extraordinary 
Gentlemen werden als thesisstudenten in het heetste vuur gesmeed tot keurtroepen die 
mij hebben bijgestaan om de demonen van dit onderzoek te bedwingen. Zonder hun 
inzet en veerkracht was dit boekje niet geworden tot wat het nu is. Zonder morren 
werden groeiproeven herhaald, PCR’s opnieuw ingezet of vermaledijde vials op de 
mysterieuze Shimadzu gestoken. Het moreel van het klein labo’s finest werd steevast 
opgekrikt met een verraderlijk streekbier of een feestdis in de Pampa’s. Hoewel hun 
namen later vast wel vereeuwigd en bezongen zullen worden, lijst ik ze hier toch 
nogmaals op. Brecht – tovenaar der TLC’s en productiemedia – met jou had ik de eer en 
het genoegen om samen de eerste ongelooflijke glucosyleringsresultaten te behalen die 
tevens het begin van een nieuw doctoraatstijdperk inluidden. Maar al die wetenschap 
verbleekte bij de talloze side-experiments die we daarnaast hebben opgezet (“ik doe da 
gewoon he”) of hoe we op een ongeëvenaarde manier legio wereldmysteries en 
samenzweringstheorieën oplosten, doorprikten of zelfs versterkten. Een pluim voor het 
out of the box-denken, het verdragen van mijn Michael Scott imitaties en je vriendschap. 
De volgende in rij was Jarno, die na ettelijke worstelpogingen met SuSy het enzym deels 
op de knieën kreeg. Zijn goedgemutstheid en kalmte waren legendarisch, alsook zijn 
alomgekende jeeps ochtend- en avondgroet. Aansluitend brak het jaar aan van de 
dweepkes Pieter (Cockeeer!) en Maarten (Van Breeempt!), die het begrip ‘in vivo 
glycosyleren’ naar een ander niveau tilden. Maarten, ik sta nog steeds versteld hoeveel 
constructen iemand kan maken én volledig testen. Hoeveel keer namen we ons niet voor 
om een paar Ferrari’s te kopen met onze bereide globotriose? En Pieter, hoeveel keer 
heb jij niet gevloekt op Beverly (nvdr: reactor B+1) of gebeld met de ontstellende 
woorden “ja lap, da medium is weer verkleurd”? Gespannen momenten werden dan ook 
geventileerd met spontane dance show-offs in het labo, de meeste bizarre imitaties 
(“Don’t you die on me Billy”) of een volmondig KHA-KHAAAA! Gasten, merci! 
Veel dank ben ik eveneens verontschuldigd aan het gouden drietal dat de MEMO-groep 
jaren in goeie banen heeft geleid en mij steevast met raad en daad heeft bijgestaan. 
Vooreerst wil ik nogmaals Marjan in de bloemetjes zetten omwille van de uren en uren 
tijd die je in mij geïnvesteerd hebt tijdens het samen vorm geven, nalezen en zeer 
kritisch evalueren van dit werkstuk. Het kostte soms wat tijd, maar de violen werden 
steeds gelijk gestemd. Ook Jo, dag en nacht bereikbaar voor “Bruin”, wil ik bedanken. 
Jouw vage schematische pentekeningen op maagdelijk wit papier bleken meer dan eens 
een waardevolle leidraad voor het structureren van papers en presentaties. Jouw 
onblusbare inzet alsook liefde voor lekker eten en cultuur lieten mij snel inzien dat zich 
achter de cynische humor een warme vriend schuilhield, wiens blikken en korte 
tussenwerpsels zoals koepuur!, urrrgh en ow fuck genoeg waren om te snappen wat je 
wilde zeggen. Tot slot mag ook de immer enthousiaste Joeri niet in de rij ontbreken. 
Hoewel je het veelal erg druk had, nam je de tijd om je licht te laten schijnen of wilde 
  
 
verklaringen te zoeken voor de rare fenomenen die optraden tijdens mijn onderzoek. 
Tezamen hebben jullie een sterke basis gelegd en mij behoed voor de valkuilen van het 
doctoreren. 
Niet in het minst wil ik ook alle andere InBio-kameraden in de schijnwerpers stellen, 
temeer omdat zij het labo écht maken tot wat het is. Mijn courante habitat (afgezien van 
de koffieruimte) was de bureau beneden waar een deel van de harde MEMO-kern 
gestationeerd was. Ondanks de grote turnover bleven enkelen de voorbije vier jaar tot 
het vaste meubilair behoren. Pieter en Gert – de boyz – waren altijd paraat voor overleg, 
nieuwe ideeën of een vroege aperitief. Met ons drie wilden we een jeugdig regime 
installeren, een activiteitenloos MEMO-weekend organiseren en goud behalen met het 
iGEM team… Achja, de lat mag soms hoog genoeg liggen. Gaspard, wiens practical jokes 
en sarcastisch geplaag vaak mythische proporties aannamen, bood graag hulp bij 
statistische problemen en bleef maar aandringen om op Linux over te stappen. Ook Sofie 
DM maakte graag tijd voor een goed gesprek en leverde een wijsheid aan die volledig in 
mijn kraam paste: “als het twee keer niet lukt, doe dan iets anders”. Ook de recentere 
aanwinsten Thomas, Bob, Maarten DM, Tom en David zullen ongetwijfeld bijdragen tot 
voortzetting van de topsfeer beneden en een nieuwe wind doen waaien. Ook ben ik zeer 
verheugd dat niemand minder dan Wouter nu plaats heeft genomen achter de bureau 
waar ik vier jaar gesleten heb. Jouw onvermoeibaar enthousiasme, werkethiek en 
grenzeloze sfeermakerij zijn niet te beschrijven, tenzij je het zelf hebt meegemaakt. 
Señor, hoed af! Samen met je kompaan Dries D hebben jullie cruciaal werk verricht in de 
lastigste en laatste uren van mijn doctoraat. Zonder jullie kon ik dit woord vooraf 
waarschijnlijk maar een maand later neerpennen.  
Om nog maar te zwijgen over de diehards van het klein labo. Jullie bureau was een vaste 
halte tijdens de ochtendkoffie (sorry voor de achtergebleven tassen!), een ware oase die 
soms ontsierd werd door een welriekende autoclaaf en waar de nieuwste nieuwtjes 
werden uitgewisseld. Hoe dikwijls kwam ik niet bij Maarten, Dries, Eric, Gilles en 
Catherine binnen met een onoplosbaar PCR-mysterie, een spoedbestelling, een 
vastgelopen HPLC of een vraag tot medium-uitlening. En tegelijk moest ik jullie 
ontgoochelen met het fameuze venting-experiment of verzette ik de post al eens naar 
Topradio. Ik zal niet snel de blik in Eric zijn ogen vergeten als we weer weekly supply 
sh*t manager bleken te zijn, alsook de ongeëvenaarde tijd waarop we dit toch maar weer 
klaarspeelden à la monkeystyle. Of de talloze weddenschappen over geografische- en 
dierenweetjes waarbij ik jammerlijk de duimen moest leggen tegen de disco lion. Of hoe 
Vrijdag-Dries mij vier jaar geleden de twijfel ontnam om te doctoreren. Aansluitend wil 
ik de goedlachse MEMO-dames Lien en Isabelle bedanken, alsook deze van het 
coördinatieteam (Hilde, Dominique, Barbara, Anneleen en Liesbet) voor de 
administratieve rompslomp in goede banen te leiden. Ook de Glyco-collega’s en in het 
bijzonder Karel, Tom, Magali en Mareike stonden paraat als het over enzymen of een 
goed feestje ging! En dan heb ik het nog niet gehad over de kleurrijke figuren van Biosurf 
zoals daar zijn: Sophie – eierkopke – Roelants, HPLC/dj Stijn, de overenthousiaste 
Isabelle en Robin – de broer die ik nooit gehad heb. De soms iets te amicale avonturen 
  
 
die Robin en ik beleefd hebben zijn meer dan memorabel, en ik zie er dan ook zeer naar 
uit om de Blue Lagoon, de kelder van een niet nader genoemd café en de Bourgoyen nog 
eens op stelten te zetten! 
Overigens wens ik ook mijn vriendengroep buiten de labomuren te bedanken, die al 9 
jaar het vaste decor vormen voor feestjes op ons boerekot, Brusseldrinks en heuse 
roadtrips. Stijn, Kèvn, Langen, Claire, Jef, Spekkie, Ruben en Ken: twas plezant! Ook Tom 
wil ik bedanken, een globetrotter van het eerste uur, met wie ik de eer heb gehad een 
groot deel van de Oude Wereld te verkennen, deels uit avonturenlust, deels uit 
weetgierigheid, zonder ons de allure van ontdekkingsreizigers aan te meten. Het maken 
van de meest absurde Slavische woordgroepen, de Kaukasische kookinitiaties en de 
talloze zoo-bezoeken op de Balkan staan allemaal in ons collectief geheugen geprent. 
Het mooiste en dierbaarste dat deze doctoraatsjaren mij echter gebracht hebben, is de 
vrouw van mijn leven, Margo. Ik zal niet gauw vergeten hoe we naar elkaar zijn 
toegegroeid tijdens de summerschool die plaatsvond in de zwoele zomer van 2013. Ik 
denk dat onze genegenheid zelfs aanstekelijk heeft gewerkt op het labo… Dat we twee 
handen op een buik zijn, is meer dan eens gebleken tijdens de laatste loodjes van mijn 
doctoraat. Bedankt dat ik kon klagen, zagen en mijn hart uitstorten wanneer het 
allemaal onmogelijk leek, bedankt dat jij de stress voor mij ventileerde, bedankt voor je 
kritische kijk en SuSy tips, bedankt voor de momenten van puur geluk, bedankt om wie 
je bent. Er wachten ons nog vele avonturen, de wereld is aan ons! 
Als laatste, en het hoogst van al in het vaandel gedragen, wil ik mijn ouders bedanken. Zij 
hebben ervoor gezorgd dat ik sta waar ik nu sta door hun onvoorwaardelijke steun en 
motivatie. Twee bijzondere mensen die meermaals (ja, zelfs wekelijks) op het labo 
geciteerd werden, waarbij ik meestal aanhief met de woorden “mijn moeder/vader zei 
altijd …”. Meestal volgde hierop een pakkende uitspraak die menig omstaander met 
verstomming sloeg en dikwijls maar het topje van de kennisijsberg waren die zij mij 
hebben meegegeven. Deze mensen hebben thuis een warm nest gecreëerd waar vele 
onderwerpen werden aangesneden (gaande van gouden reistips, ideeën voor self-
sufficiency en het maken van wijn, tot uitdieping van kennis over de klassieke auteurs), 
en waar ik altijd met raad en daad werd bijgestaan. Daarnaast waren de kleine 
hulpstukjes zoals een meegekregen bakje ingevroren appelmoes, een proper gestreken 
hemd of een telefoontje om te vragen hoe het ging meer dan welkom en vormden zij 
tegelijk de steunpilaren voor dit grote bolwerk en de mens die ik geworden ben. 
Woorden kunnen niet genoeg beschrijven hoeveel ik jullie verschuldigd ben. Mama, 
Papa, bedankt! Ook andere familieleden speelden een sleutelrol, zoals mijn zus Caroline, 
met wie ik dikwijls samen de Pinuts onveilig maakte, of mijn grootouders, die met grote 
fierheid hun streekgebonden wijsheden doorgaven vergezeld van koffie en gebak. 
Ziezo, dit zal de laatste maal zijn dat ik de hand leg aan mijn boekje. Geschreven aan een 
bureau die er al vier jaar hetzelfde uitziet en getooid is met een geluksprentje gekregen 
van mijn tante bij aanvang van mijn studies, een Oekraïens vlagje van toen de Krim nog 
  
 
niet Russisch was en een moleculaire structuur van UDP-glucose terwijl ik uitkijk op een 
beduimeld papiertje met aminozuren. De boeken kunnen toe, de blik kan op oneindig… 
Stiekem hopend dat dit werkstuk of één van mijn alternatieve levenswijsheden als 
leidraad kan dienen voor anderen. Want sed omnia praeclara tam difficilia quam rara 
sunt.1 
 
 
 
Frederik 
10 november 2014 
 
 
                                                             
1 Baruch Spinoza (1632-1677) 
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1 Chapter 1 
Introduction 
 
 
During the last couple of decades, industrial biotechnology has evolved from an infant 
technology into a cornerstone of today’s global economy and was recently identified as a 
Key Enabling Technology2 by the EU. This biotechnology branch – also called white 
biotechnology – uses micro-organisms or components thereof (such as enzymes) as 
industrial catalysts to produce valuable chemicals out of renewable carbon sources or 
waste streams. Prominent examples are the production of succinic acid1, lactic acid2,3, 
ethanol4-6, glutamic acid7, lysine8-10 and citric acid11 as bulk chemicals with various 
applications as solvents, fuel, food additives, precursors for synthesis or as building 
blocks for creating biodegradable polymers. These processes have replaced the 
traditional chemical manufacturing, hence supporting the economy to become more 
independent from fossil resources. On the other hand, biotechnology can aid with its 
complementary techniques in the existing chemical synthesis, thus shifting from stand-
alone technologies towards the beneficial integration and expansion of these two 
fields.12 Organic synthesis has the major advantages of broad reactivity and rapid 
optimization, while biological synthesis is characterized by high selectivity, mild 
conditions and sustainability. 
 
Interesting compounds in this perspective are “small molecules”, which often refers to 
specialized (secondary) metabolites such as alkaloids, flavonoids, phenolic acids, 
antibiotics or terpenoids. These molecules and analogues thereof are in high demand 
due to their interesting properties and applications in pharmaceutical, cosmetic or food 
industries, and are usually produced by physicochemical extraction or chemical 
synthesis. However, the majority of specialized metabolites in nature occurs in its 
glycosylated form, hereby greatly altering the solubility, stability or bioactivity of these 
molecules, which are desirable properties for their application in various fields. Since 
selective attachment of a sugar residue is chemically a daunting task, a myriad of 
biotechnological processes have been developed using enzymes (in vitro) or a whole-cell 
bioconversion (in vivo) approach. Key players in this context are glycosyltransferases 
(GTs), which are enzymes that regio- and stereoselectively transfer a sugar residue from 
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an activated nucleotide sugar donor (often UDP-sugar) to various small molecules.13 
These in vitro methods are however often plagued by scalability issues, the need for 
purified proteins and the requirement for (equimolar) amounts of expensive donors 
(e.g. UDP-glucose: 150 €/g; UDP-galactose: 1500 €/g). Fueled by these challenges and a 
high demand, various in vivo processes have been developed whereby the UDP-sugars 
and enzymes are formed by an (engineered) micro-organism from cheap substrates. 
These recent biotechnological advances are critically reviewed in Chapter 2 and the 
major hurdles for economic viability of the processes are identified. These include low 
conversion yields and titers, inefficient UDP-sugar formation, limited acceptor flexibility 
and problems regarding scale-up.  
 
Hence, the objective of this doctoral research is to design a novel in vivo glycosylation 
platform which is generic, easily scalable and actively couples growth and production, 
thus overcoming the aforementioned hurdles. To this end, the model organism 
Escherichia coli W was metabolically engineered to create a completely novel 
glycosylation strain for various small molecules using GTs. This new approach should 
enable the bacterium to grow and produce glycosides simultaneously, hereby using only 
sucrose as an extremely cheap (250 €/ton) and sustainable carbon source. An overview 
of the envisaged approaches to obtain these objectives is presented as a chapter based 
flowchart (Figure 1.1). 
 
To efficiently generate UDP-sugars in the cell as a donor for GTs, the expression of a 
promiscuous uridylyltransferase enzyme is necessary. In Chapter 3, the search for such 
an enzyme was started based on research from the late 70’s using crude protein extract 
from the probiotic Bifidobacterium bifidum.14 Since no sequence information was 
present on the enzyme, three uridylyltransferase candidates were cloned and 
investigated with a newly developed chemo-enzymatic assay. UgpA was identified as the 
enzyme sought after, exhibiting activity towards both glucose 1-phosphate and galactose 
1-phosphate resulting in the formation of their respective UDP-sugars. 
 
Chapter 4 describes the first engineering of E. coli W for the creation of a glucosylation 
platform. The strategy makes use of the introduction of an alternative sucrose 
metabolism in the form of a sucrose phosphorylase. This enzyme splits sucrose into 
fructose, which is used as a carbon source and glucose 1-phosphate, which is ideally 
converted into UDP-glucose by the UgpA enzyme selected in Chapter 3. A trimodular 
engineering approach is applied to obtain a split metabolism where both growth and 
production (glucosylation) can occur simultaneously. Expression of a 
glucosyltransferase from Vitis vinifera (VvGT2) enables the strain to efficiently produce 
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the promising compound β-glucogallin (1-O-galloyl-β-D-glucose) starting from only 
gallic acid and sucrose. Due to the broad activity of VvGT2, various other phenolic acids 
were tested to demonstrate the potential of this platform. 
 
Chapter 3: Quest for a promiscuous uridylyltransferase
  - Selection of 3 putative uridylyltransferases from B. bifidum
  - Developing a rapid chemo-enzymatic activity assay for gal1P
  - Engineering E. coli into a suitable screening host
  - Characterization of gene products
Chapter 4: Glucosylation platform
  - E. coli W strain engineering
  - Coupling production to growth
  - Evaluating in vivo β-glucogallin formation
  - Versatility towards other acceptors
C
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Chapter 5: Glycosylation platform
  - Expanding the glucosylation platform
  - Galactosylation strain:
          Globotriose and hyperoside prod.
  - Rhamnosylation strain:
          Isoquercetrin production
Chapter 6: Exploring sucrose synthase for in vivo glucosylation
  - Improving the affinity for sucrose by random and rational protein engineering
  - Developing a toolbox for enhanced SuSy mutant evaluation and screening
  - Coupling engineered SuSy with glucosyltransferase VvGT2
Chapter 7: Conclusions and perspectives
 
 
Figure 1.1: Flowchart of the different chapters covered in this thesis and the central 
objectives to obtain a generic and versatile in vivo glycosylation platform. 
Because of its generic nature, the glucosylation platform can be easily transformed into a 
general glycosylation platform. In Chapter 5 the possibilities are investigated to create a 
platform for the galactosylation and rhamnosylation of small molecules by expanding 
the production strain from Chapter 4 with an interconverting enzyme. Overexpression 
of either a UDP-glucose epimerase (galE) or a UDP-rhamnose synthase (MUM4) results 
in the formation of UDP-galactose or UDP-rhamnose respectively. As proof of concepts, 
the in vivo formation of the highly demanded galactosides hyperoside (quercetin 3-O-
galactoside) and globotriose (α-galactosyl-1,4-lactose) and the rhamnoside quercitrin 
(quercetin 3-O-rhamnoside) will be evaluated and discussed. 
 
Next, in Chapter 6, the potential of the promising enzyme sucrose synthase (SuSy) for 
the one-step generation of UDP-glucose from sucrose is explored. Coupling of SuSy with 
a glycosyltransferase results in an efficient UDP recycling system, which makes it 
attractive for industrial applications. However, due to its unfavorable kinetics (low 
Chapter 1:  Introduction 
4 
 
affinity for sucrose), it has been rarely used for in vivo generation of UDP-glucose. In this 
chapter, SuSy from Solanum tuberosum will be engineered to increase its affinity for 
sucrose and the obtained mutants will be evaluated using a developed screening system. 
The most active SuSy exhibiting the highest affinity for sucrose will be selected and 
coupled with the glucosyltransferase VvGT2 to assess the in vivo glucosylation potential 
of this regeneration system. 
 
In a final chapter (Chapter 7), the approaches followed in this doctoral research are 
assessed and the versatile ‘plug and play’ glycosylation platforms are evaluated. 
Suggestions are given to further optimize the platforms and expand their industrial 
applicability. 
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2.1 Abstract 
Glycosylation of small molecules like specialized (secondary) metabolites has a 
profound impact on their solubility, stability or bioactivity, making glycosides attractive 
compounds as food additives, therapeutics or nutraceuticals. The subsequently growing 
market demand has fuelled the development of various biotechnological processes, 
which can be divided in the in vitro (using enzymes) or in vivo (using whole cells) 
production of glycosides. In this context, uridine glycosyltransferases (UGTs) have 
emerged as promising catalysts for the regio- and stereoselective glycosylation of 
various small molecules, hereby using uridine diphosphate (UDP) sugars as activated 
glycosyldonors. This review gives an extensive overview of the recently developed in 
vivo production processes using UGTs and discusses the major routes towards UDP-
sugar formation. Furthermore, the use of interconverting enzymes and 
glycorandomization is highlighted for the production of unusual or new-to-nature 
glycosides. Finally, the technological challenges and future trends in UDP-sugar based 
glycosylation are critically evaluated and summarized. 
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2.2 Glycosylation: orchestrating life 
Glycosylation is one of the most prevalent and important modifications in nature as it 
plays a central role in cellular communication and the orchestration of life in general. 
Many diseases are associated with the unusual glycosylation of proteins15-17 and the 
recognition of specific cell surface glycans often forms the basis of viral and bacterial 
infections18 or cancer metastasis19. Sugar residues can be attached to a variety of 
molecules ranging from macromolecules like proteins, lipids or cell wall glycans to 
rather small molecules13 such as specialized (secondary) metabolites and 
oligosaccharides. Glycosylation of these small molecules often has a profound impact 
since it can greatly alter their solubility, stability or bioactivity.20 Remarkable examples 
are the glycosylation of vitamin C21 or anthocyanidins22 for increased stability, the 
detoxification of xenobiotics from the body by means of glucuronidation23,24, the 
glycosylation of steviol resulting in sweet tasting steviosides25, or the possibility to 
target galactosylated compounds towards the liver, making them interesting for site-
specific drug delivery26. Furthermore, alteration of the sugar residue of the same 
compound often affects its pharmacological properties: quercetin 3-O-glucoside and 
quercetin 3-O-glucuronide have antioxidant properties27,28, whereas their 3-O-
galactoside, rhamnoside or xyloside exhibit anti-inflammatory29, antiviral30 or 
anticarcinogenic31 activities, respectively. In addition, the type of sugar moiety of 
quercetin glycosides has been proven to be the major determinant in their small 
intestinal absorption.32 
 
The majority of glycosylation reactions in nature are mediated by glycosyltransferases, 
which can transfer the sugar residue from an activated sugar donor to various 
acceptors.33 These gatekeepers of glycodiversity use nucleotide sugars in 90 % of cases as 
activated donors and are often referred to as Leloir glycosyltransferases.34 The uridine 
diphosphate (UDP) sugars form the largest group of nucleotide sugars35 and 
consequently give rise to the large class of uridine glycosyltransferases (UGTs), which 
are characterized by a unique carboxy-terminal consensus sequence36. Predominant 
UDP-sugars in nature for the glycosylation of specialized metabolites are UDP-glucose, 
UDP-glucuronate, UDP-xylose, UDP-arabinose and UDP-rhamnose, while UDP-galactose 
and UDP-N-acetylglucosamine mostly occur in the formation of oligosaccharides. These 
UDP-sugars and corresponding UGTs are capable of efficiently glycosylating various 
compounds from diverse chemical classes in a regio- and stereoselective way.13,37 Some 
examples of the glycosylation potential and versatility of UGTs towards small molecules 
are schematically shown in Figure 2.1, together with their applications.  
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Figure 2.1: Schematic representation of the glycosylation of diverse classes of small 
molecules by uridine glycosyltransferases (UGTs) resulting in glycosides with various 
applications. The UDP-sugar is used as an activated donor for the regio- and 
stereoselective glycosylation, hereby releasing UDP which can be recycled via different 
routes further discussed in this chapter. 
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The microbial production of these small molecules has made an enormous progress in 
the last two decades.56 This was largely stimulated by the increasing market demand 
and by a mentality shift in replacing chemically synthetized molecules by ‘natural’ ones. 
In addition, due to vast metabolic engineering57 efforts in model organisms like 
Escherichia coli58,59 and Saccharomyces cerevisiae60, the sustainable production of 
flavonoids61,62, anthocyanidins63, terpenoids61,62, phenolic acids62, coumarins64 and 
phenylpropanoids65 has been made possible. Since their corresponding glycosides 
display attractive properties (Figure 2.1), many methodologies have been developed for 
the production thereof, which will be critically revised and compared in this review.  
2.3 State of the art glycosylation processes 
The seemingly easiest way to obtain naturally occurring glycosides is the extraction 
from native producing hosts (which are mostly plants). However, this process is often a 
low-yielding, laborious task and requires a specific method for each host. In addition, the 
yield can be highly dependent on geographical, seasonal or even political factors. 
Nevertheless, extraction remains to date a widely used technique, especially for 
obtaining anthocyanins66, triterpenoid glycosides67, polyphenol glycosides68 and 
steviosides69. Seasonal factors and low yields can be tackled by using in vitro plant cell 
cultures and metabolic engineering thereof, thus guaranteeing or improving 
production.70-72 However, cell cultures often suffer from economic issues and their use is 
currently restricted towards relatively highly priced metabolites.73 
 
Alternatively, organic synthesis of natural glycosides remains a daunting task, even 
though it has become a sport for many chemists to synthesize every molecule 
imaginable. The stereospecific formation of glycosidic linkages is frequently 
compromised by the presence of many reactive groups74, which results in the need for 
various protecting and deprotecting steps75. Furthermore, a low atom-efficiency, the 
generation of toxic waste and use of very expensive catalysts76,77 make this method unfit 
for large-scale and economically viable production. 
 
Hence, fuelled by a high demand and sustainability issues, numerous biotechnological 
solutions have been established. Most of them can be divided in two main categories: in 
vitro (enzymatic) and in vivo (bioconversion and fermentation) production. These aim at 
converting an acceptor (aglycon) into its corresponding glycoside (glycon), hereby only 
differing in the localization of the enzyme(s) involved and the metabolic state of the 
host. In general four types of carbohydrate-active enzymes are used for in vitro 
glycosylation: glycoside hydrolases (GHs), transglycosidases (TGs), glycoside 
phosphorylases (GPs) and (Leloir) glycosyltransferases (GTs).78 These enzymes have 
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been classified in the Carbohydrate-Active Enzymes database (CAZy), which provides 
updated access to more accurate sequence-based family classification linking the 
sequence to the specificity and 3D structure of the enzymes.79 Each of them have their 
own characteristics and drawbacks concerning substrate usage, yields and scale-up. GHs 
are naturally hydrolytic enzymes but can use various molecules as acceptor instead of 
water under controlled conditions. Their activity in the synthesis direction can be often 
boosted by using high substrate concentrations or adding an organic solvent to lower 
the water content, as for example in some industrially promising processes: production 
of rutin and various phenolic acid rhamnosides by an α-L-rhamnosidase from Aspergillus 
terreus80 and large-scale production of prebiotic galactooligosaccharides (GOS) with 
different galactosidases81,82. TGs on the other hand are retaining GHs which do not use 
water as an acceptor. They are widely used since they can transfer the glucosyl moiety 
from cheap carbon sources such as sucrose towards other carbohydrates or small 
molecules. Interesting examples of multigram synthesis are the production of 
ampelopsin glucosides with a dextransucrase from Leuconostoc mesenteroides83 or the 
biosynthesis of catechin glycosides with an amylosucrase from Deinoccocus 
geothermalis84. The less well-studied GPs require more expensive glycosyl phosphate 
donors and have been proven to be efficient catalysts for glycoside synthesis.85,86 Well 
known examples are the glycosylation with sucrose phosphorylase of vitamin C87, 
stilbenoids88, hydroxybenzoates89 and catechins90. In spite of their broad activity, the 
affinity of GHs, TGs and GPs towards new acceptors is generally very low and 
consequently require high concentrations of these (expensive) aglycons91. In addition, 
high substrate concentrations are evenly necessary to combat their reverse (and 
preferred) reaction, making the process overall often very costly. Due to their low 
conversion yield, restriction to mainly form O-glycosides, and hydrolytic/phosphorolytic 
nature, they are generally of no practical use when applied in in vivo systems.  
 
The last type of carbohydrate-active enzymes are the GTs – with the aforementioned 
UGTs as largest group – and display superior conversion efficiencies (up to 100 %) 
towards an enormous variety of small molecules (Figure 2.1). They are able to stereo- 
and regiospecifically form O-, N-, S- and even C-glycosides37 hereby requiring low 
acceptor concentrations. Furthermore, they can be readily applied in both in vitro and in 
vivo glycosylation systems. However, the main constraint to their use in an in vitro 
context is the need for UDP-sugars, which are extremely expensive and rarely available 
in large quantities.92 One way to overcome this is to overexpress UGTs in a micro-
organism, thus making use of their intracellular UDP-sugar pool. This methodology is 
the basis for in vivo UDP-sugar based glycosylation and eliminates the need for extensive 
enzyme purification and the addition of expensive cofactors. Figure 2.2 depicts a 
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schematic comparison of in vitro (A) and various in vivo (B to D) approaches. The latter 
can be divided in three major types depending on the addition of the aglycon and the 
metabolic state of the host(s). One of the first techniques developed was bacterial 
coupling (B), which basically consists of combining different hosts, each fulfilling a 
specific step in the formation of the glycosides. Typically, Corynebacterium glutamicum 
is used for the formation of UTP starting from the cheap precursor orotic acid (step 1). 
UTP is subsequently used by a recombinant strain (often E. coli) for the production of 
the UDP-sugar (step 2) and finally consumed by another E. coli host performing the 
glycosylation by expressing a UGT (step 3).93 Such a system has been frequently used for 
large-scale production of oligosaccharides and is characterized by high product titers 
and rates.93,94 However, the need for cell permeabilization and separate fermentations to 
obtain high cell densities of the various hosts involved, makes the overall process 
instable and less cost effective. The development of processes where these individual 
steps take place in one organism was, hence, a next logical step. 
 
 
 
 
Figure 2.2: Schematic representation of different UGT based glycosylation mechanisms. 
Based on the location of the enzymes involved, in vitro (A) and in vivo (B,C,D) processes 
can be identified. While in vitro glycosylation requires purified enzymes and expensive 
cofactors, these are generated by the host itself from cheap substrates during in vivo 
production. The evolution of different types of in vivo glycosylation is also depicted. 
Bacterial coupling (B) combines different permeabilized (dashed line) hosts, each 
carrying out a step towards glycosylation of an added acceptor. A single cell glycosylation 
(C) process on the other hand combines all these steps in one host, which may be 
permeabilized to facilitate conversion of the acceptor. Cells that actively grow and 
glycosylate simultaneously are designated as a fermentation, resting cells as a 
bioconversion. Finally, the recently developed de novo fermentation (D) processes 
produces both the acceptor and subsequently its glycoconjugate from a cheap carbon 
source, thus eliminating the need for external addition of the acceptor. 
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The advances in the fields of metabolic and genetic engineering made it possible to 
merge various different pathway steps inside a single cell. This approach can be as 
effective as combining multiple hosts, provided that the released UDP can be efficiently 
regenerated. The major advantages of using a single cell are the need for only one 
fermentation and the use of a cheap carbon source like glucose or glycerol as only 
precursor for UDP-sugars. Depending on the metabolic state of the cell, a bioconversion 
(resting cells) or fermentation (actively growing cells) approach can be discerned. 
Bioconversion often requires permeabilization of the host and high initial cell densities 
to ensure proper conversion. In addition, the production rate frequently decreases in 
time due to cell decay, in contrast to actively growing cells where the reaction speeds up. 
The potential of producing glycosides with a fermentation based system and the recent 
expansion of metabolic engineering towards microbial production of many small 
molecules gave rise to a final and novel approach: de novo fermentation of glycosides 
(Figure 2.2 D). This system eliminates the need for addition of expensive acceptors such 
as specialized metabolites and effectively couples growth and production. Few examples 
exist to date with only vanillin glucoside95,96, kaempferol 3-O-rhamnoside97, resveratrol 
glucosides98, anthocyanins99 and steviol glycosides100 being reported in the traditional 
hosts E. coli and S. cerevisiae.  
 
A comprehensive overview of all in vivo systems for UDP-sugar based glycosylation 
focussing on small molecules like specialized metabolites and oligosaccharides is given 
in Table 2.1. To give a fair comparison of the processes and to make an estimation of 
their economic viability, the production rate, conversion efficiency, titer and medium 
composition is given for each process. Remarkably, UGTs have only been successfully 
applied for the in vivo production of oligosaccharides in terms of rates and titers (up to 
188 g/L), while thus far glycosides derived from specialized metabolites are produced 
about three orders of magnitude lower. One explanation is the low solubility and toxicity 
of some of these metabolites, thus hampering efficient formation of the corresponding 
glycosides. On the other hand, it is striking how many in vivo approaches primarily 
concentrate on the expression of novel UGTs or medium optimization, while generally 
little effort has been put into the efficient generation and regeneration of UDP-sugars. In 
contrast, engineering strategies for oligosaccharide production have primarily focused 
on building an efficient UDP-sugar synthesizing module hereby exploiting the whole 
range of UDP-sugar formation techniques. The different methodologies and their 
applications in each system (in vitro/in vitro) are discussed in the next section. 
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Table 2.1: Overview of all existing in vivo processes for the glycosylation of natural small molecules using overexpressed UGTs. 
Glycoconjugate Process Hosts Culture conditions; Medium; Cofactors Acceptor Phases a Conv b 
rgc 
(g/L/h) 
Titer 
(g/L) 
Ref 
Flavonoids 
 
 
 
 
     
Quercetin 3-O-rhamnoside bioconv EC High initial cell density; M9, Glc, def quercetin Gr  Pr 0.84 0.003 0.15 
101
 
Quercetin 3-O-glucoside bioconv EC LB-medium quercetin GrPr 0.03 0.005 0.10 
102
 
Quercetin 3-O-N-
acetylglucosamine 
bioconv/ 
ferm 
EC High initial cell density; M9, Glc, def quercetin Gr  GrPr 0.84 0.015 0.38 
103
 
Quercetin 3-O-xyloside bioconv EC High initial cell density; TB-medium, Mann, Glc quercetin Gr  GrPr 0.97 0.001 0.04 104 
Quercetin 3-O-xyloside bioconv EC High initial cell density; M9, Glc, def quercetin Gr  Pr 0.86 0.005 0.15 105 
Quercetin 3-O-arabinoside bioconv EC High initial cell density; M9, Glc, def quercetin Gr  Pr 0.91 0.002 0.16 105 
Quercetin 3,7-O-
bisrhamnoside 
bioconv EC High initial cell density; M9, Glc, def quercetin Gr  Pr 1.13 d 0.003 0.07 106 
Apigenin 7-O-glucoside ferm EC TB-medium, Glc apigenin GrPr 0.91 0.001 0.039 
107
 
Baicalein 7-O-glucoside ferm EC TB-medium, Glc baicalein GrPr 0.77 0.001 0.033 
107
 
Biochanin A 7-O-glucoside f bioconv EC 
Unknown cell density; TB-medium, Mann, Glc, Fru, 
Glyc 
biochanin A Gr  Pr 0.75 0.001 0.067 108 
Naringenin 7-O-glucoside ferm SC Modified SGI medium; 10 mM oro naringenin GrPr 0.71 0.002 0.155 109 
Kaempferol 3-O-glucoside bioconv EC 
Unknown cell density; TB-medium, Manno, Glc, 
Fru, Glyc 
naringenin Gr  Pr 0.49 0.002 0.109 110 
Kaempferol 3-O-rhamnoside 
ferm 
 de novo 
EC M9, Glc, YE, def - GrPr - 0.002 0.057 97 
Stilbenoids          
Resveratrol 3-O-glucoside 
ferm 
 de novo 
EC M9, Glc, CaCO3, def - GrPr - 0.0001 0.003 98 
Resveratrol 4’-O-glucoside 
ferm 
 de novo 
EC M9, Glc, CaCO3, def - GrPr - 0.0002 0.007 98 
Chalcones          
Phloretin 2’,4’,4’-O-
triglucoside e 
bioconv EC High initial cell density; TB-medium phloretin Gr  Pr 0.11 0.003 0.163 
111
 
Phloretin C-glucoside ferm SC YPGE medium, Raff, def; 10 mM oro phloretin GrPr 0.79 0.002 0.052 112 
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Glycoconjugate Process Hosts Culture conditions; Medium; Cofactors Precursor Phases a Conv b 
rgc 
(g/L/h) 
Titer 
(g/L) 
Ref 
Anthocyanidins          
Cyanidin 3-O-Glucoside 
ferm 
 de novo 
EC Modified M9, def; 0.1 mM oro catechin Gr  GrPr - ND 0.104 99 
Pelargonidin 3-O-Glucoside 
ferm 
 de novo 
EC Modified M9, def; 0.1 mM oro afzelechin Gr  GrPr - ND 0.113 99 
Phenolic compounds          
Vanillin 4-O-glucoside 
ferm 
 de novo 
SC/SP YES medium - GrPr 0.56 g 0.002 0.12 96 
Vanillin 4-O-glucoside 
ferm 
 de novo 
SC Verduyn medium, Glc, def - GrPr - 0.008 0.50 95 
Vanillin 4-O-glucoside 
ferm 
 de novo 
SC SC medium, Glc, Scr, def - GrPr - 0.006 0.45 113 
Arbutin ferm EC LB-medium hydroquinone GrPr 0.51 0.007 0.25 114 
Terpenoids          
Rebaudioside A 
ferm 
 de novo 
SC SC medium w/o methionine, Glc - GrPr - 0.0002 0.015 100 
Plant hormones          
(+)-abscisic acid glucose ester bioconv EC Sodium phosphate buffer, Glc, def (±)-AA Gr  Pr 0.20 0.004 0.085 115 
Oligosaccharides          
Globotriose BC - perm CG+EC 250 g/L cells c; Glc, Fru, Gal, def; 50 mM oro lactose Gr  Pr 0.79 5.22 188 93 
Globotriose ferm EC High initial cell density; Glyc, def lactose Gr  GrPr 0.96 1.41 7.1 49 
Globotriose 
bioconv -
perm 
EC 200 g/L cells c; Scr, def; 2 mM UDP lactose Gr  Pr 0.22 0.61 22 116 
Globotriose BC EC Unknown cell amount; Tre; 7.4 mM UDP lactose Gr  Pr 0.05 0.16 2 117 
Globotetraose ferm EC High initial cell density; Glyc, def lactose Gr  GrPr 0.44 0.115 4.6 49 
α-Gal epitope 
bioconv -
perm 
EC 200 g/L cells c; Scr, def; 2 mM UDP lactose Gr  Pr 0.18 0.50 18 116 
α-Gal epitope 
bioconv -
perm 
PP 250 g/L cells c; Scr, def; 2 mM UDP lactose Gr  Pr 0.37 0.353 14.1 118 
α-Gal epitope bioconv A 100 g/L cells c; Scr, def lactose Gr  Pr 0.03 0.006 1 119 
α-Gal epitope 
bioconv -
perm 
EC 
130 g/L cells c; Gal, Glc, def; 2 mM Glc1P, 0.5 mM 
UDP-glc, 2 mM ATP 
lactose Gr  Pr 0.57 0.36 7.16 120 
α-Gal epitope BC EC Unknown cell amount; Tre; 7.4 mM UDP lactose Gr  Pr 0.04 0.15 1.76 117 
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Process: bioconv: bioconversion, ferm: fermentation, de novo: acceptor was not added but also microbially produced, BC: bacterial 
coupling, perm: permeabilized cells; Hosts: EC: Escherichia coli, SC: Saccharomyces cerevisiae, SP: Schizosaccharomyces pombe, CG: 
Corynebacterium glutamicum, PP: Pichia pastoris, A: Agrobacterium sp.; Culture conditions/Medium/Cofactors: M9: M9 mineral 
medium, Glc: glucose, def: defined medium, TB: terrific broth, Mann: mannitol, Fru: fructose, Glyc: glycerol, oro: orotic acid, Manno: 
mannose, YE: yeast extract, Raff: raffinose, YES: yeast extract with supplements, SC: synthetic complete, Scr: sucrose, Gal: galactose, Tre: 
trehalose; Precursor: AA: abscisic acid, GlcNAc: N-acetylglucosamine; Phases: Gr: growth phase, Pr: production phase, GrPr: 
simultaneous growth and production; rgc: volumetric production rate of glycoconjugates, ND: not determined. 
 
a Bioconversion and bacterial coupling require a growth phase for the accumulation of enzymes in contrast to fermentative processes 
often exhibiting simultaneous growth and production (GrPr). 
b Conversion (Conv) is expressed as mM glycoconjugate formed/mM acceptor added 
c Cells expressed as wet weight 
d Conversion exceeds 100 % without obvious explanation  
e The triglucoside was the major glucoside formed next to 3 other mono- and diglucosides 
f Other isoflavonoids (genistein, formononetin and daidzein) showed lower conversions and yielded glucoside mixtures 
g Conversion was based on mM glucoside/mM vanillin and precursors thereof formed 
 
 
Glycoconjugate Process Hosts Culture conditions; Medium; Cofactors Precursor Phases a Conv b 
rgc 
(g/L/h) 
Titer 
(g/L) 
Ref 
N-acetyllactosamine bioconv A 100 g/L cells c; Glc, def GlcNAc Gr  Pr 0.19 0.15 7.3 121 
N-acetyllactosamine bioconv EC 100 g/L cells c; Glc, def GlcNAc Gr  Pr 0.16 0.20 3.14 122 
N-acetyllactosamine BC - perm CG+EC 250 g/L cells c; Glc, Fru, Gal, def; 50 mM oro GlcNAc Gr  Pr 0.96 2.81 107 94 
P1 trisaccharide 
bioconv -
perm 
EC 100 g/L cells c; Scr, def; 5 mM UDP-glc GlcNAc Gr  Pr 0.67 0.38 27 123 
1
5
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2.4 Formation of common UDP-sugars: sweet routes to synthesis 
In contrast to in vitro approaches, which make use of a vast arsenal of cofactor 
regeneration techniques or interesting methods for UDP-sugar generation from cheap 
substrates, most whole cell (in vivo) approaches apply the same methodology. Despite 
their reported process variety, only three major routes exist for the formation of all 
natural UDP-sugars: a synthase, a phosphorylase and a kinase route. A schematic 
representation of these is shown in Figure 2.3 together with a UGT coupling reaction to 
illustrate their different cofactor requirements (ATP, UTP, …) for sugar activation and 
UDP recycling. 
 
Synthase route  
 
This first route has gained a lot of attention since it directly forms a highly energetic 
UDP-sugar from a disaccharide. To date, only sucrose synthase (EC 2.4.1.13) and 
trehalose synthase (EC 2.4.1.245) have been extensively used for the generation of UDP-
glucose from sucrose124,125 and trehalose126,127 respectively, due to their readily 
reversible character. Many other synthases such as cellulose synthase or lactose 
synthase have been described, but their application is restricted to the synthesis 
reaction because of their unfavorable equilibrium constants.128 The reported trehalose 
synthases originate from bacteria126,127, while the majority of sucrose synthases used 
typically originate from plants125,129,130, with a cyanobacterial homolog as only exception 
to date116. Due to the availability of sucrose and trehalose at low cost and in bulk 
quantities, various processes using the corresponding synthases can be very cost 
effective when coupled with a UGT. Moreover, coexpressing a synthase prevents 
accumulation of UDP, which has been shown to cause the frequently encountered 
problem of UGT product inhibition.124 This coupling principle has been applied both in 
in vitro and in vivo processes for the production of various oligosaccharides116,123,131 and 
glycosylated specialized plant metabolites130,132. Moreover, a fusion protein of sucrose 
synthase and a UGT has been created and used for the production of quercetin 3-O-
glucoside.133 Despite the clear potential of synthases, most reported in vitro coupling 
systems still rather illustrate only a low-yielding proof of concept. Thus far only three 
efficient bioconversion processes have been developed, producing globotriose (22 
g/L)116, α-gal epitope (18 g/L)116,118 and P1 trisaccharide (27 g/L)123 as shown in Table 
2.1. The key feature for an economically viable in vitro process, as recently pointed out 
by Nidetzky and coworkers130, is a high number of regeneration cycles (RC) for the UDP-
sugar. Through controlled feeding of the substrate phloretin and repeated co-addition of 
enzymes, they could obtain an impressive 20 g/L of the C-glucoside nothofagin with an 
RCmax of 50. 
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A major challenge when applying synthases as catalysts is improving their stability and 
kinetic parameters. For example, the affinity constant (Km) of sucrose synthase for 
sucrose often dramatically increases when recombinantly overexpressed in a 
prokaryotic host134, easily reaching up to 100 mM125 or more135. Similarly, the Km values 
for UDP and trehalose are 30 and 25 mM, respectively, for trehalose synthase from 
Pyrococcus horikoshii126. This feature makes synthases less suitable for fermentation 
systems since growing cells cannot accumulate the respective disaccharides 
intracellularly at the required concentrations, thus impeding UDP-sugar generation. The 
only example to date is the coexpression of sucrose synthase from Coffea arabica in 
yeast, which resulted in a 35 % increased de novo vanillin 4-O-glucoside production.113 
Extensive (structure based) protein engineering efforts could beneficially influence 
these kinetic parameters118,120 and subsequent production.  
 
 
 
Figure 2.3: Schematic overview of the three major routes towards UDP-sugar formation, 
each coupled with a uridine glycosyltransferase (UGT). The synthase, phosphorylase and 
kinase route are shown and differ in their need for cofactors and the regeneration of UDP. 
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Phosphorylase route 
 
Another less elaborate route comprises the use of glycoside phosphorylases, which have 
the ability to cleave disaccharides with inorganic phosphate (Pi) hereby producing an 
activated sugar 1-phosphate.136 This reaction alleviates the need for ATP to generate a 
sugar 1-phosphate, which can be subsequently coupled with a uridylyltransferase to 
yield the corresponding UDP-sugar. Although many types of phosphorylases have been 
reported, α-glucose 1-phosphate is the most prevalent phosphate sugar136 and can be 
formed through the action of a sucrose phosphorylase137 (EC 2.4.1.7), a cellobiose 
phosphorylase138 (EC 2.4.1.231) or a maltodextrin phosphorylase139,140 (EC 2.4.1.1) from 
their respective substrates. Furthermore, the cellobiose phosphorylase from 
Cellulomonas uda was engineered by directed evolution to result in a novel lactose 
phosphorylase enzyme that can efficiently generate α-galactose 1-phosphate from the 
cheap disaccharide lactose.141  
 
Although the only documented example of the phosphorylase route is the in vitro one 
pot synthesis of N-acetyllactosamine142 using sucrose phosphorylase, this methodology 
holds great promise for in vivo glycosylation. In contrast to sucrose synthase, 
overexpression of sucrose phosphorylase can enable growth143 on sucrose as only 
carbon source due to its high affinity144 for this substrate (Km ≈ 1 mM). Metabolic 
engineering of the host cell can direct the increased intracellular glucose 1-phosphate 
pool completely towards UDP-glucose, thus creating an efficient strain for in vivo 
glucosylation reactions. A first attempt based on this principle was described by Heinzle 
and coworkers145, who created an engineered E. coli strain expressing a sucrose 
phosphorylase from L. mesenteroides which efficiently produced UDP-glucose after 
permeabilization. Interestingly, the use of disaccharides as starting substrate for UDP-
sugars (phosphorylase and synthase route) generates a monosaccharide ‘byproduct’ 
(often fructose) which can be used as additional carbon source, thus unlocking the 
potential to simultaneously grow and produce glycosides using only a cheap substrate 
like sucrose.  
 
Kinase route 
 
The last route discussed is probably the most widely used both in in vitro and in vivo 
systems and is based on the combined action of a kinase and a uridylyltransferase to 
generate the required UDP-sugar (Figure 2.3). Many ATP dependent kinases have been 
discovered with specific or promiscuous activities towards a variety of monosaccharides 
for the generation of sugar 1-phosphates. The galactokinase (GalK, EC 2.7.1.6) from E. 
coli and Streptococcus pneumoniae naturally produces galactose 1-phosphate, but also 
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has activity towards other galactose derivatives146,147 and glucose147. Furthermore, GalK 
has been the subject of site-directed and random mutagenesis to further expand the 
activity spectrum and has been extensively used for the phosphorylation of galacturonic 
acid, galactosamine, talose, and various L-sugars such as L-glucose.148-150 Another kinase 
which gained a lot of attention is the N-acetylhexosamine kinase (NahK, EC 2.7.1.162) 
from Bifidobacterium longum, which predominantly acts on N-acetylglucosamine and N-
acetylgalactosamine151, but it also shows activity towards other hexosamine 
derivatives152-154. The latter kinases are mainly used for the in vitro synthesis of UDP-
sugars, whereas most in vivo routes naturally generate a sugar 6-phosphate pool which 
can be easily interconverted through a phosphosugar mutase as depicted in Figure 2.3. 
The best  documented example is phosphoglucomutase (Pgm) which forms glucose 1-
phosphate from glucose 6-phosphate. The formed sugar 1-phosphates are the substrates 
for specific or promiscuous sugar 1-phosphate uridylyltransferases and this process 
functions as salvage pathway for UDP-sugar formation in many organisms. Regarding in 
vivo systems, GalU (EC 2.7.7.9) and GlmU (EC 2.7.7.23) have been frequently used for the 
formation of UDP-glucose and UDP-N-acetylglucosamine respectively103, while in vitro 
synthesis more often relies on uridylyltransferases with broad activity. These 
promiscuous uridylyltransferases are often referred to as SLOPPY (EC 2.7.7.64)155 and 
have been cloned from various organisms like B. bifidum156, B. longum146, H. sapiens157, P. 
sativum158 or the extremophile P. furiosus159 for the formation of UDP-sugars derived 
from galactose, arabinose, xylose, glucuronic and galacturonic acid and N-
acetylgalactosamine. 
 
The kinase-uridylyltransferase route has been frequently applied both in in vitro and in 
vivo systems coupled with a UGT for the production of various glycosides. In spite of the 
need for expensive cofactors (ATP and UTP) during the in vitro formation of UDP-sugars, 
these (one pot) multi-enzymatic conversion processes have been repeatedly applied for 
multigram-scale production of oligosaccharides and derivatives such as globotriose160, 
N-acetyllactosamine oligomers161 and T-MUC1 glycopeptide162. To reduce the high costs, 
efficient systems for the regeneration of the UDP-sugar have been developed based on 
the coupling with pyruvate kinase.163,164 This versatile enzyme catalyzes the transfer of a 
phosphate group from PEP to a nucleoside diphosphate (NDP), yielding pyruvate and 
the corresponding nucleoside triphosphate (NTP). This system is of particular interest 
since it eliminates product inhibition by accumulating UDP. In the case of these tailor 
made oligosaccharides, their market price justifies the costs of cofactors, regeneration 
systems and large-scale enzyme purification.  
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Taking everything into account, in vitro application of the kinase route is only 
advantageous for rapid, small-scale production of (novel) glycosides or UDP-sugars. In 
response to this fact, many efficient in vivo production processes have been developed, 
mostly relying on bacterial coupling or bioconversion while genuine (de novo) 
fermentation approaches are rather uncommon. In contrast to bacterial coupling and 
bioconversion where the kinase and uridylyltransferase are actively overexpressed, few 
engineering efforts have been made regarding UDP-sugar formation in the hosts for 
fermentation based glycosylation. As pointed out by Chen and coworkers122, glucose 1-
phosphate formation (mediated by Pgm) is a major bottleneck and overexpression of 
Pgm and GalU can result in a 10-fold higher glycoside production. Furthermore, 
fermentation systems could benefit from an improved recycling of the released UDP 
towards UTP, which is often built-in in a bacterial coupling93 or bioconversion 
process120. A nucleotide diphosphate kinase (Ndk) naturally catalyzes this reaction and 
overexpression of this enzyme has been shown to enhance the formation of cyanidin 3-
O-glucoside in growing E. coli cells99. 
2.5 Interconverting common UDP-sugars 
In principle, production of a required UDP-sugar can be achieved by using one of the 
three routes discussed in Figure 2.3. The most common UDP-sugars are however formed 
through the kinase route since no synthase or phosphorylase alternatives exist for their 
generation. This in contrast to UDP-glucose, which can be rapidly generated via all three 
routes from various substrates, thus acting as a central pivot and starting point for the 
production of a large variety of UDP-sugars. These can be elegantly formed through the 
(combined) action of a large variety of epimerases, dehydrogenases or decarboxylases 
as shown in Figure 2.4. While epimerases can be used for both in vivo and in vitro 
systems, dehydrogenases and decarboxylases are (economically) restricted to in vivo 
processes due to the need for expensive cofactors like NAD(P)+. 
 
The first UDP-sugars that can be generated from UDP-glucose are UDP-galactose, UDP-
glucuronate and UDP-rhamnose. The formation of UDP-galactose by a UDP-glucose 4-
epimerase (GalE) is by far the best studied epimerization reaction which has been 
exploited in many in vitro or in vivo processes116,119,123. Despite its widespread use, it is 
often identified as the rate-limiting step in enzymatic systems so that the (galacto)kinase 
route is a preferred alternative.164,165 In most cases, GalE from E. coli is used due to its 
broad pH range, general stability and high specific activity166, with the highly 
thermostable GalE from P. horikoshii as a notable exception167.  
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A less known multifunctional and interesting enzyme is rhamnose synthase (RHM), 
which catalyzes the conversion from UDP-glucose to UDP-rhamnose. RHM is only 
present in plants and the N-terminus of the enzyme carries out a dehydratase reaction 
while the C-terminus is responsible for a sequential epimerase and reductase 
reaction.168 Recently, expression of RHM from A. thaliana in E. coli resulted in an 
efficient bioconversion process for the production of quercetin 3-O-rhamnoside and 
kaempferol 3-O-rhamnoside.101 In bacteria, rhamnosylation occurs via dTDP-rhamnose, 
requiring three enzymes (RmlBCD) for its generation starting from dTDP-glucose169 
which often yields lower titers170. The UDP-rhamnose pathway thus proves to be a 
promising alternative for in vivo rhamnosylation and can be efficiently exploited for 
example when coupled with sucrose synthase.  
 
Finally, UDP-glucuronate can be formed by a dehydrogenase enzyme Ugd, using two 
NAD+ molecules which are activated by a tyrosine kinase.171 Expression of UGD from A. 
thaliana in yeast has shown to elevate the UDP-glucuronate pool172, whereas a fission 
yeast strain was metabolically engineered for the production of various (sterol) 
glucuronides.173 Besides the metabolic importance of glucuronidation and the central 
role of UDP-glucuronate as a major constituent of glycosaminoglycans (GAG)174, it is also 
a hub towards the formation of UDP-galacturonate, UDP-apiose and UDP-xylose, which 
itself acts as an intermediate for UDP-arabinose formation. 
 
Decarboxylation of UDP-glucuronate results in the formation of UDP-apiose and UDP-
xylose in a 2 to 1 ratio through the plant enzyme UDP-apiose/UDP-xylose synthase 
(AXS).175 Depending on whether the decarboxylated intermediate undergoes a reduction 
or a ring rearrangement, UDP-xylose or UDP-apiose are formed, respectively, with the 
latter being highly unstable.176 Recently, bacterial UDP-xylose synthases (Uxs) have also 
been characterized from Sinorhizobium meliloti177, Bacteroides fragilis178 and 
Micromonospora echinospora104. The latter Uxs and AXS from A. thaliana have both been 
successfully expressed in E. coli for the in vivo production of quercetin 3-O-
xyloside.104,105 Coupling UDP-xylose formation with a UDP-xylose 4-epimerase (UXE) 
efficiently generates UDP-arabinose and similarly produces quercetin 3-O-arabinoside 
when expressed in E. coli. This enzyme is present in green plants but has recently been 
cloned from S. meliloti177. Finally, UDP-glucuronate can be easily epimerized into UDP-
galacturonate with a UDP-glucuronate 4-epimerase (Gla), an enzyme very similar to 
GalE, which is present in plants but has also been discovered in Klebsiella pneumonia179 
and S. pneumoniae180. 
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Figure 2.4: Overview of the interconverting enzymes for the generation of the most 
common UDP-sugars found in nature derived from the central molecule UDP-glucose. EC 
numbers and the abbreviated gene products are shown next to the reaction. Names 
colored in green are only present in plants, names in blue are (also) present in bacteria. 
 
Next to UDP-glucose, UDP-N-acetylglucosamine is another core metabolite which can be 
easily formed in vivo and in vitro. It is the building block for chitin, various GAG174 and is 
omnipresent in the sugar moiety of many glyconjugates such as 2-deoxystreptamine-
containing aminoglycosides52. As shown in Figure 2.5, UDP-N-acetylglucosamine can be 
interconverted into UDP-N-acetylgalactosamine by a UDP-N-acetylglucosamine 4-
epimerase (GalE2). This bacterial enzyme has been used for the enzymatic production of 
the oligosaccharides globotetraose and isoglobotetraose181 and resulted in the in vivo 
production of globotetraose when overexpressed in an E. coli mutant49. Both UDP-N-
acetylglycosamines can also be converted into their corresponding glycosaminuronate 
by the dehydrogenases WbpO182 and WbpA183. Although these enzymes have thus far 
not been used for the production of rare UDP-sugars, they could become increasingly 
popular since glycoconjugates containing a carboxyl moiety are ligands to the activation 
receptors of human natural killer cells184.  
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Figure 2.5: Overview of the interconverting enzymes for the generation of the most 
common UDP-sugars found in nature derived from the central molecule UDP-N-
acetylglucosamine. EC numbers and the abbreviated gene products are shown next to the 
reaction. Names in blue are present in bacteria. 
2.6 Glycorandomization: beyond nature’s glycosylation toolbox 
As illustrated in the previous sections, UGTs have the capability to glycosylate a myriad 
of acceptors, hereby using a large variety of UDP-sugars. Due to the importance of 
specialized metabolites as major drug leads and the profound effects of adding a sugar 
residue to these compounds, there is a growing interest in unusual or new-to-nature 
glycosides. The latter form the basis for the next generation glycosylated therapeutics185 
by combining new or unusual sugars with chemically synthesized aglycon libraries. 
Producing such glycosides with glycosyltransferases results in two key challenges: the 
formation of exotic UDP-sugars and the search for or engineering of promiscuous UGTs. 
 
Unusual or new UDP-sugars can be formed by either exploiting the diversity provided by 
nature through the use of rare UDP-sugar modifying enzymes or by exploiting the 
chemical synthesis potential to produce new and diverse sugar libraries (Figure 2.6).186 
Such unusual NDP-sugar modifying enzymes are mainly found in (soil) bacteria, which 
mostly produce exotic glycosides for communication or for their never-ceasing chemical 
warfare. While the arsenal of unusual UDP-sugars may seem overwhelming, the most 
common starting point are UDP-4-keto-6-deoxy-sugars which are formed by a 4,6-
dehydratase from UDP-glucose or UDP-N-acetylglucosamine.187,188 These deoxysugars 
may subsequently undergo eight different types of modifications: epimerization, 
isomerization, transamination, group-transfer (formylation, acetylation, sulfation, 
methylation,…), reduction and oxidation, amino oxidation, pyranose/furanose 
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interconversion and dehydration reactions, whereby the underlying mechanisms and 
types of NDP-sugars formed have been excellently reviewed.187,189,190  
 
These useful classes of modifying enzymes have only scarcely been used to create in 
vitro diversity due to the need for equimolar amounts of expensive cofactors like 
NAD(P)H or S-adenosyl methionine.191,192 Notwithstanding the advances in enzymatic 
synthesis, these processes are often plagued by low yields, which has greatly stimulated 
an in vivo approach. Generally, the cluster coding for the unusual sugar biosynthesis is 
altered or expanded in the native host or introduced in a recombinant host by means of 
metabolic engineering.193,194 Interesting examples thereof are the formation of a UDP–4-
amino-4-deoxy-L-arabinose (UDP-Ara4FN)195 and UDP–2-acetamido-2-deoxy-xylose 
(UDP–XylNAc)196 pool in E. coli or the expansion of the natural deoxysugar metabolism 
of various Streptomyces species towards 4-epi-L-daunosamine197 and 4-deacetyl-L-
chromose B198 decorated anthracyclines. It should however be noted that most of the 
unusual deoxysugars are dTDP-sugars, but due to the structural resemblance between 
(d)TDP and UDP and similarity between the mechanisms of their modifying enzymes, 
they can easily be interchanged.199 Furthermore, the existing enzyme machinery will 
probably be greatly expanded or become more specific due to recent advances in the 
field of (functional) metagenomics which gives access to the enormous biodiversity.200 
 
Another approach to produce new-to-nature sugar (libraries) is the exploitation of the 
vast array of chemical methodologies. These methods make use of selective aldol 
reactions201,202 or ring-closing metathesis203 for the formation of novel 
monosaccharides, but commonly available sugars may also be chemically 
modified152,153,204. Activation of these sugars is achieved by coupling with promiscuous 
(anomeric) kinases and uridylyltransferases to yield the corresponding UDP-sugars 
(Figure 2.6). As pointed out in section 2.4, both GalK and NahK display broad kinase 
activity147,152-154, and have been the subject of protein engineering as well, resulting in an 
E. coli Y371H/M173L GalK which literally opened the gate for unnatural sugars205. 
Regarding promiscuous uridylyltransferases, the SLOPPY enzyme from B. longum has 
proven to be an efficient in vitro catalyst towards an enormous range of unusual or 
modified sugar 1-phosphates.146 In addition, the uridylyl/thymidylyltransferase (RmlA; 
EC2.7.7.24) from Salmonella enterica has been frequently applied for both in vivo and in 
vitro generation of various UDP-sugars.150,206 Various engineering efforts (rational 
design and directed evolution) have improved the activity and promiscuity of RmlA  
towards C2 to C4 modified sugars and nucleotides.206-208 Another remarkable example is 
the mutagenesis of a Cps2L thymidylyltransferase from S. pneumonia, resulting in a 
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novel (uridylyl) catalyst for the production of a series of UDP-furanoses and UDP-3-O-
alkylglucoses and UDP-mannose.199 
 
 
Figure 2.6: Chemo-enzymatic glycorandomization is based on the combination of an 
aglycon library with various (new or unusual) UDP-sugars. These can be formed by either 
exploiting the diversity of nature, using unusual UDP-sugar modifying enzymes or by 
exploiting the potential of chemistry to create new sugar libraries. The latter can be 
converted into the corresponding UDP-sugar via the combined action of a promiscuous 
kinase and uridylyltransferase. A chemically diverse aglycon library can be subsequently 
glycosylated with a promiscuous UGT using the new or unusual UDP-sugars, which results 
in a glycorandomized library. 
The culminating step in glycorandomization is coupling the diversity of UDP-sugars with 
an aglycon (library). Despite the enormous wealth of UGTs, the majority of them is 
highly specific towards both the UDP-sugar and the aglycon, often rendering them 
unable to glycosylate even closely resembling analogues. An exception are some 
bacterial UGTs – characterized by a rather open and large aglycon binding pocket – 
which show promiscuous activity towards an enormous variety of chemical classes. To 
date, two bacterial UGTs have been extensively used: YjiC from Bacillus 
licheniformis108,209 and OleD from Streptomyces antibioticus150,210, the latter being 
extensively engineered into an enhanced multifunctional biocatalyst generating O-, S- 
and N-glycosides of well over 100 extremely diverse compounds.210-214 Interestingly, the 
reversibility of some GTs (including OleD as best studied example) has been employed 
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to generate 22 nucleotide sugars from corresponding 2-chloro-4-nitrophenyl β-D-
glycosides.215 Since the released 2-chloro-4-nitrophenolate can be readily detected at 
410 nm, this resulted in the first generally applicable high throughput screen for UGTs, 
which is an indispensable tool in screening their glycosylation potential in 
glycorandomization trials and eliminated the need for tedious UDP-sugar 
synthesis.128,215 
2.7 Future outlook 
The merging and recent advances in the fields of metabolic engineering, protein 
engineering and chemo-enzymatic glycorandomization have paved the way for UGT 
mediated production of virtually any glycoside. In this respect, in vitro glycosylation 
approaches are of great importance for discovery-scale synthesis of glycosides. These 
systems generally benefit from a facilitated downstream processing, and don’t suffer 
from acceptor toxicity or solubility issues when compared to in vivo processes. However, 
scale-up towards economically viable processes is hampered by the need for purified 
proteins and expensive cofactors. Key requirements for successful in vitro application of 
UGTs in industry will consist of (thermo)stable enzymes, a high regeneration of UDP 
(RCmax of 50 or more), efficient conversion of the aglycon and cheap starting substrates. 
From this point of view, sucrose synthase is emerging as an efficient (re)generator of 
UDP-glucose from cheap sucrose as recently reported by Nidetzky and coworkers.130 
Also coupling two UGTs for the biocatalytic rearrangement of glycosides holds promise, 
as illustrated by the conversion of inexpensive phlorizin (O-glucoside) into nothofagin 
(C-glucoside).216 
 
To overcome the issues regarding scalability and process costs, in vivo production of 
glycosides has become an interesting alternative since the microbial host produces its 
enzymes and endogenous UDP-sugar pool out of cheap substrates. Although some highly 
efficient producer strains have been developed for the multigram-scale production of 
oligosaccharides, the glycosylation of specialized metabolites lacks far behind. A major 
reason is the inadequate formation of UDP-sugars, which results in rapid depletion of 
these UDP-sugars when UGTs are overexpressed. To this end, the productivity of many 
strains could be greatly improved when most engineering strategies are revised as a 
function of the metabolic state of the host and the introduction of active UDP-sugar 
formation routes. In the latter case, sucrose synthase or sucrose phosphorylase could be 
of particular interest, since these directly form the activated precursors from the bio-
economically attractive and more sustainable substrate sucrose. In this way, the classic 
engineering strategies relying on the bottleneck enzyme phosphoglucomutase (Pgm) for 
the generation of glucose 1-phosphate (as a precursor for UDP-glucose) are skipped. 
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Moreover, intracellularly released fructose (from sucrose) can function as a substrate 
for growth, thus opening the possibility for simultaneous growth and production, which 
results in a fermentative system. In addition, the formed UDP-glucose can subsequently 
act as a versatile pivot for many other natural and unusual UDP-sugars by 
overexpressing UDP-sugar interconverting or modifying genes. The wealth of these 
exotic enzymes and UGTs provided by nature may even be further expanded by using 
the powerful tools developed in metagenome research217,218 and structure based protein 
engineering149,206,219,220. These methodologies will converge in the development of an 
easily scalable glycosylation host which is industrially applicable. However, some 
technological challenges remain regarding the evaluation of undesired events or side-
reactions taking place in the cell: degradation of UDP-sugars, modification or 
metabolization of the aglycon, insolubility of overexpressed enzymes, aglycon or 
glycoside transport problems, or a redox imbalance by overconsumption of NAD(P)H. In 
addition, the toxicity of the aglycon can be a major hurdle for in vivo approaches, but can 
be partly resolved by controlled feeding or the de novo production of the aglycon, thus 
detoxifying the cell through glycosylation96.  
 
Although large-scale glycosylation is still in its infancy, many progress has been made in 
the microbial production of an overwhelming variety of specialized metabolites. 
Stimulated by a more systematic metabolic engineering approach, production pathways 
have been divided in modules which can be varied on various levels such as 
transcription, translation and even enzyme properties. This multivariate modular 
metabolic engineering (MMME) technique has proven to be very promising221 as it 
alleviates the need for high throughput screens. To boost in vivo glycosylation and more 
specifically the de novo production of glycosides, UDP-sugar formation (and concomitant 
glycosylation) should be considered and implemented as a new module. In this way, 
aglycon and UDP-sugars modules can be varied to determine the optimal pathway 
conditions which can greatly enhance the product yields and titers. Eventually, the 
modular merging of novel and robust glycosylation strategies with microbial production 
of aglycons will unlock a new era for a myriad of glycosides, as extraction techniques 
will be increasinly replaced by de novo production. 
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3.1 Abstract 
Sugars (cellulose, pectin, glycogen, starch) are the building blocks of life  and play a 
central role at the same time in the organization thereof. Adding a sugar residue to a 
molecule can greatly alter its stability or bioactivity, and can even aid in organ specific 
(drug) delivery. However, sugars usually need to be ‘activated’ into a uridine-
diphosphate (UDP) sugar before they can be linked by glycosyltransferases to a 
molecule of interest. This activation is usually mediated through uridylyltransferases, 
which reversibly catalyze the transfer of a UDP group to a sugar 1-phosphate. Many 
specific uridylyltransferases have been described in great detail, but those having a 
broad substrate range are absent in most bacteria. One exotic enzyme activity was 
reported in the late 70’s from the crude extract of Bifidobacterium bifidum exhibiting 
activity towards both glucose 1-phosphate (glc1P) and galactose 1-phosphate (gal1P), 
but detailed information lacked about the sequence. 
 
In this chapter, 3 uridylyltransferase candidates (galT1, galT2 and ugpA) were cloned 
from B. bifidum, expressed in an engineered E. coli mutant and investigated with a newly 
developed chemo-enzymatic assay. GalT1 and GalT2 showed UDP-glucose-hexose-1-
phosphate uridylyltransferase activity (EC 2.7.7.12), whereas UgpA showed the sought 
after promiscuous UTP-hexose-1-phosphate uridylyltransferase activity (EC 2.7.7.10). 
The activity of UgpA towards glc1P was about 33-fold higher than towards gal1P. 
Furthermore, the physiological roles of the other GalT’s were also investigated and 
revealed that GalT1, as part of the bifidobacterial Leloir pathway, was about 357-fold 
more active than GalT2, the functional analog in the galacto-N-biose/lacto-N-biose 
(GNB/LNB) pathway. These results suggest that GalT1 plays a more significant role than 
previously thought and predominates when B. bifidum grows on lactose and human milk 
oligosaccharides. GalT2 activity is only required during growth on substrates with a GNB 
core such as mucin glycans. 
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3.2 Introduction 
In 1899 a bacterium was isolated by Henri Tissier from the faeces of a breast-fed 
infant.222 He introduced the name Bacillus bifidus (later reclassified as Bifidobacterium 
bifidum) after the Latin word bifidus, meaning forked, because of its Y-shaped 
morphology. Bifidobacteria are considered to benefit human health through inhibition of 
pathogens and regulation of intestinal microbial homeostasis.223 They are a 
predominant part of the gut microbiota of breastfed infants and occur naturally in the 
lower part of the human gastrointestinal tract, where common mono- and disaccharides 
are scarce.224 Therefore, bifidobacteria have developed alternative and exotic pathways 
that enable them to utilize various oligosaccharides such as mucin glycans and the two 
types of human milk oligosaccharides (HMO) based on their core sugars: lacto-N-biose I 
(LNB, type I) and N-acetyllactosamine (LacNAc, type II).151,225,226 Growth of B. bifidum on 
these oligosaccharides by action of extracellular glycosidases has been investigated in 
great detail, demonstrating rapid release and subsequent uptake of LNB.227 LNB is 
hypothesized to be the bifidus factor in HMO and thus a key factor in intestinal 
colonization.50,228 Degradation of this disaccharide and the related galacto-N-biose 
(GNB) occurs through the GNB/LNB pathway.151 
 
Table 3.1: Locus tags of the genes investigated in this study based on the B. bifidum 
PRL2010 genome229 and their gene products. 
Gene Locus Tag Gene product 
ugpA BBPR_0976 UTP-glucose-1-phosphate uridylyltransferase 
galE1 BBPR_1456 UDP-glucose 4-epimerase 
galT1 BBPR_0406 UDP-glucose-hexose-1-phosphate uridylyltransferase 
galK BBPR_0407 galactokinase 
lnbp BBPR_1055 galacto-N-biose/lacto-N-biose I phosphorylase 
nahK BBPR_1052 N-acetylhexosamine kinase 
galT2 BBPR_1051 UDP-glucose-hexose-1-phosphate uridylyltransferase 
galE2 BBPR_1050 UDP-glucose 4-epimerase 
 
The GNB/LNB pathway was discovered in Bifidobacterium longum and is encoded by the 
lnpABCD operon. This operon codes for a galacto-N-biose/lacto-N-biose I phosphorylase 
(LNBP), a N-acetylhexosamine 1-kinase (NahK), a UDP-glucose-hexose-1-phosphate 
uridylyltransferase (GalT2), and a UDP-glucose 4-epimerase (GalE2).151 Metabolic 
profiling and genome sequencing of various B. bifidum strains229-232 reveal that a similar 
GNB/LNB gene cluster is present in this species and the corresponding locus tags are 
listed in Table 3.1. However, this cluster is organized differently as two sugar kinases lie 
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between the coding sequences for LNBP and NahK (Figure 3.1). LNBP catalyzes the first 
reaction of this pathway, the phosphorolytic cleavage of a galactosyl-beta-1,3-N-
acetylhexosamine (GNB or LNB) into an N-acetylhexosamine (HexNAc) and galactose 1-
phosphate (gal1P).233 Due to its similarity to the Leloir pathway and the direct 
generation of gal1P without action of a galactokinase (GalK), the GNB/LNB pathway is 
considered an energy-saving variant of the Leloir pathway (Figure 3.2). Therefore, it has 
been suggested that this is the main pathway for galactose metabolism in bifidobacteria 
and that it prevails over the more common Leloir pathway.151,234,235 
 
BBPR_1051BBPR_1050 BBPR_1052 BBPR_1055 BBPR_1056 BBPR_1057 BBPR_1058
BL1643BL1644 BL1642 BL1641
LNBPNahKGalT2GalE2
BL1640 BL1639 BL1638
BBPR_1053 BBPR_1054
1 kbp
Bifidobacterium bifidum
Bifidobacterium longum
ABC-transporter for sugar
LNBPNahKGalT2GalE2 ABC-transporter for sugarsugar kinases
 
Figure 3.1: Schematic representation of the GNB/LNB gene cluster in B. longum NCC2705 
(gene BL1638 to BL1644) and B. bifidum PRL2010 (gene BBPR_1050  to BBPR_1058). Two 
sugar kinases interrupt the GNB/LNB pathway of B. bifidum and it is not organized as in 
the lnpABCD operon (BL1641 to BL1644) of B. longum. 
 
However, based on the presence of other uridylyltransferases and transcriptome 
profiling of B. bifidum, there are indications that the key intermediate gal1P may be 
metabolized via routes other than the GNB/LNB pathway. In this study we investigate 
the function of three annotated yet poorly characterized uridylyltransferases – GalT1, 
GalT2 and UgpA – of B. bifidum and their activity towards gal1P. GalT1 and GalT2 are 
both annotated as UDP-galactose-1-phosphate uridylyltransferases, yet share little (12.1 
%) sequence identity, while UgpA is annotated as an UTP-glucose-1-phosphate 
uridylyltransferase (EC 2.7.7.9). In this paper, the enzymes were cloned and 
overexpressed in an engineered E. coli strain in order to eliminate interference with the 
enzymes investigated, and were screened for both activities, using a new chemo-
enzymatic assay. More detailed characterization of these uridylyltransferases provides 
new insights in gal1P degradation and its metabolic implications in B. bifidum. 
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Figure 3.2: Overview of the Leloir pathway (A) and GNB/LNB pathway (B) in 
Bifidobacterium bifidum. LNBP, NahK, GalT2 and GalE2 are encoded in the same gene 
cluster.151 In contrast, the classic Leloir pathway (A) is encoded by scattered genes and 
evidence is lacking for the existence of metabolic crossover between both pathways. Gene 
locus tags of the corresponding enzymes are listed in Table 3.1. 
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3.3 Materials and methods 
3.3.1 Bacterial strains and plasmids 
All plasmids and strains used in this study are listed in Appendix 1 and 2 respectively. E. 
coli DH5α (subcloning) was used for plasmid cloning and propagation, while E. coli 
MG1655 ΔgalETKM ΔgalU ΔushA Δugd Δagp (hereafter named sMEMO_WT) was used 
for the expression and crude extract preparation of the uridylyltransferases. E. coli BL21 
(DE3) was used for the expression of the His6 tagged uridylyltransferases. The λ-red 
pKD46 plasmid, plasmid pKD4 for amplification of the kanamycin resistant marker and 
plasmid pCP20 for removal of this marker were used for the one step inactivation in E. 
coli MG1655 as described by Datsenko and Wanner.236 
3.3.2 Reagents 
T4 DNA-ligase and all restriction enzymes were purchased from New England Biolabs 
(Ipswich, Massachusetts). PrimeSTAR polymerase was purchased from Takara Bio 
(Japan). All chemicals used in crude extract preparation and assays were purchased 
from Sigma Aldrich (Germany), except for gal1P and UTP purchased from Merck 
(Darmstadt, Germany) and UDP-glucose and N-acetylglucosamine 1-phosphate from 
Carbosynth (Berkshire, UK). 
3.3.3 Culture media 
E. coli cultures were grown on Luria-Bertani (LB) medium (Difco) with the necessary 
antibiotics (50 µg/mL kanamycin, 100 μg/mL ampicillin, 25 µg/mL chloramphenicol) 
for maintenance and selection of the plasmids. B. bifidum (ATCC 29521) was grown 
anaerobically at 37 °C on LMG Medium 144 (per liter of medium: 23 g special peptone 
(Difco), 1 g soluble starch, 5 g NaCl, 0.3 g cysteine hydrochloride and 5 g glucose). The 
anaerobic environment, consisting of 5 % H2 and 95 % N2, was created by an anaerobic 
chamber (Concept 1000, Ruskinn Technology Ltd, UK). 
3.3.4 DNA isolation, manipulation and construction of uridylyltransferase 
vectors 
Genomic DNA (gDNA) was obtained by harvesting the cells of the culture by 
centrifugation at 22000 × g (Heraeus Biofuge, Thermo). Cells were washed with saline 
and heated for 5 min at 100 °C. The cell debris was removed by centrifugation at 22000 
× g for 10 min and the supernatant was used as gDNA. All primers used in this study are 
listed in Appendices Appendices A5 (deletion primers) and A6 (cloning primers) and the 
gDNA of B. bifidum was used for the amplification of ugpA, galT1 and galT2 genes. gDNA 
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of E. coli MG1655 was used for the amplification of galU. All the genes were amplified 
two times independently and sequenced to ensure no mutations occurred in the 
constructs. The amplified galU and ugpA fragments were cut with EcoRI-HF and SacI-HF 
and ligated into the pCX-Kan-P22 vector resulting in pCX-Kan-P22-galU and pCX-Kan-
P22-ugpA respectively. The galT1 and galT2 fragments were cut with NdeI-HF and PmeI 
and ligated into the p10-Trc vector resulting in the p10-Trc-galT1 and p10-Trc-galT2 
plasmids. In addition, both vectors were also redesigned so that an N-terminal His6 tag 
was added to allow purification, resulting in the p10-Trc-His-galT1 and p10-Trc-His-
galT2 plasmids. These plasmids were created by using a 2 pieces Gibson assembly 
method237 using cloning primers for the amplification of the p10-Trc backbone and His-
galT1 and His-galT2 inserts listed in Appendix A6. All plasmids were sequenced and 
showed no mutations. 
3.3.5 Construction of deletion mutants and expression strains 
To eliminate interference of the crude enzyme extract with the substrates used in the 
assay an E. coli MG1655 knockout mutant was created by application of the one step 
deletion system of Datsenko and Wanner236. The linear DNA for the deletion of each 
target gene was amplified using deletion primers (Fw/Rv_gene_del) as mentioned in 
Appendix A5. The galETKM operon and the genes galU, ushA, ugd and agp were deleted 
resulting in the sMEMO_WT mutant (Appendix A2) as an expression host for the 
recombinant uridylyltransferases. Transformation of the constructed pCX-Kan-P22-
galU, pCX-Kan-P22-ugpA, p10-Trc-galT1 and p10-Trc-galT2 plasmids in this sMEMO_WT 
mutant resulted in the sMEMO_GalU, sMEMO_UgpA, sMEMO_GalT1 and sMEMO_GalT2 
strains respectively. The p10-Trc-His-galT1 and p10-Trc-His-galT2 plasmids were 
transformed in BL21(DE3), resulting in sMEMO_His_GalT1 and sMEMO_His_GalT2 
strains. 
3.3.6 Preparation of crude enzyme extracts 
The sMEMO_GalU, sMEMO_UgpA, sMEMO_GalT1 and sMEMO_GalT2 strains were grown 
in tubes containing 5 mL LB (plus kanamycin or chloramphenicol when required) for 8 h 
at 37 °C. The culture served as 2 % inoculum for 250 mL Erlenmeyer flasks containing 
50 mL LB medium with 1 % glucose (and kanamycin or chloramphenicol when 
required). Strains sMEMO_GalT1 and sMEMO_GalT2 were induced with 0.2 mM IPTG 
after inoculation. Shake flasks were incubated at 37 °C and 200 rpm for 16 h. Cells were 
harvested by centrifugation (Heraeus Biofuge, Thermo) for 10 min at 5000 × g. The cell 
pellet was washed first with saline and then with 50 mM MOPS buffer (pH 6.5 or pH 7 
depending on the assay). Finally, the pellet was dissolved in 5 mL of the above MOPS 
buffer and disrupted by sonication for 2 x 4 min (Branson sonifier, 50 % duty cycle, 
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output 3). The crude enzyme extract was obtained by centrifugation for 20 min at 22000 
× g. Protein concentration was determined via Bradford assay.238 
3.3.7 Purification of GalT enzymes 
For the purification of both GalT1 and GalT2 enzymes, strains sMEMO_His_GalT1 and 
sMEMO_His_GalT2 were cultivated on 100 mL LB medium and chloramphenicol at 30 °C 
and 200 rpm. When absorbance at 600 nm reached 0.6, IPTG was added at a final 
concentration of 0.4 mM. The crude extract was obtained in the same way as described 
above and both enzymes were purified on Ni-nitrilotriacetic acid agarose gel (QIAGEN, 
Hilden, Germany) according to the manufacturer’s instructions. After purification a 
buffer exchange was performed to 50 mM MOPS buffer (pH 7) using an Amicon Ultra-4 
centrifugal filter unit (30 kDa NMWL) from Merck (Darmstadt, Germany). Protein 
concentration was determined via Bradford assay 238. 
3.3.8 Assay for UTP-hexose-1-phosphate uridylyltransferase activity 
The assay was based on the article of Wu and coworkers239, but redesigned for 
pyrophosphate quantification. UTP-hexose-1-phosphate uridylyltransferase activity was 
measured in a 20 µL reaction mixture containing 50 mM MOPS buffer (pH 6.5), 2 mM 
UTP, 2 mM hexose 1-phosphate (glucose 1-phosphate (glc1P) or gal1P), 2 mM MgCl2, 1 U 
of inorganic pyrophosphatase from E. coli, and various concentrations of crude enzyme 
extract. The reaction mixture was incubated at 37 °C for 15 min and was stopped by 
adding 180 µL of a 10 mM EDTA solution. Final activity was determined by quantifying 
the released phosphate during the reaction using a malachite green assay as described 
below. One unit of UTP-hexose-1-phosphate uridylyltransferase activity was defined as 
the amount of enzyme that formed 1 µmol of UDP-hexose per minute under these 
conditions. 
3.3.9 Assay for UDP-glucose-hexose-1-phosphate uridylyltransferase 
UDP-glucose-hexose-1-phosphate uridylyltransferase activity was measured by using a 
continuous coupled assay for glc1P quantification. The assay mixture consisted of 100 
µL assay solution (50 mM MOPS buffer (pH 7), 2 mM NAD+, 10 mM MgCl2, 30 µM 
glucose-1,6-diphosphate, 1.2 U/mL phosphoglucomutase from rabbit muscle and 1.2 
U/mL glucose 6-phosphate dehydrogenase from L. mesenteroides), 50 µL of substrate 
solution (50 mM MOPS buffer (pH 7), 4 mM gal1P and 4 mM UDP-glucose) and a 50 µL 
dilution of crude enzyme extract or purified enzyme in 50 mM MOPS buffer (pH 7). 
Reaction was performed at 37 °C in a microtiter plate and NADH formation was 
monitored continuously by measuring the absorbance at 340 nm. One unit of UDP-
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glucose-hexose-1-phosphate uridylyltransferase activity was defined as the amount of 
enzyme that formed 1 µmol of glc1P per minute under these conditions. 
3.3.10 Kinetic analysis 
The kinetic constants were derived from initial rate analysis by varying the 
concentration of individual substrate. For the UTP-hexose-1-phosphate 
uridylyltransferase assay, UTP was varied from 0 to 2 mM in the presence of 2 mM 
hexose 1-phosphate (glc1P or gal1P). Hexose 1-phosphate was subsequently varied 
from 0 to 2 mM at 2 mM saturation of UTP. For the UDP-glucose-hexose-1-phosphate 
uridylyltransferase assay, gal1P was varied from 1 to 0.02 mM in the presence of 1 mM 
UDP-glucose. Kinetic parameters were calculated from an S-V plot by non-linear 
regression analysis using the Michaelis-Menten kinetic equations in R (‘nlstools’ 
package). 
3.3.11 Malachite green assay 
Phosphate concentration of the samples in the micromolar range was determined using 
a malachite green assay: to 50 µL of sample, 30 µL reagent A, 100 µL milliQ water and 30 
µL reagent B was added (in this order). The mixture was incubated for 20 min in a 
microtiter plate at room temperature and absorbance was measured at 630 nm. Reagent 
A consists of 50 mM of ammonium heptamolybdate in 3 M of sulphuric acid. Reagent B 
consists of 0.093 % (w/v) malachite green and 0.93 % (w/v) polyvinyl alcohol (Mw 
14000). Concentrations were determined using a phosphate standard (serial dilutions 
ranging from 0 – 100 µM). 
3.3.12 LC-MS 
The products – phosphorylated and nucleotide sugars – of the enzymatic reactions were 
also verified by Liquid Chromatography coupled to a Mass Spectrometer (LC-MS) using a 
Cosmosil Hilic (Nacalai USA, San Diego) column (4.6 x 250 mm) with isocratic separation 
(0.1 M ammonium acetate (50 %) and acetonitrile (50%) at a flow rate of 1 mL/min at 
35 °C for 30 min). The LC system was coupled to a  Micromass Quattro LC (McKinley 
Scientific, USA). Detection was performed in negative mode ESI-MS with a capillary 
voltage of 2.53 kV, a cone voltage of 20 V, cone and desolvation gas flows of 93 and 420 
L/h, and source and cone temperatures of 150 and 350°C, respectively. 
3.3.13 Nucleotide sequences accession number 
The accession numbers of the cloned genes are listed in Appendix A3. 
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3.4 Results 
3.4.1 Cloning of the uridylyltransferase genes 
The nucleotide sequences of ugpA, galT1 and galT2 from B. bifidum ATCC 29521 were 
99.4 %, 99.6 % and 99.5 % identical to the BBPR_0976, BBPR_0406 and BBPR_1051 
genes of B. bifidum PRL2010229. The predicted functions of these genes are UTP-glucose-
1-phosphate uridylyltransferase (ugpA) and galactose-1-phosphate uridylyltransferase 
(galT1 and galT2), respectively. These genes were expressed in the E. coli MG1655 
mutant and an assay was performed to determine their function as described in the 
Materials and Methods section. 
3.4.2 Assay validation 
A new UTP-hexose-1-phosphate uridylyltransferase assay was developed based on the 
principle of phosphate detection as described by Wu and coworkers239. Crude extracts 
with this uridylyltransferase activity release pyrophosphate, which is converted to 
organic phosphate (Pi) when coupled with a pyrophosphatase. The subsequent reaction 
of phosphate with a malachite green reagent is spectrophotometrically detected in the 
micro molar range. A schematic overview of this assay is given in Figure 3.3. Since the 
detailed composition of the reagents for malachite green detection of phosphate was not 
available, a reverse engineering effort was done to determine this. The result is the 2-
component mixture described in 3.3.11 and was able to quantify inorganic phosphate up 
to 100 µM.  
 
 Validation of the UTP-hexose-1-phosphate uridylyltransferase assay was performed 
using commercially available uridine-5′-diphosphoglucose pyrophosphorylase from 
baker's yeast (Sigma-Aldrich, 40 – 60 % protein concentration, ≥ 50 U/mg protein). One 
unit was defined as forming 1 µmol glucose 1-phosphate (glc1P) at 25 °C at pH 7.6 in 1 
minute. Enzyme dilutions were incubated for 10 min with 2 mM of UTP and glc1P under 
the conditions described in section 3.3.8 and released phosphate was measured with the 
malachite green assay. A specific activity of 65.2 ± 1.7 U/mg protein was found. This 
coupled assay with subsequent malachite green phosphate detection proved to be a 
stable and precise method for determination of the specific activity. Validation of the 
UDP-glucose-hexose-1-phosphate uridylyltransferase assay was performed by adding 
100 µL of 2 mM glc1P to the assay solution. 
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Figure 3.3: Schematic overview of the developed UTP-hexose-1-phosphate uridylyl-
transferase activity assay (A), screening of the crude enzyme extract dilutions for this 
activity (B) and the measurement of the specific activity towards glc1P and gal1P (C). 
 
3.4.3 Expression host validation 
An E. coli MG1655 mutant (sMEMO_WT) was created as an efficient screening host for 
the different uridylyltransferases from B. bifidum. The Leloir pathway (galETKM) and 
the gene coding for UTP-glucose-1-phosphate uridylyltransferase (galU) were deleted to 
prevent interference with the investigated enzymes. The degradation of hexose 1-
phosphate or UDP-hexose substrates was also prevented by knocking out UDP-sugar 
hydrolase (ushA), UDP-glucose 6-dehydrogenase (ugd) and an acid glucose-1-
phosphatase (agp). The crude extract of sMEMO_WT was tested against the substrates of 
both assays to detect possible interference. No activity was observed for the UDP-
glucose-hexose-1-phosphate uridylyltransferase assay. Testing of the crude extract 
against a hexose 1-phosphate and UTP showed no activity for the UTP-hexose-1-
phosphate uridylyltransferase assay. However minor activity was observed with UTP as 
sole substrate after extended incubation times (> 30 min) and using undiluted crude 
extracts. This is probably due to UTP hydrolysis by an unidentified hydrolase. Since 
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incubation times were always lower than 15 min and dilutions starting from 0.05 were 
used, sMEMO_WT was considered a suitable screening host. 
3.4.4 UTP-hexose-1-phosphate uridylyltransferase activity 
Crude enzyme extract dilutions of UgpA, GalT1 and GalT2 were screened for UTP-
hexose-1-phosphate uridylyltransferase activity against 2 mM hexose 1-phosphate 
(glc1P or gal1P) and 2 mM UTP. Only UgpA showed activity against both substrates. 
Formation of the corresponding UDP-hexose (UDP-glucose or UDP-galactose 
respectively) was confirmed by LC-MS. The specific activity of UgpA crude extract 
towards glc1P was 13 U mg-1, which was about 33-fold higher than towards gal1P. The 
apparent Km values were also calculated and seemed to be similar for both substrates 
(Table 3.2). As a reference point for the substrate usage spectrum, the UgpA equivalent 
of E. coli (GalU) was also assayed against both substrates, showing only activity towards 
glc1P. The specific activity of the GalU crude extract was about 6.9-fold lower compared 
to UgpA. 
 
Table 3.2: Kinetic parameters for UgpA and GalU crude protein extracts a 
  H1P UTP 
 Sp act (U mg-1) Km (mM) Km (mM) 
UgpA (G1P) 13.0 ± 0.08 0.098 ± 0.011 0.042 ± 0.006 
UgpA (gal1P) 0.40 ± 0.01 0.148 ± 0.034 0.032 ± 0.010 
GalU (G1P) 1.88 ± 0.03 0.010 b 0.070 b 
GalU (gal1P) ND - - 
a Reactions carried out at pH 6.5 and 37 °C. ND: not detected. Experiments were carried out in 
triplicate and standard deviations are shown. 
b Data from Weissborn et al. 240. Reaction carried out at pH 7.8 and 37 °C. 
3.4.5 Activity of GalT1 and GalT2 
The 3 recombinant uridylyltransferase crude extracts were screened for UDP-glucose-
hexose-1-phosphate uridylyltransferase activity against 2 mM UDP-glucose and 2 mM 
gal1P at pH 7 and 37 °C. GalT1 showed high activity; a 0.01 dilution of the crude extract 
converted all gal1P into glc1P within a 5 min incubation. The same dilution of GalT2, 
however, displayed a very weak activity which was 417-fold lower compared to GalT1. 
The activity did not improve after adding cysteine, Fe2+, or Zn2+, as proposed in 
literature.241,242 Altering the expression conditions (0.1 mM IPTG induction), lowering of 
the assay temperature to 25 °C or raising the buffer pH to 8.5 had no effect either. To 
confirm these results, the His6 tagged GalT1 and GalT2 were purified from the 
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sMEMO_His_GalT1 and sMEMO_His_GalT2 strains and different dilutions were used to 
measure activity. Other acceptors than gal1P were also tested, including N-
acetylgalactosamine 1-phosphate (galNAc1P) and N-acetylglucosamine 1-phosphate 
(glcNAc1P) in the presence of 2 mM UDP-glucose and the specific activities are given in 
Table 3.3. GalT2 showed a 357-fold lower activity than GalT1, which is consistent with 
the results based on the crude extracts. The apparent Km of GalT1 for gal1P in the 
presence of 2 mM UDP-glucose was 0.29 ± 0.08 mM, which is in the range of previous 
findings.243 The apparent Km of GalT2 for gal1P was 0.61 ± 0.1 mM, while the Km of GalT2 
towards galNAc1P was only 65.1 ± 15.9 µM. 
 
Table 3.3: Kinetic parameters of the purified GalT1 and GalT2 enzymes as function of 
various hexose 1-phosphates a 
Enzyme (H1P) kcat (s-1) Km (mM)  kcat/Km (M-1s-1) 
GalT1 (gal1P) 73 ± 1.8 0.29 ± 0.08 251240 
GalT1 (galNAc1P) ND - - 
GalT1 (glcNAc1P) ND - - 
GalT2 (gal1P) 0.24 ± 0.01 0.61 ± 0.1 400 
GalT2 (galNAc1P) 0.31 ± 0.03 0.07 ± 0.02 4802 
GalT2 (glcNAc1P) 0.22 ± 0.01 - - 
a Reactions carried out at pH 7 and 37 °C for various acceptors. Experiments were carried out in 
triplicate and standard deviations are shown. ND: not detected. 
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3.5 Discussion 
3.5.1 Assay and expression host validation 
A new and reliable assay was developed that allows fast screening and characterization 
of enzymes with UTP-hexose-1-phosphate uridylyltransferase activity. The same assay 
can be used to investigate various other enzymes that liberate pyrophosphate, such as 
mannose-1-phosphate guanylyltransferase (EC 2.7.7.13) or isoprene synthase (EC 
4.2.3.27). The development of the described expression host, lacking the Leloir pathway 
and relevant degradation reactions, bypasses the need to purify the enzymes 
investigated. These assays proved to be indispensable tools to characterize UgpA, GalT1 
and GalT2 and gain new insights in the LNB/GNB metabolism of bifidobacteria. 
3.5.2 Specificity of UgpA 
Our results indicate that UgpA is a promiscuous UTP-hexose-1-phosphate uridylyl-
transferase that catalyzes the formation of UDP-hexose from hexose 1-phosphate. Based 
on this activity and the size of the monomer (55 kDa), this enzyme is probably 
homologous to the enzyme purified from B. bifidum by Lee et al. but was never properly 
annotated.14,244 They described the reverse (pyrophosphorylase) action of UgpA, which 
showed the same reactivity towards UDP-galactose as towards UDP-glucose. However, 
our findings indicate a 33-fold lower activity in the synthesis direction of UDP-galactose. 
Because of this promiscuity, a new EC number (EC 2.7.7.10) was proposed to distinguish 
it from UTP-glucose-1-phosphate uridylyltransferase (EC 2.7.7.9; GalU) that 
predominantly acts on glc1P in prokaryotes.240,245 However, due to the activity on 
different sugar 1-phosphates, the absence of similarity with GalU-type enzymes, and a 
high level of identity with promiscuous eukaryotic uridylyltransferases, we suggest that 
UgpA should be classified as an UTP-monosaccharide-1-phosphate uridylyltransferase 
(EC 2.7.7.64, synonym of UDP-sugar pyrophosphorylase, USP)158,246,247. Moreover, a 
UDP-sugar pyrophosphorylase from B. longum (BLUSP) was recently cloned, showing 82 
% amino acid identity with UgpA, and was used for the efficient synthesis of a variety of 
UDP-sugars146. 
3.5.3 Specificity of GalT enzymes 
We observed that both GalT1 and GalT2 possessed UDP-glucose-hexose-1-phosphate 
uridylyltransferase activity (EC 2.7.7.12; GalT), yet the activity of GalT2 was 357-fold 
lower compared to GalT1. A similar result was reported in the large scale preparation of 
LNB, where GalT1 of B. longum was used instead of GalT2.50,151 GalT2 shows a broad 
acceptor specificity, with a 9-fold higher affinity towards galNAc1P than gal1P. The 
Chapter 3:  Unraveling the Leloir pathway of Bifidobacterium bifidum 
43 
 
amino acid sequences of both GalT enzymes shared almost no identities (12.1 %), which 
could be explained by convergent evolution of similar enzymatic function. However, it 
was shown that the majority of catalytic residues are under different evolutionary 
constraints in both type of enzymes and they likely have different functions.248 This is 
supported by the fact that purified GalT2 was 28 % more active towards galNAc1P than 
gal1P as substrate, providing a link between growth on GNB/LNB and aminosugar 
metabolism. 
3.5.4 galT gene clusters 
GalT enzyme activity, which is essential for the transfer of the uridine nucleotide moiety 
from UDP-glucose to gal1P, is widespread in many organisms. However, based on the 
enzyme dissimilarities between GalT1 and GalT2, two classes seem to exist. Class I 
enzymes (GalT1 type) are found in various eukaryotic organisms and bacteria, while 
Class II enzymes (GalT2 type) are almost exclusively present in Firmicutes and 
Actinobacteria.249,250 Coding sequences for GalT1 or GalT2 do not co-occur in the same 
organism, with some Clostridiales and bifidobacteria as exceptions. Based on 
comparative bifidobacterial genome analysis, only B. bifidum, B. longum and B. breve 
strains possess both galT1 and galT2, being part of a galTK gene cluster and a GNB/LNB 
degradation gene cluster, respectively.229,231,251 A schematic phylogenetic overview of 
these gene clusters is given in Figure 3.4. Metabolic and genetic explanations for the 
unique coexistence of both GalT enzymes in B. bifidum, B. longum and B. breve strains 
remain unclear, but is coupled to the occurrence of the GNB/LNB pathway, which is 
apparently absent in other bifidobacteria227,232. 
3.5.5 Metabolic implications 
The occurrence of three uridylyltransferases in B. bifidum that act on gal1P can have 
metabolic implications that have been overlooked. While the Leloir pathway is in most 
organisms the major, if not the only, pathway for the degradation of galactose, an 
alternative route was discovered in B. longum under the form of the GNB/LNB pathway. 
The same gene cluster is also present in B. bifidum and it is suggested that this energy-
saving variant of the Leloir pathway is the main pathway for galactose metabolism.151 
However, glycoprofiling of B. bifidum during growth on HMO shows the release of 
lactose and LNB as prominent disaccharides. While LNB enters the GNB/LNB pathway, 
galactose is released by action of a β-galactosidase227 from lactose. Our findings suggest 
that galactose is primarily metabolized via the Leloir pathway, together with gal1P 
originating from LNB or GNB. 
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Although GalT2 (as part of the GNB/LNB pathway) is put forward to play the key role in 
gal1P degradation151, we suggest that GalT1 (as part of the Leloir pathway) 
predominates when grown on lactose, galactooligosaccharides (GOS) and HMO. In 
addition to the 357-fold lower activity of GalT2, transcription data showed the 
upregulation of galT1 during growth on these substrates relative to glucose252,253. It is 
often stated that the genes of the GNB/LNB pathway are upregulated during growth on 
oligosaccharides or mucin, but whether a part or the whole cluster is upregulated is 
highly dependent on the substrate. Growth on LNB-containing oligosaccharides (HMO) 
only requires LNBP and NahK activity in principle, yielding gal1P and glcNAc1P. The 
latter is metabolized into fructose 6-phosphate (F6P) by action of a 
phosphoglucosamine mutase, a N-acetylglucosamine 6-phosphate deacetylase, and a 
glucosamine 6-phosphate deaminase, which then enters the bifid shunt254. A significant 
upregulation of these genes was observed when grown on HMO.229,255  
 
Substrates with a GNB core (such as mucin glycans) require LNBP and NahK activity, 
yielding gal1P and galNAc1P, yet also require GalT2 and GalE2 activity to be converted 
to glcNAc1P in order to enter the bifid shunt. This hypothesis is supported by the 
substrate preference of GalT2 towards galNAc1P and by transcriptional data of 
bifidobacteria grown on lactose, HMO, GOS or mucin based media.229,252,253 A proposed 
metabolic route for lactose, LNB and GNB degradation is depicted in Figure 3.5. The 
metabolic implications of UgpA are probably limited to UDP-sugar generation, to 
provide the Leloir pathway with initial amounts of UDP-glucose.235,245 This is supported 
by the fact that the Km for hexose 1-phosphate is more than 2-fold lower compared to 
GalT1. 
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Figure 3.5: Proposed routes for the metabolization of galactose, lacto-N-biose I (LNB) and 
galacto-N-biose (GNB) in B. bifidum. All 3 substrates yield gal1P which is solely 
metabolized by the Leloir pathway (left). Depending on the presence of LNB or GNB, N-
acetylglucosamine (glcNAc) or N-acetylgalactosamine (galNAc) are respectively formed 
through the action of LNBP. Utilization of glcNAc only requires N-acetylhexosamine kinase 
(NahK) activity to generate glcNAc1P. However, GNB rich substrates such as mucin need 
the full set of enzymes encoded by the GNB/LNB gene cluster (right). GalNAc is 
phosphorylated to GalNAc1P by NahK, which is subsequently converted by GalT2 and 
GalE2 via a Leloir like pathway to glcNAc1P which can then enter the Bifid Shunt via 
fructose 6-phosphate (F6P) by consequent action of a glucosamine mutase, a deacetylase 
and a deaminase. glcN6P: glucosamine 6-phosphate. 
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3.6 Conclusions 
In this chapter 3 uridylyltransferases (UgpA, GalT1 and GalT2) from B. bifidum were 
characterized by expression in an engineered E. coli strain and using the crude extracts, 
thus avoiding the need to purify the enzymes. The extracts were easily screened for 
hexose-1-phosphate uridylyltransferase activity due to the development of a novel 
chemo-enzymatic assay based on phosphate detection in the micromolar range. UgpA 
was identified as the promiscuous uridylyltransferase with activity towards both glc1P 
and gal1P. This interesting feature together with its 7-fold higher activity compared to 
GalU has enabled the implementation in the next chapters. GalT1 and GalT2 exhibited 
UDP-glucose-hexose-1-phosphate uridylyltransferase activity and their function in 
respect to substrate usage in B. bifidum was discussed based on the data obtained in 
vitro. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
 
4 Chapter 4 
Development of an in vivo 
glucosylation platform by coupling 
production to growth 
Production of phenolic glucosides by a GT of V. vinifera 
 
 
Contents 
 
4.1 Abstract ........................................................................................................................................... 50 
4.2 Introduction .................................................................................................................................. 51 
4.3 Materials and methods .............................................................................................................. 54 
4.3.1 Materials and Molecular Agents .................................................................................................. 54 
4.3.2 Creation of the production plasmids.......................................................................................... 54 
4.3.3 Creation of the E. coli W mutant strains ................................................................................... 54 
4.3.4 Media ....................................................................................................................................................... 55 
4.3.5 Growth in shake flasks ..................................................................................................................... 55 
4.3.6 Growth in bioreactors ...................................................................................................................... 56 
4.3.7 Product analysis and quantification ........................................................................................... 56 
4.3.8 Purification and structural elucidation of compounds ....................................................... 56 
4.3.9 Mathematical methodologies ........................................................................................................ 57 
4.4 Results and discussion ............................................................................................................... 58 
4.4.1 Introduction ......................................................................................................................................... 58 
4.4.2 Altering the sucrose metabolism of E. coli W to efficiently generate glc1P ............... 58 
4.4.3 Coupling growth and production ................................................................................................ 60 
4.4.4 Optimization of production medium for glucosylation of gallic acid ........................... 63 
4.4.5 Production of β-glucogallin ............................................................................................................ 65 
4.4.6 Screening for the glucosylation potential of different acceptors ................................... 68 
4.4.7 Productivity comparison with the WT strain ......................................................................... 70 
4.5 Conclusions .................................................................................................................................... 72 
Chapter 4:  Development of an in vivo glucosylation platform 
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this chapter was submitted as:  
 
De Bruyn, F., De Paepe, B., Beauprez, J., Maertens, J., De Cocker, P., Stevens, C., Mincke, S., 
Soetaert, W., and De Mey, M. (2014) Development of an in vivo glucosylation 
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4.1 Abstract 
Glycosylation of small molecules can significantly alter their properties such as 
solubility, stability and/or bioactivity, making glycosides attractive and highly 
demanded compounds. Consequently, many biotechnological glycosylation approaches 
have been developed, with enzymatic synthesis and whole-cell biocatalysis as the most 
prominent techniques. However, most processes still suffer from low yields, production 
rates and inefficient UDP-sugar formation. To this end, a novel metabolic engineering 
strategy is presented for the in vivo glucosylation of small molecules in Escherichia coli 
W. This strategy focuses on the introduction of an alternative sucrose metabolism using 
sucrose phosphorylase for the direct and efficient generation of glucose 1-phosphate as 
precursor for UDP-glucose, and fructose, which serves as a carbon source. By targeted 
gene deletions, a split metabolism is created whereby glucose 1-phosphate is rerouted 
from glycolysis to product formation (i.e. glucosylation). Further, the production 
pathway was enhanced by increasing and preserving the intracellular UDP-glucose pool. 
Expression of a versatile glucosyltransferase from Vitis vinifera (VvGT2) enabled the 
strain to efficiently produce 14 glucose esters of various hydroxycinnamic and 
hydroxybenzoic acids with conversion yields up to 100 %. To our knowledge, this fast 
growing (and simultaneously producing) E. coli mutant is the first versatile host 
described for the glucosylation of phenolic acids in a fermentative way using only 
sucrose as a cheap and sustainable carbon source. 
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4.2 Introduction 
In nature, the majority of specialized (secondary) metabolites exist in its glycosylated 
form. Addition of a sugar residue to such molecules significantly alters the solubility, 
stability and/or bioactivity20, which are desirable properties when glycoconjugates are 
applied as nutraceuticals, therapeutics or cosmetics. Small (lipophilic) molecules such as 
flavonoids, phenolic acids, alkaloids or terpenoids are an interesting class within plant 
specialized metabolites due to their myriad of applications ranging from 
cardioprotective42, anticarcinogenic40 and antiviral30 to antioxidative44 or sweetening25 
effects. Furthermore, glucosylation of these compounds, which is catalyzed by 
glucosyltransferases (GTs), proves to be the key factor in metabolic homeostasis13 of 
plants. These enzymes transfer a glucose residue regio- and stereoselectively from the 
activated sugar donor UDP-glucose (UDP-glc) to the respective acceptors.37 
 
Chemical synthesis of glucosides (and glycosides in general) has proven to be a very 
daunting task, requiring many protecting and deprotecting steps.75 In addition, large-
scale synthesis is hampered by a low yield and a low atom efficiency. To tackle these 
difficulties, many enzymatic processes have been developed using either glycoside 
hydrolases, or phosphorylases or the mentioned GTs for the generation of various 
glucosides.78 However, whereas glycoside hydrolases often suffer from an unfavorable 
equilibrium, typically shifted towards hydrolysis rather than the synthesis reaction 
which results in low yields86, glycoside phosphorylases require high concentrations of 
acceptor molecules for efficient catalysis91. The main constraint to the use of GTs in 
biocatalysis is the need for equimolar amounts of UDP-glc, which is very expensive and 
rarely available in large quantity.92 To overcome this issue, a lot of effort has been 
invested both in the enzymatic regeneration of these nucleotide sugars163,181 and in 
coupling GTs with sucrose synthase130. Despite these efforts, production rates remain 
low and the overall processes costly. An alternative approach is the use of microbial 
whole-cell systems for the in vivo glucosylation of various acceptors.98,102,124,256 The used 
(engineered) cells generate the aforementioned expensive cofactors in situ and the 
expression of GT enzymes, thus bypassing the need for extensive protein purification.  
 
Most of these microbial processes are bioconversions which use resting cells, hence 
resulting in inefficient UDP-sugar formation.114,257 They typically require an initial 
growth phase and expensive growth media to obtain high cell densities that function as 
passive biocatalysts during the subsequent production phase. Furthermore, the majority 
of glycosylation systems to date rely on phosphoglucomutase (Pgm) for the generation 
of glucose 1-phosphate (glc1P) as precursor for UDP-glc, despite the fact that this 
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reaction has been frequently identified as a major bottleneck.122 As a result, most in vivo 
glycosylation strains are plagued with low product titers and rates, rendering them unfit 
for large-scale applications. However, production rates and space-time yields could be 
greatly improved when formation of glycosides occurs simultaneously with biomass 
accumulation. Reassessing existing engineering strategies in such a way that the carbon 
source is equally invested in growth and production bypasses the need for a trade-off 
between both. Since growth is the main driving force of a cell, a steady supply of the 
UDP-sugars and its precursors is ensured. 
 
 
 
 
Figure 4.1: Overview of the novel metabolic engineering strategy which consists of (1) 
introducing sucrose phosphorylase (BaSP) in E. coli W for the direct generation of glucose 
1-phosphate; (2) creation of a split metabolism by preventing glucose 1-phosphate 
degradation and rerouting it towards UDP-glucose; (3) formation and preservation of an 
enlarged UDP-glucose pool; and (4) the expression of a versatile glucosyltransferase 
VvGT2 for the glucosylation of various phenolic acids. 
 
In this contribution, a novel metabolic engineering strategy that couples production to 
growth is presented for the in vivo glucosylation of small molecules in Escherichia coli W. 
This strategy, depicted in Figure 4.1, focuses on (1) the introduction of an alternative 
sucrose metabolism, using sucrose phosphorylase, for the efficient generation of glc1P, 
the precursor of UDP-glc; (2) the creation of a split E. coli W metabolism, resulting in the 
reduced or eliminated use of glc1P for growth, preserving it for UDP-glc formation; (3) 
enhancing and securing UDP-glucose formation; and (4) the expression of the versatile 
glucosyltransferase VvGT2 from Vitis vinifera for the glucosylation of various phenolic 
acids. To our knowledge, these compounds have not been the subject of in vivo 
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glucosylation in spite of their interesting properties as (dietary) antioxidants, which 
hold a large and steadily growing market.62 Due to this engineering strategy, sucrose is 
split in fructose, which is used as a carbon source, and glc1P, which fuels the formation 
of glucosides, resulting in a strain that simultaneously grows and produces. 
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4.3 Materials and methods 
4.3.1 Materials and Molecular Agents 
All plasmids used were constructed using Gibson assembly237 and all PCR fragments 
were amplified using Q5 polymerase from New England Biolabs (Ipswich, 
Massachusetts). Oligonucleotides were purchased from IDT (Leuven, Belgium). The 
plasmids and bacterial strains used in this study are listed in appendices A1 and A2. A 
list of primers for the creation of gene knockouts and a list of primers for the cloning of 
the expression plasmids are given in appendices A5 and A6, respectively. E. coli DH5α 
was used for plasmid cloning and propagation, while E. coli W was used for expression 
of the production plasmids and creation of gene knockouts. β-glucogallin was purchased 
from Carbosynth (Berkshire, UK). All other chemicals used were purchased from Sigma 
Aldrich (Germany) unless otherwise indicated. 
4.3.2 Creation of the production plasmids 
The plasmids for the production of glucosylated compounds were constructed by 
cloning the genes of interest (sucrose phosphorylase from Bifidobacterium adolescentis 
(BaSP), glucosyltransferase from Vitis vinifera (vvGT2), and glucose-1-phosphate 
uridylyltransferase from E. coli (galU) and Bifidobacterium bifidum (ugpA)) first in a 
pCX-Kan expression vector with medium-strength constitutive promoter P22 
originating from a previously constructed promoter library59,156,258. This resulted in the 
corresponding pCX-Kan-P22-gene (pBaSP, pVvGT2, pUgpA and pGalU) plasmids. The 
gene accession numbers are listed in appendix A3 and an overview of the total cloning 
strategy is given in appendix A7. The genes with P22 promoter were then amplified and 
ligated following Gibson assembly237 into an amplified pUC57 backbone containing 200 
bp homologous sequential linkers (L4 to L7) flanking the insert, which permits rapid 
assembly and switching of genes. Assembly of the amplified L4-P22-BaSP-L5 insert and 
pCX-Kan backbone led to the construction of pCX-Kan-L4-P22-BaSP-L5. This plasmid 
was used for the consequent (homology based) stitching and creation of the final 
constitutive production plasmids pCX-Kan-L4-P22-BaSP-L5-P22-VvGT2-L6 
(pBaSP/VvGT2) and pCX-Kan-L4-P22-BaSP-L5-P22-VvGT2-L6-P22-GalU/UgpA-L7 
(pBaSP/VvGT2/GalU or pBaSP/VvGT2/UgpA). 
4.3.3 Creation of the E. coli W mutant strains 
All E. coli W knockout mutants were created by using the one step deletion method of 
Datsenko and Wanner.236 The genes cscAR, pgm, agp, ushA and glgC were subsequently 
deleted. Each knockout mutant was transformed with the plasmid pCX-Kan-P22-BaSP 
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(pBaSP) for the reintroduction and evaluation of the sucrose metabolism and with the 
plasmids pBaSP/VvGT2, pBaSP/VvGT2/GalU or pBaSP/VvGT2/UgpA for assessing the 
production potential of glucosylated compounds. E. coli W was transformed with pCX-
Kan-P22-VvGT2 (pVvGT2) to compare production between the engineered strains and 
the wild type (WT). 
4.3.4 Media 
Luria Broth (LB) medium consisted of 10 g L-1 tryptone peptone (Difco, Belgium), 5 g L-1 
yeast extract (Difco) and 10 g L-1 NaCl and was autoclaved for 21 min at 121 °C. 
 
Minimal medium contained 2 g L-1 NH4Cl, 5 g L-1 (NH4)2SO4, 3 g L-1 KH2PO4, 7.3 g L-1 
K2HPO4, 8.4 g L-1 MOPS, 0.5 g L-1 NaCl, 0.5 g L-1 MgSO4 ∙ 7H2O, 20 g L-1 sucrose, 1 mL L-1 
trace element solution and 100 µL L-1 molybdate solution. The medium was set to a pH 
of 7 with 1 M KOH and filter sterilized. 
 
Trace element solution consisted of 3.6 g L-1 FeCl2 ∙ 4H2O, 5 g L-1 CaCl2 ∙ 2H2O, 1.3 g L-1 
MnCl2 ∙ 2H2O, 0.38 g L-1 CuCl2 ∙ 2H2O, 0.5 g L-1 CoCl2 ∙ 6H2O, 0.94 g L-1 ZnCl2, 0.0311 g L-1 
H3BO4, 0.4 g L-1 Na2EDTA ∙ 2H2O, 1.01 g L-1 thiamine ∙ HCl. The molybdate solution 
contained 0.967 g L-1 Na2MoO4 ∙ 2H2O. 
 
Production medium has the same composition as the minimal medium but the pH is set 
to 6.5 and MES buffer is used instead of MOPS. Gallic acid (0.5 g L-1) was added as 
acceptor and 1 g L-1 citric acid to prevent medium auto-oxidation. 
4.3.5 Growth in shake flasks 
E. coli W mutant precultures were grown in 50 mL glass tubes containing 5 mL LB 
medium with the necessary antibiotics (50 μg mL-1 kanamycin) for maintenance and 
selection of the various plasmids used. Cultures were grown for 16 h at 37 °C and 200 
rpm and used for the 2 % inoculation of 100 mL minimal medium in 500 mL shake 
flasks. Experiments for glucogallin production were carried out in production medium. 
Glucosylation of various hydroxycinnamic acids (HCA) and hydroxybenzoic acids (HBA) 
was evaluated by adding 1 g L-1 of these compounds to the minimal medium. All shake 
flask cultures were grown at 37 °C and 200 rpm and samples were collected at regular 
intervals for the measurement of extracellular metabolites and optical density at 600 nm 
(OD600) using a Jasco V-630Bio spectrophotometer (Easton, UK). 
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4.3.6 Growth in bioreactors 
To evaluate the metabolic parameters, 100 mL cultures were grown overnight on 
minimal medium and used to inoculate (5 %) Biostat B+ reactors (Sartorius Stedim, 
Germany) with a 1 L working volume. The fermentor culture was maintained at 37 °C 
and 4 M of KOH and 0.5 M H2SO4 were used to keep the pH to 6.8. The gas flow was fixed 
at 1 vvm and the agitation ranged from 200 to 1200 rpm as function of the dissolved 
oxygen (kept above 40 %). Off-gas analysis (EGAS-1, Sartorius AG, Germany) provided 
on-line measurement of O2 and CO2. Growth experiments were performed in minimal 
medium without MOPS buffer and all parameters described above were monitored using 
MFCS/win software (Sartorius AG). 
4.3.7 Product analysis and quantification 
Culture samples containing HCA or HBA were primarily analyzed by TLC on Silica gel 60 
F254 precoated plates (Merck, Germany). The plates were run in a solvent system of ethyl 
acetate/butanone/formic acid/water in a volume ratio of 5:3:1:1 in a closed TLC 
chamber and were developed using standard visualization techniques or agents: UV 
fluorescence (254 nm) or by staining with 10 % (v/v) H2SO4 and subsequent charring. If 
no glucoside standard was available, acceptor and product spot intensities were 
processed and quantified using ImageJ259. β-glucogallin and gallic acid were 
simultaneously detected with the method of Takemoto et al.260 using a Prevail Organic 
Acids column (5 µm, Grace, USA) at 30 °C and a Varian HPLC system (Agilent 
technologies, California). Sucrose, fructose and glucose were detected using an X-bridge 
Amide column (35 μm, Waters, USA) at 35 °C. The mobile phase consisted of a mixture of 
75 % acetonitrile, 24.8 % water and 0.2 % triethylamine at a flow rate of 1 mL min-1. The 
accumulation of extracellular glucose 1-phosphate (glc1P) was analyzed by an 
enzymatic assay as previously described by De Bruyn et al.156  
4.3.8 Purification and structural elucidation of compounds 
Glucosylated compounds were purified from the culture broth using centrifugation of 
the culture broth (10 min at 5000 × g) and adding 1.5 g of activated carbon to 50 mL of 
the supernatant. After 3 min of adsorption, the mixture was poured onto a glass sintered 
filter and subsequently washed with 300 mL of water to remove salts and 
monosaccharides, 120 mL of 10 % EtOH to remove disaccharides, 90 mL of 20 % EtOH 
and 60 mL of 30 % EtOH. The HBA or HCA glucose esters were eluted with 3 times 30 
mL of 50 % EtOH. Ethanol was removed from the purest fractions by evaporation at 40 
°C and the samples were freeze dried (Christ Alpha 1-4 LSC Freeze Dryer, SciQuip, UK). 
The only exception to this procedure was the glucoside of syringic acid which 
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crystallized at 4 °C and was filtered off and washed with cold water. 1H NMR (300 MHz) 
and 13C NMR (75 MHz) spectra were run with a Bruker Avance III 400 MHz 
spectrometer (Bruker, Germany) at room temperature. The compounds were diluted in 
deuterated water, DMSO or acetone, quoted in parts per million (ppm) and referenced to 
tetramethylsilane (TMS, δ=0) or the appropriate residual solvent peak. The NMR spectra 
of novel glucosides are listed in appendix A12.  
4.3.9 Mathematical methodologies 
SigmaPlot (Systat Software, California) was used for fitting the data and calculation of 
standard errors. Maximal specific growth rate (µmax) was calculated using a three 
parameter exponential growth model. Biomass yield (YXS) and product yield (YPX) were 
calculated as slopes of a linear regression model. Specific production rate (qp) was 
obtained as the product of YPX and µ during the exponential growth phase. 
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4.4 Results and discussion 
4.4.1 Introduction 
In this work, we describe the transformation of E. coli W into an efficient glucosylation 
platform for phenolic acids. E. coli W was the bacterial host of choice since it is a safe, 
fast-growing strain261 that has a good tolerance for acidic conditions and osmotic 
stress262. Furthermore, it can be easily grown to high cell density cultures263 and 
uniquely possesses exotic gene clusters to cope with a wide variety of aromatic 
compounds261, thus rendering it a very attractive production host for industrial 
purposes. A detailed overview of the engineering strategy, which couples production to 
growth, is shown in Figure 4.1 and will focus on the interesting class of phenolic acids as 
target for glucosylation. At first, production of β-glucogallin (BGG, 1-O-galloyl-β-D-
glucose), a glucose ester derived from gallic acid, was chosen as a proof of concept since 
it has many beneficial properties besides a highly effective and stabile antioxidant. BGG 
is commonly found in oak (Quercus sp.)264 as the first step towards gallotannin 
biosynthesis265 and is proven to be a therapeutic lead to treat diabetic complications41. 
Furthermore it exhibits antibacterial activity266 and is an efficient UV-
photoprotectant267. In the following sections, an overview will be given of the various 
steps of the metabolic engineering strategy to transform E. coli W in a platform organism 
for in vivo glucosylation of gallic acid and other phenolic acids. 
4.4.2 Altering the sucrose metabolism of E. coli W to efficiently generate glc1P 
Sucrose is an industrially important and sustainable carbon source for microbial 
fermentation. In this context, E. coli W recently gained attention since it is a fast-growing 
strain that can utilize sucrose due to the presence of the cscBKAR regulon.261 This 
regulon, shown in Figure 4.2, consists of a sucrose permease (cscB), a fructokinase 
(cscK) and a sucrose hydrolase (cscA). cscR, however, codes for a protein that represses 
expression of these sucrose utilization genes at low sucrose concentrations.268 The cscA 
and cscR genes were simultaneously inactivated with the method of Datsenko and 
Wanner236 resulting in an E. coli W ΔcscAR mutant which is unable to grow on sucrose as 
sole carbon source. Transforming this strain with plasmid pBaSP, which constitutively 
overexpresses a sucrose phosphorylase from Bifidobacterium adolescentis137, restored 
growth on sucrose when grown on minimal medium.  
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Figure 4.2: Metabolic representation of the cscBKAR regulon of E. coli W and the various 
reactions it codes for. A comparison is shown between the native sucrose metabolism (A) 
and the introduction of an alternative sucrose metabolism by deleting cscAR and 
overexpressing the sucrose phosphorylase BaSP (B). 
 
Both E. coli W WT and ΔcscAR + pBaSP were cultured and characterized on 1-L 
bioreactors to ensure no limitation of oxygen. The obtained growth profiles and 
parameters (Figure 4.3 and Table 4.1) show that the WT strain reaches the upper limit 
of growth rates reported in E. coli W under controlled conditions261,269. The maximal 
specific growth rate µmax of the ΔcscAR + pBaSP mutant on the other hand was half the 
one of the WT strain. However, when the sucrose concentration fell below 10 g/L, the 
WT slowed down and started to accumulate equimolar amounts of fructose and glucose 
(not shown), which were rapidly cometabolized when the sucrose concentration fell 
below 3 g/L. This is caused by the repression effect of CscR at low sucrose 
concentrations and has been described by Nielsen and coworkers268. Conversely, the 
ΔcscAR + pBaSP mutant displays a more constant growth. 
 
Table 4.1: Kinetic parameters of WT and ΔcscAR + pBaSP grown on bioreactor scale in 
minimal medium. 
 WT ΔcscAR + pBaSP 
µmax (h-1) 0.92 ± 0.08 0.48 ± 0.04 
CDW/OD 0.284 ± 0.001 0.249 ± 0.005 
YXS (g/g) 0.33 ± 0.02 0.29 ± 0.05 
qS (g/g/h) 2.68 ± 0.03 1.75 ± 0.31 
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In addition, Table 4.1 shows a comparable biomass yield (YXS) for both strains. This 
proves the simultaneous metabolization of fructose/glucose for the WT, and 
fructose/glc1P for the ΔcscAR + pBaSP strain, respectively. The ΔcscAR + pBaSP mutant 
initially accumulated 1.8 g/L of fructose, which was subsequently cometabolized with 
sucrose as depicted in Figure 4.3. This fructose overflow is due to the constitutive 
expression of BaSP, resulting in the continuous splitting of sucrose into intracellular 
glc1P and fructose. Since extracellular glc1P levels are much lower, this indicates that 
glc1P is the preferred substrate and is rerouted towards glycolysis. The extracellular 
fructose is reconsumed by action of a phosphotransferase system (PTS) for fructose270, 
thus bypassing the fructokinase CscK. After consumption of fructose, extracellular glc1P 
(absent in the WT) started to increase, reaching a maximal concentration of 0.58 g/L. 
Finally, all glc1P was metabolized and invested as biomass. 
4.4.3 Coupling growth and production 
Due to the consumption of glc1P, which is intended as a precursor for the formation of 
UDP-glc and not for growth, various genes need to be knocked out as depicted in Figure 
4.1. The major biochemical routes directing glc1P towards the formation of biomass are 
encoded by the genes pgm, agp and glgC, and the enzymatic reactions they code for are 
shown in Appendix A4. Pgm is the key switch for converting glc1P into glucose 6-
phosphate, rerouting it towards glycolysis, while GlgC forms the precursor ADP-glucose 
for the synthesis of the storage metabolite glycogen.271 Agp is an acid glucose-1-
phosphatase which is believed to be the main scavenger for glc1P in E. coli.271 Deleting 
these genes preserves glc1P for UDP-glc formation, hence improving the glucosylation 
capacity. However, to prevent degradation of accumulated UDP-glc, also ushA, which 
encodes a UDP-sugar hydrolase, was knocked out. The resulting mutant (sGLC) strains 
are shown in Table 4.2 and were transformed with pBaSP, to gain more insight in the 
substrate flow and biomass yield. 
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Figure 4.3: Culture growth and sugar utilization of E. coli W WT (top) and ΔcscAR + pBaSP 
(bottom) grown in minimal medium on bioreactor scale. Cell dry weight (●) was 
measured together with the extracellular sugars: fructose (▲), glucose 1-phosphate (△) 
and sucrose (■).  
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Table 4.2: Overview of the E. coli W mutants used in this chapter. Detailed information on 
the deleted genes is given in Appendix A2. 
Strain Code 
E. coli W ∆cscAR sGLC1 
E. coli W ∆cscAR ∆pgm sGLC2 
E. coli W ∆cscAR ∆pgm ∆agp sGLC3 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA sGLC4 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC sGLC5 
 
The transformants were grown and characterized on shake flasks in minimal medium. 
All strains exhibited growth on sucrose with a µmax comparable to sGLC1 + pBaSP as 
shown in Figure 4.4, except for sGLC5 + pBaSP which grew significantly faster (µmax = 
0.62 ± 0.02). Interestingly, mutants sGLC1 to 3 displayed a similar overall biomass yield 
(YXS ≈ 0.31 g/g), indicating that glc1P was still metabolized in spite of the agp gene 
deletion. Strains sGLC4 and sGLC5 displayed a significantly lower YXS of 0.26 ± 0.01 g/g, 
illustrating an altered metabolism. This could be explained by deletion of a futile cycle 
catalyzed by UshA, which hydrolyzes UDP-glc again into glc1P and by inhibiting (ΔglgC) 
glycogen formation, thus preventing glc1P to re-enter glycolysis during glycogen 
degradation. However, extracellularly accumulated glc1P during growth of sGLC5 on 
sucrose was again metabolized when the strain entered the stationary phase (data not 
shown).  
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Figure 4.4: Comparison of the maximal specific growth rates µmax (black) and calculated 
biomass yields YXS (gray) of the sGLC transformants expressing BaSP when grown on 
minimal medium. Error bars represent the standard deviation (n = 3). 
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This observation suggests that other sugar phosphatases are present besides Agp. 
Possible alternative candidates for glc1P degradation are the sugar phosphatases YihX 
and YidA, which were first discovered in a high-throughput screen of purified proteins 
of the haloacid dehalogenase (HAD)-like hydrolases.272 To verify this, the putative genes 
yihX and yidA were additionally knocked out in sGLC5. These mutants were also 
transformed with pBaSP, resulting in the strains sGLC5 ∆yihX + pBaSP and sGLC5 ∆yidA 
+ pBaSP. Both strains were cultured in minimal medium and exhibited a decreased µmax 
of 0.42 ± 0.02 h-1 and 0.45 ± 0.01 h-1, respectively. However, the observed biomass yields 
(0.25 ± 0.02 g/g and 0.26 ± 0.03 g/g) were not significantly different from sGLC5 + 
pBaSP and glc1P was equally degraded at the end of the exponential phase. Despite 
these parallel putative sugar phosphatase knockouts, the metabolism was not fully split. 
It is possible that both phosphatases complement each other so that a double knockout 
would truly prevent glc1P degradation. In addition, two other poorly studied enzymes 
may divert glc1P towards glycolysis. A first candidate is the phosphoglucosamine 
mutase (GlmM) enzyme, which has proven to effectively catalyze the formation of 
glucose 6-phosphate from glc1P in vitro, albeit at a rate 1400-fold lower than that 
observed with its natural substrate glucosamine 1-phosphate (glc1NP).273 In addition, it 
was shown that expression of glmM could partially complement a Δpgm mutant strain 
when grown on galactose, indicating that GlmM catalyzes at least to some extent the in 
vivo interconversion of glucose phosphate isomers.274 However, since the Km of GlmM 
towards glc1P is 10-fold higher than towards glc1NP273, the role of GlmM as substitute 
for Pgm should not be overestimated. A second and more interesting candidate is the β-
phosphoglucomutase YcjU, which presumably catalyzes the interconversion of β-glucose 
1-phosphate (βglc1P) to β-glucose 6-phosphate. It was observed that overexpression of 
ycjU in E. coli led to a higher glucoside production than combined overexpression of 
pgm/galU when grown on glucose.275 However, it is very unlikely that GalU (or other 
nucleotidyltransferases) would exhibit anomeric flexibility as this is highly conserved in 
nature.207 A plausible explanation is either a spontaneous interconversion of αglc1P into 
βglc1P or the existence of a mutatrotase in E. coli, thus rerouting glc1P (mediated by 
YcjU) towards glycolysis. 
4.4.4 Optimization of production medium for glucosylation of gallic acid 
Prior to evaluating the production potential of the various developed mutants, the 
ability of the WT strain to produce BGG was investigated. To this end, the WT was 
transformed with the constructed plasmid pVvGT2, which constitutively expresses a 
glucosyltransferase from Vitis vinifera. VvGT2 catalyzes the formation of 1-O-acyl-
glucose esters of phenolic acids in vitro, with gallic acid (GA) as the preferred 
substrate.276 As a preliminary test, 1 g/L of GA was added to minimal medium and 
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inoculated with the transformant. After 16 h of growth, the supernatant was 
investigated using TLC and a spot was observed with the same retention as BGG (Rf = 
0.5). The compound was purified by preparative TLC and its structure was confirmed by 
both NMR and MS (687 m/z as a [2M+Na]), thus proving the likelihood of in vivo BGG 
production. 
 
On the other hand, the medium had acquired a dark green to off-brown color after 16h 
of incubation due to auto-oxidation of GA. This is likely due to Fe2+ present in the 
minimal medium which is complexated by GA, causing a significant drop in the reduction 
potential with rapid oxidation into Fe3+ (in the presence of O2) as a result.277 At pH 6, 
Fe2+ is typically complexated by 2 or 3 gallic acid ligands generating a dark blue complex 
(λmax from 542 to 561 nm) and an oxygen radical species277 initiating degradation of 
other GA molecules. Since the optical cell density is measured at 600 nm, this 
discoloration greatly interferes with a correct estimation of the growth characteristics. 
To minimize these undesirable effects, different GA concentrations were tested in 
minimal medium at different pH levels as well as the addition of citric acid as a chelating 
agent for Fe2+. After 16 h, the absorbance at 400 nm was evaluated. Media containing 5 
g/L GA showed significantly more discoloration compared to 0.5 g/L GA (p=0.008, data 
not shown) and lowering the pH, with addition of citric acid, proved to be the best 
composition as shown in Figure 4.5.  
pH = 7 pH = 6.5 pH = 6
O
D
4
0
0
 (
-)
0,0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
0 g/L citric acid
1 g/L citric acid
2 g/L citric acid
 
Figure 4.5: Optical density at 400 nm of different minimal media containing 0.5 g/L of GA 
at pH=7, 6.5 and 6 and addition of 1 or 2 g/L of citric acid (C) after 16 h. 
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Since GA is a phenolic acid with reported antimicrobial activity against E. coli (ATCC 
25922)278,279, a final experiment was conducted for the determination of the maximal 
specific growth rate at different gallic acid concentrations. The results are shown in 
Figure 4.6 and indicate no significant inhibition of growth up to 10 g/L. This in contrast 
to a minimal inhibitory concentration reported of 1 g/L in E. coli UB1005279, which 
illustrates the adaptation of E. coli W to phenolic compounds. Therefore, the 
composition of the production medium was defined as minimal medium put on pH 6.5 
with 1 g/L of citric acid and 0.5 g/L of GA. MES was used instead of MOPS buffer, since 
its buffer ranges from 5,5 to 6,7. Although pH 6 gave less discoloration, it is less close to 
the physiological optimum (pH 7). E. coli W + pVvGT2 was able to produce BGG at a 
specific rate of 14.7 ± 4.5 mg/g CDW/h when grown in this production medium and was 
used as a reference for the engineered strains described hereafter. 
 
 
 
Figure 4.6: Maximal specific growth rates of E. coli W at different concentrations of gallic 
acid in minimal medium pH 6.5 and citric acid. 
 
4.4.5 Production of β-glucogallin 
In order to merge the effects of a split metabolism and BGG production, various 
production plasmids were constructed and are schematically shown in Table 4.3. The 
use of a constitutive P22 promoter sequence59 results in uniform expression of the genes 
and does not require expensive inducers like IPTG. Furthermore, it is very difficult to 
fine-tune multiple genes carrying inducible promoters, since most expression systems 
exhibit an all-or-nothing effect.59 
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Table 4.3: Schematic representations of the gene organization in each production plasmid 
used in this chapter. P22: constitutive promoter, Ln: homologous sequential linker, 
hairpin: terminator sequence. Gene function is described in Appendix A4. 
Plasmid name Genetic diagram 
pVvGT2 
            
VvGT2
P22
 
pBaSP/VvGT2 
P22 P22
L6VvGT2BaSP L5L4
 
pBaSP/VvGT2/GalU 
L6VvGT2BaSP L5L4 L7GalU
P22 P22 P22
 
pBaSP/VvGT2/UgpA 
L6VvGT2
P22
BaSP L5L4 L7UgpA
P22 P22
 
 
To present a first and fair comparison, all sGLC strains were transformed with the 
pBaSP/VvGT2 plasmids and grown on production medium. When the cultures reached 
an OD of 1, 0.5 g/L of GA was added and production of BGG was measured. The 
calculated specific production rates are shown in Figure 4.7 and unexpectedly depict a 
higher productivity for the WT compared to sGLC1 to sGLC3. Deletion of ushA in sGLC4 
however, coding for a promiscuous UDP-sugar hydrolase, resulted in a 10-fold 
productivity increase. This can be explained by prevention of UDP-glc hydrolysis, which 
gives rises to an enlarged UDP-glucose pool. Although the precise regulation 
mechanisms of UshA are not known, its deletion has a profound effect regarding in vivo 
glucosylation reactions. Indeed, a ΔushA mutant is commonly used for the in vivo 
glycosylation of compounds104,108 though a comparison between WT and this mutant 
lacks in these studies. Additionally, deletion of glgC did not significantly improve the 
productivity compared to sGLC4, but showed less biological variation. 
 
Up to this point, the UDP-glucose pool in these strains is only formed by action of the 
native GalU enzyme. Therefore, all sGLC strains were transformed with either the 
constructed pBaSP/VvGT2/GalU or pBaSP/VvGT2/UgpA plasmid. These plasmids 
constitutively co-express a UTP-glucose-1-phosphate uridylyltransferase (GalU or 
UgpA), thus ensuring the formation of UDP-glucose from the accumulated glc1P.240 Both 
GalU, native in E. coli, and UgpA from B. bifidum were studied, since the latter has been 
proven to exhibit a 7-fold higher activity in crude extracts (Chapter 3) and since the 
regulation of GalU is not fully understood. The transformants were again grown on 
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production medium in shake flasks and GA was added when the OD reached 1. 
Remarkably, sGLC2, sGLC4 and sGLC5 mutants containing pBaSP/VvGT2/GalU didn’t 
reach OD 1 within 24 h.  To  this  end,  only  the  growing  strains  were evaluated and are 
 
 
Figure 4.7: Comparison of WT + VvGT2 and sGLC strains expressing both BaSP and VvGT2, 
grown in production medium on shake flasks. Errors are standard errors (n=2). 
 
 
Figure 4.8: Evaluation of the specific productivity of the sGLC strains expressing 
BaSP,VvGT2 and a uridylyltransferase GalU or UgpA. Strains were grown on production 
medium on shake flasks. Errors are standard errors (n=2). 
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are depicted in Figure 4.8. When comparison was available, it was clear that UgpA led to 
a significantly higher production than GalU. Overexpression of UgpA in mutants sGLC1 
to sGLC3 significantly increased the BGG production on average by 2.7-fold, probably 
resupplying the UDP-glucose pool depleted by VvGT as hypothesized above. However, 
this was not visible in sGLC4 and sGLC5. Since sGLC5 + pBaSP/VvGT/UgpA showed in 
general a shorter lag phase and less biological variation when compared to sGLC4, this 
strain was used for further experiments. 
4.4.6 Screening for the glucosylation potential of different acceptors 
The used VvGT2 glucosyltransferase was first characterized by Terrier and coworkers276 
and showed broad in vitro activity towards many different hydroxycinnamic and 
hydroxybenzoic acids. The derived glucose esters of these hydroxycinnamic and 
hydroxy-benzoic acids are often applied as efficient acyl donors for the biosynthesis and 
thus decoration of numerous plant specialized metabolites.280,281 Attachment of phenolic 
residues to plant polymers such as arabinoxylan can induce crosslinking in cell walls via 
dehydrodimerization and is said to be the initiator for lignification in grasses.282 
Furthermore, these phenolic aglycons have proven to be powerful antioxidants. The 
trend in replacing synthetic antioxidant food additives with natural ones has boosted the 
search for biotechnological production alternatives with many success stories.62 
Addition of a sugar moiety to these phenolates can confer extra stability, improved 
solubility20 or even organ specific drug delivery26. Despite these attractive properties, 
efficient and economically viable production of these glucosides does not exist and relies 
on expensive chemical or enzymatic synthesis.265,283 
 
Due to the ability of the final production mutant (sGLC5 + pBaSP/VvGT/UgpA) to 
produce BGG in an efficient way with full conversion, various phenolic acceptors were 
screened for their glucosylation potential in vivo. The glucosylation mutant was grown in 
shake flasks containing 100 mL minimal medium with 1 g/L of acceptor mentioned in 
Table 4.4. The acceptor range tested by Terrier and coworkers276 was extended with 
vanillic, nicotinic, p-aminobenzoic, ferulic, cinnamic, isophthalic, terephthalic, 
cyclohexanecarboxylic and salicylic acid. The production and growth were monitored 
during 48 h and 13 out of 15 acceptors showed a spot on TLC with a retention 
comparable to BGG, except for salicylic and p-hydroxybenzoic acid. A newly developed 
and quick method based on activated carbon adsorption was developed as described in 
4.3.8 for the efficient separation of the putative glucose esters. Structures were 
elucidated and confirmed by NMR sprectoscopy as β-D-glucose esters of the added 
acceptors. The references to the spectra of previously reported glucosides are shown in 
Table 4.4 next to the acceptor name. To undoubtedly prove that the acceptors were 
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glucosylated solely through the action of VvGT2 and not by cryptic genes in E. coli W, the 
WT strain was grown in the same media. The supernatant was visualized on TLC after 
48 h and no spot with a retention comparable to the glucose esters was observed. 
 
Table 4.4: Glucosylation potential of the final production mutant towards various 
phenolic acids.  
Acceptor 
µmax 
(h-1) 
rp,max 
(mg/L/h) 
qp 
(mM/g CDW/h) 
Conversion a 
(%) 
caffeic acid 284 0.24 ± 0.02 171 ± 9 0.55 ± 0.02 100 
sinapic acid 283 0.22 ± 0.03 111 ± 6 0.53 ± 0.02 82 
protocatechuic acid 285 0.23 ± 0.05 183 ± 12 0.51 ± 0.04 100 
p-coumaric acid 284 0.23 ± 0.01 128 ± 5 0.55 ± 0.01 100 
vanillic acid 285 0.28 ± 0.03 126 ± 6 0.62 ± 0.03 100 
nicotinic acid 286 0.25 ± 0.04 34.6 ± 1.6 0.28 ± 0.02 45 
p-aminobenzoic acid 287 0.11 ± 0.02 137 ± 11 0.63 ± 0.03 100 
ferulic acid 283 0.25 ± 0.03 166 ± 8 0.54 ± 0.03 100 
cinnamic acid 288 0.13 ± 0.02 75.7 ± 4.5 0.45 ± 0.02 47 
isophthalic acid 0.19 ± 0.03 84.1 ± 6.3 0.62 ± 0.05 100 
terephthalic acid 0.23 ± 0.02 89.7 ± 4.9 0.69 ± 0.02 100 
cyclohexanecarboxylic acid 0.11 ± 0.02 144 ± 13 0.58 ± 0.04 100 
syringic acid 285 0.23 ± 0.02 160 ± 8 0.55 ± 0.02 100 
salicylic acid 0.03 ± 0.02 - - - 
p-hydroxybenzoic acid 0.21 ± 0.02 - - - 
a Maximal conversion is expressed as mM glucoside/mM acceptor added after 48 h hours 
 
Apparently the potential of VvGT2 is as broad in vivo as it is in vitro, and may be 
explained by the similarity in the conjugated system of hydroxycinnamic and 
hydrobenzoic acids. The newly tested nicotinic acid showed 45 % conversion after 48 h, 
indicating the promiscuity towards a heterocyclic aromatic ring. Remarkably, VvGT2 
also showed a high activity towards cyclohexanecarboxylic acid, which was completely 
converted, proving that even aromaticity is no necessity for VvGT2. To our knowledge, 
the β-D-glucose esters of terephthalic, isophthalic and cyclohexanecarboxylic acid have 
not been described before and details about the 1H and 13C NMR spectra are shown in 
Appendix A12.  
 
To make a fair comparison of the glucosylation potential of the production strain 
towards various acceptors, the specific production rate qp was calculated and expressed 
in mM of glucoside/g CDW/h. Although there is a big difference in growth rate, probably 
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caused by toxicity of some compounds289, the calculated qp values are quite comparable 
with nicotinic acid as sole exception. The obtained profiles (Appendix A13) showed the 
coupling of growth to production, which results in a non-linear production rate. The 
rp,max shown is the maximal production slope during the growth phase. Interestingly, all 
acceptors could enter the E. coli cell and the glucose esters were subsequently secreted 
back into the medium. An explanation lies in the fact that E. coli W is the most versatile 
host in the degradation of aromatic compounds in comparison to E. coli B, C or K12.261 
Degradation routes are not necessarily a drawback since the associated gene clusters 
often express a promiscuous transporter. Table 4.5 shows the gene clusters responsible 
for the metabolization or transportation of compounds comparable to the acceptors 
investigated. The mechanisms of secretion of the glucosides are not known in E. coli W, 
but uptake of β-D-glucosides is often linked with cellobiose uptake (and degradation)290, 
which is encoded by the bgl regulon261. Interestingly, the bglX gene codes for a β-
glucosidase and has been shown to hydrolyze o-nitrophenyl-β-D-glucopyranoside.291 
Possible hydrolysis (decreasing spot intensity) due to this undesirable glucosidase was 
observed with production of protocatechuyl-glucose (data not shown).  
 
Table 4.5: Gene clusters and number of genes responsible for the metabolization or active 
transport of aromatic compounds in E. coli W.292 
Gene cluster Aromatische componenten # genes 
hpa 3- or 4- hydroxyphenylacetic acid (HPA) and 3,4-diHPA 11 
paa Phenylacetic acid 14 
mhp 3-hydroxyphenylpropionic and 3-hydroxycinnamic acid 8 
hca Phenylpropionic and cinnamic acid 5 
 
4.4.7 Productivity comparison with the WT strain 
To validate the engineering strategy which envisioned coupling growth and production 
for the glucosylation of various phenolic acids, the performance of the WT + pVvGT2 was 
compared to sGLC5 + pBaSP/VvGT2/UgpA. To this end, three representative compounds 
(caffeic, terephthalic and p-aminobenzoic acid) from different phenolic subclasses were 
added to minimal medium, whereafter the growth and production of the WT + pVvGT2 
were followed up over time. The growth and conversion profiles are shown in Appendix 
A13, clearly illustrating the improved glucosylation potential of the engineered strain 
sGLC5 + pBaSP/VvGT2/UgpA. As depicted in Figure 4.9, the specific productivity (qp) 
increased 3.5 to 35-fold compared to the WT, and all 3 acceptors were fully converted 
within 48 h. Expression of VvGT2 in the WT strain probably rapidly consumes the 
intracellular UDP-glc pool, which is not as efficiently regenerated as in the engineered 
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strain. Furthermore, production is linear over time and continues in the stationary 
phase, thus resembling a bioconversion process.  
gallic caffeic terephthalic p-aminobenzoic
q
p
 (
m
M
 a
cc
ep
to
r/
g 
C
D
W
/h
)
0,0
0,2
0,4
0,6
0,8
100 %
100 %
100 %
100 %
32 %
4 % 2 %
21 %
 
 
Figure 4.9: Comparison of the specific productivities qp between the WT + pVvGT2 (black) 
and the final production strain sGLC5 + pBaSP/VvGT/UgpA (gray). The conversion of the 
added acceptor after 48 h of incubation is shown above the bars.  
 
When the created platform is compared to other reported in vivo processes for the 
glucosylation of specialized metabolites, the importance of engineering UDP-glc 
formation becomes clear. All processes display glucoside production rates between 
0.001 and 0.01 g/L/h, which is at least a factor 10 to 100 lower than our developed 
process. As a result, most reported glucoside titers are around 100 mg/L (Table 2.1), 
with 500 mg/L of vanillin 4-O-glucoside95 and 250 mg/L of arbutin114 as notable 
exceptions. Moreover, these systems mostly use expensive growth media (TB, LB) and 
enzyme inducers to obtain proper glucosylation. Strains with an ushA deletion107,108,110 
generally show a 2-fold increase in glucoside production, yet this effect is less significant 
than the data we obtained, due to indirect glc1P generation from glucose via the 
bottleneck enzyme Pgm. Despite the possibilities of this novel in vivo platform, 
economic feasibility and large-scale production should be evaluated. Both on strain level 
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(complete split of the metabolism) and process level (fed-batch high cell density 
fermentations and downstream processing), more research will be needed to fully 
optimize this process. Furthermore, glucosylation of (other) acceptors or increasing 
their concentration could give rise to issues regarding toxicity, low solubility, transport 
or by degradation or metabolization of the acceptors by the host. This would require 
tailor-made solutions on a strain level, by deleting unwanted side reactions or enhancing 
transport. Toxicity on the other hand can be countered by controlled feeding, continuous 
extraction of the glucoside from the broth or adaptive evolution of the strain. Moreover, 
the rationale of the split metabolism is not restricted to E. coli W and can be effectively 
applied to other industrial hosts. 
4.5 Conclusions 
In this contribution the systematic creation and evaluation of a glucosylation platform in 
the form of an engineered E. coli strain is described. To this end, the existing sucrose 
metabolism of E. coli W was deleted (ΔcscAR) and successfully replaced by 
overexpressing a sucrose phosphorylase (BaSP). In this way, the released fructose is 
used as a carbon source for growth and glucose 1-phosphate as a precursor for UDP-
glucose. Through specific gene deletions (pgm, agp, ushA and glgC), the organism could 
effectively channel glucose 1-phosphate to UDP-glucose, which was consumed by the 
overexpressed glucosyltransferase (VvGT2) from Vitis vinifera. This enabled the final 
production strain to efficiently glucosylate gallic acid in vivo, yielding the interesting 
glucose ester β-glucogallin at a specific production rate (qp) of 93.1 ± 9.9 mg/g CDW/h. 
Due to the promiscuity of VvGT2, the created strain could easily convert 14 other 
phenolic acids into their corresponding glucose esters (up to 100 % conversion), 
resulting in three new-to-nature glucosides. The engineering strategy which coupled 
production to growth proved to be very effective as the qp’s were up to 35-fold higher 
when compared to the wild type strain. This novel glucosylation approach could 
overcome existing economic hurdles and pave the way for large-scale production of 
glycosides. 
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5.1 Abstract 
Flavonoids are bio-active specialized plant metabolites which mainly occur as different 
glycosides. Due to the increasing market demand, various biotechnological approaches 
have been developed which use Escherichia coli as a microbial catalyst for the 
stereoselective glycosylation of flavonoids. Despite many metabolic engineering efforts, 
most processes still display low production rates and titers, thus rendering them 
unsuitable for large-scale applications. In this contribution, we expanded a previously 
developed in vivo glucosylation platform in E. coli W, into a strain for galactosylation and 
rhamnosylation of the flavonol quercetin. The main rationale of the novel metabolic 
engineering strategy relied on the introduction of an alternative sucrose metabolism in 
the form of a sucrose phosphorylase, which divided sucrose into fructose for growth and 
glc1P as precursor for UDP-glucose.  Due to the pivotal role of UDP-glucose, 
overexpression of interconverting enzymes galE and MUM4 ensured the formation of 
both UDP-galactose and UDP-rhamnose, respectively. By coupling this in vivo UDP-sugar 
formation with a flavonol galactosyltransferase (F3GT) and rhamnosyltransferase 
(RhaGT), 0.94 g/L hyperoside (quercetin 3-O-galactoside) and 1.12 g/L quercitrin 
(quercetin 3-O-rhamnoside) could be obtained, respectively. These strains, effectively 
coupling growth and production, also showed activity towards other promising dietary 
flavonols like kaempferol, fisetin, morin and myricetin. Finally, the flexibility of the 
galactosylation platform to produce specialty oligosaccharides from lactose was also 
assessed. Replacing F3GT with a lipo-oligosaccharide galactosyltransferase (LgtC), 
enabled the strain to efficiently produce 2.8 g/L of globotriose (α-galactosyl-1,4-lactose).  
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5.2 Introduction 
Flavonoids are a large and diverse class of specialized plant metabolites which have 
attracted much attention in recent years because they have various beneficial effects on 
human health. Among other, biological activities ranging from anticancer293 and 
antioxidant294 to anti-inflammatory295, antimicrobial296 and antiviral296,297 effects have 
been attributed to them. As a final step in their biosynthesis, flavonoids are often 
glycosylated which has a profound effect on their solubility, stability or bio-activity.13,20 
For example, the best studied flavonol quercetin predominantly occurs as different 
glycosides, which make up to 75 % of our daily flavonoid intake. Over 350 different 
quercetin glycoforms have been reported to date with varying pharmacological 
properties.298,299 In this context, hyperoside (quercetin 3-O-galactoside) and quercitrin 
(quercetin 3-O-rhamnoside) have gained a lot of attention as valuable products for the 
pharmaceutical industry. They are the major glycosides found in apple peels299,300 and 
are powerful antioxidants resulting in cytoprotective effects301-304. Both have shown to 
be promising antiviral agents by blocking replication of the influenza virus305 or 
inhibiting the viruses hepatitis B306 and SARS307. Furthermore, they have been attributed 
with anti-inflammatory29,308, antidepressant309,310, apoptotic311 and antifungal312 
activities, rendering them interesting therapeutics resulting in a steadily increasing 
market demand. 
 
To date, the majority of quercetin and its glycosides are extracted from plant material, 
which is generally a laborious and low-yielding process requiring many purification 
steps.313 In vitro plant cell cultures or engineered plants can be used to overcome the 
low yields and improve production70-72, however since metabolic engineering of plants 
is controversial and still in its infancy73, this approach is often restricted to small-scale 
production. Although chemical synthesis of quercetin (glycosides) has proven to be 
feasible314-316, stereo- or regiospecific formation of glycosidic linkages is often hampered 
by the presence of various reactive groups74. The need for many protecting and 
deprotecting steps75, the generation of toxic waste and a low atom-efficiency77 make 
these production processes not sustainable nor economically viable. 
 
As a result, the microbial production of specialized (secondary) plant metabolites has 
made an enormous progress in the last two decades.56 Advances in the fields of 
metabolic engineering and synthetic biology have accelerated the sustainable 
production of flavonoids61,62,317 in model organisms like Escherichia coli and 
Saccharomyces cerevisiae, rendering them in real microbial cell factories. Subsequently, 
strategies for the in vivo glycosylation of flavonoids have also been developed. These are 
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based on both the overexpression of specific glycosyltransferases, which transfer a 
sugar residue from an activated nucleotide sugar to a molecule in a stereo- and 
regioselective way, and the engineering or introduction of the targeted nucleotide sugar 
pathway. In this way, various quercetin glycosides have already been produced in E. coli 
such as the naturally occurring 3-O-glucoside102, 3-O-xyloside104 and 3,7-O-
bisrhamnoside106, or the new-to-nature quercetin 3-O-(6-deoxytalose)318. Despite these 
engineering efforts, the reported product rates and titers are still in the milligram range, 
rendering these microbial hosts unsuitable as industrial catalysts. In addition, since the 
developed strategies typically rely on bioconversion processes using resting cells, which 
require a growth phase to gain biomass with a subsequent production phase, it is 
difficult to improve the production rates or the active generation of the UDP-sugar 
involved. Furthermore, such systems often entail expensive growth media or the 
addition of enzyme inducers, making the overall process very costly. 
 
To tackle these problems, we previously developed an efficient platform for the 
glucosylation of small molecules in E. coli W.319 Through metabolic engineering, a 
mutant was created which couples production of glucosides to growth, using only 
sucrose as a cheap and sustainable carbon source. The rationale of the engineering 
strategy is depicted in Figure 5.1. Here, sucrose is split by a sucrose phosphorylase from 
Bifidobacterium adolescentis (BaSP) into fructose to be used for growth purposes and a 
glucose 1-phosphate (glc1P) as precursor for UDP-glucose (UDP-glc) formation. To 
impede the conversion of glc1P into biomass, the endogenous genes for 
phosphoglucomutase (pgm) and an acid glucose-1-phosphatase (agp) were knocked out. 
Glc1P is subsequently rerouted by overexpression of a uridylyltransferase from 
Bifidobacterium bifidum (UgpA) towards UDP-glc, whose metabolization is prevented by 
knocking out the UDP-sugar hydrolase (ushA) and the galactose operon (galETKM). This 
system can however easily be expanded towards other UDP-sugars such as UDP-
galactose (UDP-gal), UDP-rhamnose (UDP-rha) or UDP-glucuronate in view of the 
pivotal role of UDP-glc, which is an ideal starting point for the production of a large 
variety of UDP-sugars. In this contribution, the system’s flexibility is demonstrated by 
the possibility to galactosylate and rhamnosylate exogenously fed quercetin in E. coli W, 
yielding hyperoside and quercitrin, respectively.  
 
Unlike other systems, our engineered hosts display growth-coupled in vivo glycosylation, 
resulting  in  gram-scale  production of  hyperoside  and  quercitrin.  In  addition,  this  
novel approach can be used for the production of various other galactosides or 
rhamnosides. This  is of particular  interest  since rhamnosides  play an important role in  
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cell and tissue aging320 and galactosides are targeted towards the liver, making them 
interesting for site-specific drug delivery26. Harnessing the power of this glycosylation 
strategy into production strains of specialized metabolites will unlock new possibilities 
for the de novo production of glycosides from renewable resources. 
5.3 Materials and methods 
5.3.1 Materials and Molecular Agents 
All plasmids used were constructed using Gibson assembly method237 or CLIVA321. All 
PCR fragments were amplified using Q5 polymerase from New England Biolabs 
(Ipswich, Massachusetts). Oligonucleotides were purchased from IDT (Leuven, Belgium). 
The plasmids and bacterial strains used in this study are listed in appendices A1 and A2. 
A list of primers for the creation of gene knockouts/knockins and a list for the cloning of 
the expression plasmids are given in appendices A5 and A6, respectively. E. coli DH5α 
was used for plasmid cloning and propagation, while E. coli W was used for expression 
of the production plasmids and creation of gene knockouts and knockins. Globotriose, 
hyperoside, quercitrin, isoquercitrin, kaempferol and myricetin were purchased from 
Carbosynth (Berkshire, UK). All other chemicals used were purchased from Sigma 
Aldrich (Germany) unless otherwise indicated. 
5.3.2 Creation of the production plasmids 
First, the expression plasmid for the production of the galactosides hyperoside and 
globotriose were constructed as depicted in Appendix A9. The constitutive expression 
plasmid pCX-Kan-L4-P22-BaSP-L5-P22-VvGT2-L6-P22-UgpA-L7 (pBaSP/VvGT2/UgpA) 
constructed in Chapter 4 was used as a PCR template for the generation of the 
backbones. Plasmids pKan-L5-P22-LgtC-L6 (pLgtC) and pKan-L5-P22-F3GT-L6 (pF3GT) 
were synthesized by GeneArt® (Life Technologies) and used as PCR template for the 
inserts. LgtC was a C-terminal 25 amino acid truncation of the lgtC gene from N. 
meningitidis and the f3gt sequence from Petunia hybrida was codon optimized. The 
accession numbers and functions of all the genes used are listed in Appendices A3 and 
A4, respectively. Gibson or CLIVA assembly of backbones and inserts resulted in the 
construction of the production plasmids pCX-Kan-L4-P22-BaSP-L5-P22-LgtC-L6-P22-
UgpA-L7 (pBaSP/LgtC/UgpA) and pCX-Kan-L4-P22-BaSP-L5-P22-F3GT-L6-P22-UgpA-
L7 (pBaSP/F3GT/UgpA). These were subsequently used for the amplification of a 
pBaSP/LgtC or pBaSP/F3GT backbone. The galE and galE2 sequences were amplified 
from the genomic DNA of E. coli and Bifidobacterium bifidum, respectively, and inserted 
in a pUC-P22 backbone with linkers L4 and L5 flanking the gene as shown in Appendix 
A9. These intermediate pUC plasmids served as template for the amplification of the L4-
Chapter 5:  Building a versatile glycosylation platform 
80 
 
P22-gene-L5 fragment and were inserted using Gibson assembly into the backbones at 
the position of BaSP. This resulted in the final galactosylation plasmids pGalE/GT/UgpA 
and pGalE2/GT/UgpA, with GT either LgtC or F3GT. 
 
Plasmids for rhamnosylation were similarly constructed and are shown in Appendix 
A11. The plasmids pKan-L5-P22-RhaGT-L6 (pRhaGT) and pUC-L4-P22-MUM4-L5 
(pMUM4) were synthesized by GeneArt® (Life Technologies) and used as PCR template 
for the inserts. Sequences MUM4 and RhaGT (AtUGT78D1) from A. thaliana were codon 
optimized. pBaSP/VvGT2/UgpA was used for backbone amplification, which was 
subsequently used for a 3-pieces Gibson assembly with MUM4 and RhaGT, resulting in 
the rhamnosylation plasmid pCX-Kan-L4-P22-MUM4-L5-P22-RhaGT-L6-P22-UgpA-L7 
(pMUM4/RhaGT/UgpA).  
5.3.3 Creation of the E. coli W production mutants 
The overall E. coli W knockout mutants were created by using the one step deletion 
system of Datsenko and Wanner.236 The sGLC4 strain created in Chapter 4 was used as a 
starting point to delete the lacZYA operon. Subsequently, lacY was constitutively 
overexpressed by knocking in a truncated P22 promoter (Appendix A8). Subsequently, 
BaSP, with constitutive promoter P22, was knocked in flanked by L4 and L5 with 
constitutive promoter P22 at two different sites resulting in ΔmelA::L4-P22-BaSP-L5 and 
ΔglgC::L4-P22-BaSP-L5. The strategy is schematically shown in Appendix A10. L4-P22-
BaSP-L5 was amplified from its corresponding pUC vector and the homologous regions 
adjacent to melA and glgC were amplified from the gDNA of E. coli. Using built-in 
homologous overlaps, a 3-pieces Gibson assembly was carried out and the resulting 
mixture was used as a template for amplification. The obtained knockout/knockin linear 
DNA was used to transform sGLC1 and sGLYC1 (E. coli W ∆cscAR ∆pgm ∆agp ∆ushA 
ΔlacZYA::P22-lacY, Appendix A2) according to the Datsenko and Wanner protocol. The 
transformants were plated on minimal sucrose medium agar plates and grown 
overnight. Finally, the galETKM operon was deleted, yielding the final base strain E. coli 
W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔmelA::L4-P22-BaSP-L5 ΔgalETKM.  
 
These strains and the E. coli W wild type were transformed with the production 
plasmids described above, resulting in the galactosylation (sGAL) and rhamnosylation 
(sRHA) strains given in Table 5.1. Additionally, strains for the production of globotriose 
as a proof of concept were also created and denoted as sGLOBO. 
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Table 5.1: Overview of the quercetin galactosylation (sGAL) and rhamnosylation (sRHA) 
mutants used in this chapter. Strains for globotriose production are denoted as sGLOBO. 
Strain Code 
E. coli W + pF3GT sGAL1 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::P22-BaSP + pGalE/F3GT/UgpA sGAL2 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::P22-BaSP + pGalE2/F3GT/UgpA sGAL3 
E. coli W + pRhaGT sRHA1 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::P22-BaSP + pMUM4 + pRhaGT sRHA2 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::P22-BaSP + 
pMUM4/RhaGT/UgpA 
sRHA3 
E. coli W + pLgtC sGLOBO1 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY + pBaSP/LgtC/UgpA sGLOBO2 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalTKM + pBaSP/LgtC/UgpA sGLOBO3 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::P22-BaSP + pGalE/LgtC/UgpA sGLOBO4 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::P22-BaSP + pGalE2/LgtC/UgpA sGLOBO5 
5.3.4 Media 
LB medium and minimal (sucrose) medium are described in Chapter 4. Minimal medium 
agar plates with sucrose (50 g/L) had the same composition as minimal medium, but 
contained 15 g/L of agarose. The agarose and salts were autoclaved separately at 121 °C 
for 21 min. Sucrose was filter sterilized through a 0.22 µm corning filter (Fisher, 
Belgium) and heated for 1 min in a microwave oven at 800 W prior to mixing it with the 
warm agarose and salt solutions. 1 mL/L of mineral solution (described in Chapter 4) 
was sterilely added prior to pouring the plates. 
5.3.5 Growth in shake flasks and sampling 
E. coli W mutant precultures were grown in 5 mL LB medium with the necessary 
antibiotics (50 μg/mL kanamycin or carbenicillin) for maintenance and selection of the 
plasmids. The cultures were grown for 16 h at 37 °C and 200 rpm and used for the 2 % 
inoculation of 100 mL minimal sucrose or lactose medium in 500 mL shake flasks. For 
the production of hyperoside and quercitrin, quercetin was added to the minimal 
medium at a concentration of 0.15 or 1.5 g/L. Production of globotriose was achieved by 
adding lactose to the minimal medium. Growth conditions were the same as described in 
Chapter 4. Samples were taken at regular intervals from the broth and the supernatant 
was used for the analysis and quantification of sugars. For the simultaneous analysis of 
quercetin and its glycosides, 200 µL of the culture was collected and extracted with 800 
µL ethyl acetate. The organic layer was collected, evaporated in a SpeedVacTM vacuum 
concentrator (Thermo Fisher, USA) and dissolved in 200 µL of DMSO for HPLC 
quantification. 
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5.3.6 Growth in bioreactors 
The description of the bioreactor set-up and conditions is given in Chapter 4. Production 
experiments were performed on minimal sucrose medium without MOPS buffer and 
with the addition of quercetin or lactose as acceptors. 
5.3.7 Product analysis and quantification 
Culture samples were primarily analyzed by TLC on Silica gel 60 F254 precoated plates 
(Merck, Germany). All plates were run in a closed TLC chamber and developed using 
standard visualization techniques or agents: UV fluorescence (254 nm) or by staining 
with 10 % (v/v) H2SO4 and subsequent charring. The mobile phase for simultaneous 
detection of the various flavonols and corresponding glycosides consisted of an ethyl 
acetate:acetic acid:formic acid:water (100:11:11:27 v/v) mixture.322 If no flavonol 
glycoside standard was available, product spot intensities were processed and 
quantified using ImageJ259. For the detection of globotriose, lactose and sucrose, an 
isopropanol:water:NH4OH mixture was used in a 7:3:2 volume ratio.93 HPLC 
quantification of globotriose, lactose, sucrose, fructose and glucose was performed using 
an X-bridge Amide column (35 μm, Waters, USA) as described in Chapter 4. Quercetin, 
hyperoside, quercitrin and isoquercitrin were detected with the method described by 
Pandey et al.104 using a Varian HPLC system (Agilent technologies, California). Mass 
spectrometry for determination of the various flavonol glycosides was performed with a 
Micromass Quattro LC (McKinley Scientific, USA). Detection was performed in negative 
mode ESI-224 MS with a capillary voltage of 2.53 kV, a cone voltage of 20 V, cone and 
desolvation gas flows of 93 and 420 L/h, and source and cone temperatures of 150 and 
350 °C, respectively. 
5.3.8 Purification and structural elucidation of compounds 
Supernatant from the bioreactors was used for the purification of globotriose and 
quercetin glycosides. Purification of globotriose consisted of heating the supernatant 
first to denature the remaining proteins. Activated carbon was added (2 g to 50 mL) to 
the cleared supernatant and globotriose was separated and purified according to the 
method of Koizumi et al.93 Quercetin glycosides were extracted from the broth with an 
equal volume of ethyl acetate after which the organic layer was evaporated to dryness. 
The remaining products were dissolved in the solvent system described in 5.3.7 and run 
on a preparative TLC plate. The band containing hyperoside (Rf 0.53) or quercitrin (Rf 
0.75) was scraped off, extracted with ethyl acetate and evaporated to yield a bright 
yellow powder. Products were confirmed by NMR. Spectra were reported 
elsewhere.101,323,324 
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5.4 Results and discussion 
5.4.1 Using E. coli W as a host for in vivo glycosylation 
E. coli W is a fast-growing non-pathogenic strain which tolerates osmotic stress, acidic 
conditions, and can be cultured to high cell densities, making it an attractive host for 
industrial fermentations.261 Moreover, E. coli W is able to grow on sucrose as sole carbon 
source261, which is an emerging feedstock for the production of bio-products, due to its 
widespread availability and exceptional performance in life-cycle assessments.325 In the 
recent light of developing sustainable processes, E. coli W was selected as host for 
sucrose-based in vivo glycosylation reactions. Prior to the production of the glycosides 
hyperoside and quercitrin in E. coli W, the toxicity of the acceptor quercetin was 
evaluated. To this end, the wild type (WT) strain was grown on minimal sucrose 
medium containing different concentrations of quercetin ranging from 0.05 to 5 mM. No 
significant (p < 0.05) growth inhibition was observed and all cultures reached a biomass 
concentration of 1.28 ± 0.09 g CDW/L at the beginning of the stationary phase. This is in 
contrast to the gradual addition of quercetin to avoid (supposed) lysis of E. coli cells as 
reported by Kim et al.103  
 
To evaluate the potential of in vivo glycosylation, the WT strain was transformed with 
the plasmids pF3GT or pRhaGT, which constitutively expressed the flavonol 3-O-
galactosyltransferase from Petunia hybrida or the flavonol 3-O-rhamnosyltransferase 
from A. thaliana, respectively. In a first test, 5 mM of quercetin was added to minimal 
medium and inoculated with the new transformants WT + pF3GT (sGAL1) and WT + 
pRhaGT (sRHA1). After 16 h of growth, the supernatants of both cultures showed a new 
yellow product spot when analyzed on TLC. The spot of sGAL1 had the same retention 
time as a hyperoside standard (Rf = 0.5), which was subsequently purified and 
confirmed by both NMR and MS to be quercetin 3-O-galactoside. However, the product 
spot obtained after incubation of sRHA1 with quercetin had a different retention factor 
(Rf = 0.55) than the quercitrin standard (Rf = 0.74). Purification and analysis showed 
that the compound was isoquercitrin (quercetin 3-O-glucoside). As opposed to other 
reports on wild type E. coli strains expressing RhaGT, which simultaneously produced 
quercitrin (quercetin 3-O-rhamnoside) and iso-quercitrin101,170, no rhamnoside could be 
detected. Examination of the E. coli W genome revealed that the gene cluster responsible 
for the endogenous production of dTDP-rhamnose is not present261,271, which functions 
as an alternative rhamnosyldonor for RhaGT in E. coli B and K12 derivatives.101 
 
In a more detailed experiment, sGAL1 and sRHA1 were grown on minimal medium with 
two different concentrations (0.5 and 5 mM) of quercetin. Growth and glycoside 
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formation were monitored during 30 h. The final titers and specific productivities (qp) 
are shown in Figure 5.2. Remarkably, an increase in quercetin concentration resulted in 
a 2 to 3-fold increase in productivity and titer, indicating that quercetin transport is 
rate-limiting and crucial for efficient in vivo glycosylation. sGAL1 continuously produced 
hyperoside during the exponential phase, which is reflected in the relatively high 
specific productivity. On the other hand, sRHA1 only started to accumulate significant 
amounts of isoquercitrin at the end of the exponential phase. At this stage, the specific 
growth rate dropped from 0.35 ± 0.04 h-1 to 0.06 ± 0.01 h-1, which subsequently affected 
the corresponding productivities for isoquercitrin.  
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Figure 5.2: Comparison of the specific productivities (qp) and glycoside titers reached 
after 30 h of incubation of strains sGAL1 and sRHA1. Strains were grown on minimal 
medium containing 0.15 or 1.5 g/L (0.5 or 5 mM) of quercetin. The 3-O-galactoside and 3-
O-glucoside of quercetin were produced by sGAL1 and sRHA1, respectively. Errors 
represent standard deviations (n=2). 
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5.4.2 Construction of an advanced sucrose-based glycosylation strain 
We previously created an in vivo glucosylation platform by metabolic engineering of E. 
coli W which was able to simultaneously grow and produce various phenolic glucosides. 
This growth coupled production is a highly desirable feature for industrial fermentation 
processes since the need for a carbon source trade-off between growth and production 
is bypassed. The engineering strategy relies on the introduction of an alternative sucrose 
metabolism in the form of a sucrose phosphorylase from Bifidobacterium adolescentis, 
BaSP, which splits sucrose into fructose, to be used for growth, and glc1P as precursor 
for UDP-glc formation. The genes pgm, agp and ushA were deleted to prevent 
metabolization of glc1P and UDP-glc, thus dividing the routes for growth and 
production.  
 
In the basic glucosylation strain, BaSP is expressed on a medium-copy plasmid under 
control of a medium-strong constitutive promoter (P22). To allow a more modular 
assembly and variation of the genes encoding the glycosyltransferase and the UDP-sugar 
pathway, these were combined on a single plasmid, while BaSP was integrated in the 
genome of E. coli W. Chromosomal integration may be advantageous because of a 
significant increase in gene stability, no need for antibiotics to retain the plasmid and a 
reduced metabolic load. However, expression levels can differ between different 
integration sites due to structural differences such as supercoiling DNA regions326,327 
which can impair growth. Subsequently, two different DNA sites were assessed for BaSP 
integration, being melA and glgC, which encode an α-galactosidase and a glucose-1-
phosphate adenylyltransferase, respectively. To this end, an adapted knockin-knockout 
procedure for large DNA fragments was developed, which is schematically shown in 
Appendix A10. The BaSP sequence, under control of promoter P22 and flanked by 
homologous linkers L4 and L5, was first knocked in in E. coli W ΔcscAR to evaluate the 
effect of the integration site. This resulted in the respective E. coli W strains ΔcscAR 
ΔmelA::L4-P22-BaSP-L5 and ΔcscAR ΔglgC::L4-P22-BaSP-L5, which were grown on 
minimal sucrose medium and compared to strain ΔcscAR + pBaSP. The resulting 
maximal specific growth rates (µmax) are shown in Figure 5.3. The influence of the 
knockin locus on the expression of sucrose phosphorylase and on the maximal specific 
growth rate is clear. Interestingly, integration at the melA position resulted in a strain 
with a µmax which was not significantly different from its plasmid bearing equivalent. 
Given these results, the same knockin-knockout method was performed at the melA site 
to yield the final production base strain E. coli W ΔcscAR Δpgm Δagp ΔushA 
ΔlacZYA::P22-lacY ΔgalETKM ΔmelA::L4-P22-BaSP-L5 (sGLYC2, Appendix A2).  
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Figure 5.3: Effect of the chromosomal integration site on the expression of the knocked in 
BaSP gene, under control of promoter P22 and flanked by homologous linkers L4 and L5. 
Strains were grown in shake flasks (n=2) and the resulting µmax was compared to E. coli W 
ΔcscAR + pBaSP. 
 
5.4.3 Enhanced production of bio-active quercetin glycoforms 
In nature, UDP-glc serves a pivotal role in the formation of other UDP-sugars by using 
various interconverting enzymes.155 UDP-gal is generated by a UDP-glucose 4-epimerase 
(GalE), while UDP-rha synthesis is catalyzed by a UDP-rhamnose synthase (MUM4). GalE 
naturally occurs in E. coli W, but due to its tight and complex regulation, an alternative 
homologous epimerase (GalE2) from B. bifidum was also selected and cloned. On the 
other hand, UDP-rhamnose synthesis is restricted to plants, whereas E. coli W is unable 
to form endogenous dTDP-rhamnose as alternative rhamnosyl donor due to lack of the 
rfb cluster261,271. To this end, the MUM4 sequence from A. thaliana was codon optimized 
and ordered as plasmid pMUM4 to achieve UDP-rhamnose formation in E. coli W (Figure 
5.1).  
 
Two production plasmid variants pGalE/F3GT/UgpA and pGalE2/F3GT/UgpA were 
created, as described in materials and methods, to ensure the formation of hyperoside. 
Both plasmids were transformed in sGLYC2 to yield the galactosylation strains sGAL2 
and sGAL3. In a similar way, the rhamnosylation plasmid pMUM4/RhaGT/UgpA was 
constructed and transformed in sGLYC2, resulting in strain sRHA3. Alternatively, sRHA2 
was also created, carrying plasmids pRhaGT and pMUM4. The obtained galactosylation 
and rhamnosylation strains were grown on minimal medium with two levels (0.5 and 5 
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mM) of quercetin. Growth and production were monitored to calculate the specific 
productivities, as shown in Figure 5.4. Again, higher extracellular quercetin 
concentrations resulted in a 5-fold increase in qp. However, no significant difference in 
productivity was observed between sGAL2 and sGAL3 at 5 mM quercetin, indicating that 
UDP-galactose formation is as efficient with both GalE homologs and not the rate 
limiting step. The highest hyperoside titer obtained was with sGAL3 (0.94 g/L), which 
was 3.5-fold higher compared to sGAL1.  
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Figure 5.4: Comparison of the specific productivities qp of the sGAL (hyperoside 
formation) and sRHA (quercitrin formation) strains. Strains were grown on minimal 
medium containing 0.5 mM (gray bars) and 5 mM (black bars) quercetin. 
 
In contrast to sRHA1, incubation of sRHA2 and sRHA3 showed a product spot on TLC 
with an altered retention factor corresponding to quercitrin. Analysis of the compound 
using MS proved the formation of the 3-O-rhamnoside and consequently the in vivo 
activity of MUM4. A quercitrin titer of 1.18 g/L was obtained after 30 h incubation of 
sRHA3 when 5 mM quercetin was added to the medium, which corresponded to a 53 % 
conversion. Detailed analysis showed that also 51 mg/L of isoquercitrin was produced 
extracellularly, with a specific productivity of 3.17 ± 1.01 mg/g CDW/h, showing the 
preference of RhaGT for UDP-rhamnose when different UDP-sugar donors are present. 
Remarkably, the specific productivity of sRHA2 was significantly lower (5-fold decrease) 
compared to sRHA3. Possible explanations are either a higher metabolic burden caused 
by a two plasmid system or a too low activity of the native GalU, which is not sufficient 
for adequate formation of UDP-glc. Furthermore, the potential of the novel metabolic 
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engineering strategy, which couples growth and production, becomes apparent in the 
form of a 20-fold increase in specific productivity of sRHA3 compared to sRHA1. 
 
To our knowledge, this is the first reported in vivo production of hyperoside. To 
demonstrate the scalability of the engineered strain, strain sGAL3 was cultured in a 1-L 
bioreactor to ensure a constant pH set at 6.80 and avoid oxygen limitation. A detailed 
overview of growth, production and consumption of sucrose is given in Figure 5.5. After 
an observed lag-phase of 5 h (possibly due to shear stress from the impellers), the strain 
displayed a growth rate of 0.32 ± 0.02 h-1 while simultaneously producing hyperoside. A 
specific productivity was observed of 65.9 ± 2.6 mg/g CDW/h which is comparable to 
the one on shake flask. When nearly all quercetin was converted, hyperoside formation 
slowed down. This can be explained by the observed correlation between quercetin 
concentration and qp, but also by the reported reversibility of F3GT328. A continuous 
supply of quercetin using a fed-batch mode will likely result in a constant qp and 
improve the existing titer. 
 
 
Figure 5.5: Production of hyperoside (▽) in a 1-L bioreactor on minimal medium 
containing 2.5 mM (755 mg/L) quercetin (▼) using strain sGAL3. Cell dry weight (●) was 
measured together with extracellular sucrose (■). 
 
To the best of our knowledge, the obtained hyperoside and quercitrin titers are the 
highest reported to date, which proves the potential of this novel metabolic engineering 
strategy. A more fair comparison with other in vivo processes can be made based on 
production rates. To this end, the maximal production rates (rp,max) of reported 
processes were compared to those obtained in this contribution, the here obtained 
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maximal production rate was 6 to 50-fold higher as illustrated in Figure 5.6. However, in 
view of the growth coupled production obtained with the strains developed, even higher 
production rates are likely achievable. 
 
 
Figure 5.6: Comparison of the maximal production rates obtained using the developed 
galactosylation and rhamnosylation platform (*) with reported maximal rates found in 
literature101-103,105.  
5.4.4 Beyond quercetin: in vivo glycosylation of other flavonols 
Quercetin is the most abundant and best studied dietary flavonol. However, other 
flavonols such as kaempferol, fisetin, morin and myricetin significantly contribute to our 
daily flavonoid intake and their beneficial effects are extremely diverse.329,330 
Kaempferol 3-O-rhamnoside for example inhibits breast cancer cell proliferation 
through activation of the caspase cascade pathway331 while its galactoside has a 
remarkable anti-inflammatory effect332. Myricetin glycosides on the other hand, which 
naturally occur in the mediterranean shrub Myrtus communis, display antioxidant and 
antimutagenic activity333, but also exert potent antipsychotic and anxiolytic-like 
effects334. In addition, fisetin can act as a novel inhibitor in prostate cancer 
management335 and has proven to be an interesting antiseptic336. Finally, morin 
glycosides have shown to be responsible for the antimicrobial effect in the leaves of 
Psidium guajava337, whereas its aglycon has been recently identified as a promising 
insulin-mimetic for diabetes treatment.338 As the sugar moiety is a major determinant of 
the intestinal absorption of dietary flavonoids and their subsequent bioactivity32,339, we 
investigated the potential of the created E. coli W mutants towards both galactosylation 
and rhamnosylation of various flavonols.  
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To this end, strains sGAL3 and sRHA3 were grown in tubes with 5 mL minimal medium, 
each containing 5 mM of kaempferol, myricetin, morin or fisetin. Growth and production 
were monitored over 48 h and various spots were observed on TLC with similar 
retention factors as hyperoside and quercitrin. Mass spectrometry was used to identify 
the compounds, which confirmed the in vivo galactosylation of myricetin, kaempferol 
and fisetin (Table 5.2). All compounds occurred mainly with an m/z of [M+114], 
illustrating the complexation with trifluoroacetic acid from the mobile phase. The 
galactoside of morin was produced at a slow rate, which is in accordance to the very low 
in vitro activity of F3GT towards this flavonol.328 A possible explanation lies in the 
presence of an unusual hydroxyl group at the 2’ position, which may sterically hinder 
the deprotonation and consequent galactosylation of morin at hydroxyl group 3.340  
 
Table 5.2: Galactosylation and rhamnosylation potential of strains sGAL3 and sRHA3 
respectively towards other flavonols. Specific productivity qp and titer reached after 48 h 
of incubation are shown. ND = not detected. 
 3-O-galactoside 3-O-rhamnoside 
Flavonol titer (mg/L) qp 
(mg/gCDW/h) 
titer (mg/L) qp (mg/gCDW/h) 
Kaempferol 84 ± 14 3.46 ± 0.86 416 ± 37 a 12.1 ± 1.4 
Myricetin 52 ± 7.1 2.88 ± 0.22 72.3 ± 9.1 2.8 ± 0.5 
Morin  34 ± 5.8 1.65 ± 0.15 116 ± 21 b 2.5 ± 1.5 
Fisetin 134 ± 22 9.32 ± 0.55 403 ± 31 c 11.3 ± 0.9 
a 3-O-glucoside was also detected at 52 ± 17 mg/L 
b 3-O-glucoside was also detected at 21.7 ± 6.2 mg/L 
c 3-O-glucoside concentration was lower than 5 mg/L 
 
Incubation of sRHA3 with the different flavonols investigated showed two distinct 
glycoside spots on TLC, which corresponded to the 3-O-rhamnoside and 3-O-glucoside. 
Kaempferol proved to be the best substrate for RhaGT and was predominantly 
rhamnosylated (8:1 ratio), with a titer exceeding 400 mg/L, which is 2-fold higher than 
previously reported101. Fisetin on the other hand was efficiently glucosylated, yet the 
formation of its rhamnoside was not as efficient, with a titer below 5 mg/L. A similar 
preference towards glucoside formation was also observed with myricetin and morin, 
which indicates that the positioning of the hydroxyl groups is the determining factor for 
glycosylation with RhaGT. The production of preferred rhamnosides, galactosides or 
glucosides may be largely improved by using UGTs that are more specific towards 
certain flavonols and UDP-sugars. Subsequent implementation of these UGTs in the 
developed in vivo glycosylation strains presents an efficient alternative for the large-
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scale production of various flavonol glycoforms, which are to date mainly extracted from 
plant material. 
5.4.5 Production of the oligosaccharide globotriose 
Besides glycosylated flavonols, the developed glycosylation platform is a flexible tool for 
the production of other molecules. For example, galactose residues widely occur in 
diverse oligosaccharide structures such as blood group antigens341, globosides342, Lewis 
antigens343, galactomannan344, Galili epitopes345 and human milk oligosaccharides346. 
Hence, the galactosylation potential of the metabolically engineered strains was 
investigated for the production of the interesting oligosaccharide globotriose 
(galactosylated lactose; α-D-Gal-(1→4)-β-D-Gal-(1→4)-D-Glc). Globotriose has 
promising pharmaceutical properties due to its involvement in numerous pathogenic 
recognition processes. In addition, it naturally occurs as globotriaosyl-ceramide, is a part 
of the P1PK Blood Group System, which consists out of three membrane associated 
antigens and has a function in the immune system related to B cell differentiation.347 
Furthermore, the globotriose moiety of the antigen binds specifically to the Shiga toxin 
from Shigella dysenteriae or Shiga like toxins from pathogenic E. coli strains.348 This 
process forms the base for diseases such as hemorrhagic colitis and hemolytic uremic 
syndrome. Hence, the clinical applications of freely soluble (or conjugated) globotriose 
are as pathogen-capturing drugs to combat for example urinary tract infections.349,350 
 
Globotriose production can be achieved by replacing the flavonol galactosyltransferase 
(F3GT) on the production plasmids by LgtC, a lipo-oligosaccharide α-1,4-galactosyl-
transferase from Neisseria meningitidis, which is able to galactosylate lactose 
moieties351. When overexpressed however, LgtC is prone to proteolysis323, so by deleting 
the C-terminal 25 amino acids of the lgtC gene, the stability and expression of this 
enzyme can be increased. This truncated sequence was flanked by the homologous 
linkers L5 and L6 to allow rapid assembly of the globotriose production plasmids, which 
were subsequently transformed in the mutant strains as described in Materials and 
Methods, yielding the sGLOBO strains. A metabolic overview of the globotriose 
production strategy is shown in Figure 5.7. To avoid hydrolysis of the acceptor lactose, 
lacZ was additionally knocked out. On the other hand, since lactose permease (LacY) 
activity is necessary for adequate influx of the acceptor lactose271, the lacZYA operon 
was replaced with a constitutively expressed lacY gene (ΔlacZYA::P22-lacY) as shown in 
Appendix A8.  
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Figure 5.7: Schematic representation of the globotriose production strategy in E. coli W. 
Exogenously fed lactose is transported into the cell by constitutive expression of lacY and 
galactosylated by the galactosyltransferase LgtC. The sucrose phosphorylase BaSP splits 
sucrose in a fructose part for growth and a glucose 1-phosphate part for the formation of 
UDP-galactose through UgpA and GalE. Targeted gene deletions (red) prevent the 
consumption of these intermediates for biomass formation while the lacZ knockout 
prevents degradation of the acceptor lactose.  
 
In a first experiment, sGLOBO1 (E. coli W + pLgtC) and sGLOBO2 (E. coli W ∆cscAR ∆pgm 
∆agp ∆ushA ΔlacZYA::P22-lacY + pBaSP/LgtC/UgpA) were grown overnight on minimal 
medium with 1 g/L lactose. Only visualization of the supernatant of sGLOBO2 on TLC 
showed a production spot with a similar retention factor as the globotriose standard. 
This is probably caused by hydrolytic activity of LacZ in sGLOBO1, which prevents the 
intracellular accumulation of lactose and concomitant globotriose formation. The 
product was purified from the supernatant with activated carbon and confirmed to be 
globotriose by MS.  
 
To determine the optimal lactose concentration, sGLOBO2 was grown on minimal 
medium with lactose ranging from 1 to 10 g/L. The average maximal specific growth 
rate, which was independent of the different lactose concentrations used, was 0.32 ± 
0.02 h-1 as shown in Figure 5.8. Conversely, the specific productivity qp showed a 49 % 
increase from 1 to 10 g/L lactose, which may indicate that higher extracellular lactose 
concentrations result in an increased inflow of lactose in the cell. Furthermore, the 
product to biomass yield (YPX) was linear during exponential growth, proving growth-
coupled production. However, increasing the lactose concentration even further to 50 
g/L did not show a significant productivity increase when compared to 10 g/L. 
Therefore, the lactose concentration in the following experiments was set to 10 g/L.   
 
Chapter 5:  Building a versatile glycosylation platform 
93 
 
 
Figure 5.8: Maximal specific growth rates (left) and specific production rates of 
globotriose (right) of sGLOBO2 in minimal sucrose medium containing different lactose 
concentrations. 
 
In sGLOBO2, the native GalE activity is solely responsible for the formation of UDP-
galactose. To investigate the effects of this operon, three other sGLOBO strains were 
created whereby either the galTKM part (sGLOBO3) or the whole operon galETKM 
(sGLOBO4) was deleted. In the latter strain, galE was additionally overexpressed 
yielding sGLOBO5. The latter two have a constitutive knockin of BaSP at the melA 
position, which is believed to code for an α-galactosidase that can hydrolyze 
globotriose.49 The strains were grown on minimal medium containing 10 g/L of lactose 
and the obtained specific productivities are shown in Figure 5.9. Comparison of 
sGLOBO4 and 5 with sGLOBO3 clearly shows that overexpression of galE from E. coli or 
galE2 from B. bifidum does not result in a significantly increased globotriose production.  
 
A plausible explanation could be that constitutive overexpression of galE(2) does not 
result in a higher UDP-galactose pool and only complements for the chromosomal galE. 
It has indeed been observed that expression of galE is higher than that of the promoter-
distal genes galTKM.352 Another possibility may be that LgtC is the rate limiting step in 
globotriose formation. On the other hand, it is remarkable that a ΔgalTKM deletion has a 
profound impact on globotriose production, which was at least 15-fold lower. This may 
indicate that ribosomal translation or the stability and/or synthesis of the 
corresponding mRNA is hampered in this strain, which is supported by the fact that the 
mRNA termination is disrupted. Furthermore, GalE is an endogenously SsrA-tagged 
protein, resulting in its degradation to rescue stalled ribosomes.353  
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Figure 5.9: Comparison of the specific globotriose productivity of the created sGLOBO 
strains. Strains were grown on minimal medium containing 10 g/L of lactose. 
Since sGLOBO5 showed the least biological variation, it was chosen to investigate the 
potential for large-scale globotriose production. Subsequently, the strain was grown in a 
1-L bioreactor on minimal medium with 10 g/L lactose. The obtained fermentation 
profiles are shown in Figure 5.10 and clearly illustrate growth coupled globotriose 
production. At the end of the exponential phase, 1.9 g/L globotriose had accumulated 
extracellularly which increased further to 2.8 g/L during the stationary phase. The 
product to biomass yield YPX was 360 ± 14 mg/g CDW, which is comparable to the one 
observed on shake flask. However, the maximal specific growth rate of 0.22 ± 0.01 h-1 
was significantly lower (possibly due to shear stress), resulting in a lower productivity 
and accumulation of fructose. Fine-tuning of this fermentation set-up will likely improve 
the production rates (rp) which are, in contrast to existing processes (rp = constant)49,323, 
exponentially increasing (rp = YPX . µ . X) due to growth coupled production.  
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Figure 5.10: Production of globotriose in a 1-L bioreactor on minimal medium containing 
10 g/L of lactose using strain sGLOBO5. Cell dry weight (●) was measured together with 
the extracellular sugars globotriose (▾), sucrose (■) and fructose (○). 
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5.5 Conclusions 
In this contribution, the generic nature of the previously created glucosylation host was 
demonstrated by expanding it towards a galactosylation and rhamnosylation platform. 
To this end, UDP-glucose was converted into UDP-galactose or UDP-rhamnose by 
expressing a UDP-glucose epimerase (galE) or a UDP-rhamnose synthase (MUM4), 
respectively. As a proof of concept, the bio-active flavonol quercetin was selected for 
galactosylation and rhamnosylation, yielding hyperoside (quercetin 3-O-galactoside) 
and quercitrin (quercetin 3-O-rhamnoside), respectively. To achieve this, the flavonol 3-
O-galactosyltransferase (F3GT) from Petunia hybrida and the flavonol 3-O-
rhamnosyltransferase from Arabidopsis thaliana (RhaGT) were overexpressed in the 
engineered E. coli W mutants, respectively. The created strains were able to produce 940 
mg/L of hyperoside and 1176 mg/L of quercitrin at specific production rates of 68.7 
mg/g CDW/h and 47.8 mg/g CDW/h, respectively, which are the highest reported to 
date. Interestingly, both GTs showed in vivo activity towards other dietary flavonols, 
whereby over 400 mg/L of kaempferol 3-O-rhamnoside could be formed extracellularly. 
Finally, the flexibility of the engineered strain towards other acceptors than flavonols 
was illustrated by overexpressing the UGT LgtC, which galactosylates lactose. In this 
way, 2.8 g/L of the therapeutic oligosaccharide globotriose was produced in a 1-L 
bioreactor with a specific productivity of 117 mg globotriose/g CDW/h.  
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6.1 Abstract 
Sucrose Synthase (SuSy) is a promising enzyme which catalyzes the reversible 
conversion of sucrose and UDP into fructose and UDP-glucose. Since SuSy efficiently 
generates UDP-glucose from a cheap carbon source, it has been frequently used in 
bioconversion experiments or enzymatic synthesis of various glycoconjugates. When 
SuSy is coupled with a (uridine) glycosyltransferase (UGT), UDP is recycled which makes 
the overall process economically attractive. However, the use of SuSy in (in vivo) 
glycosylation systems has been hampered by its low affinity for sucrose, low stability or 
difficult expression.  
 
To this end, a SuSy from Solanum tuberosum was selected due to its excellent overall 
stability and was engineered to obtain a robust enzyme with increased affinity for 
sucrose. To rapidly screen and characterize various SuSy mutants, a screening system 
was developed, which consisted of developing a growth-based high-throughput screen 
and creating a continuous assay to quickly identify altered kinetic parameters. 
Introduction of an S11E mutation resulted in a 3-fold higher affinity for sucrose due to 
mimicking phosphorylation of the serine residue. This improved enzyme was 
coexpressed with the glucosyltransferase VvGT2 in an engineered E. coli W host to 
produce the glucose ester of vanillic acid. The permeabilized cells efficiently produced 
vanilloyl-β-D-glucose at a rate of 0.41 ± 0.11 g/L/h with 68 % conversion. This newly 
developed system for the glucosylation of specialized metabolites alleviates the need to 
purify the proteins involved and is easily scalable. 
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6.2 Introduction 
Sucrose synthase (SuSy – EC 2.4.1.13) is a key enzyme in the sucrose catabolism of green 
plants.354 It catalyzes the reversible conversion of sucrose and a nucleoside diphosphate 
(preferably uridine diphosphate, UDP) into fructose and a nucleoside diphosphate 
glucose (often UDP-glucose, UDP-glc).355 The function of SuSy shows a strong correlation 
with cellulose synthesis356, sugar import357, environmental stress response358, nitrogen 
fixation and phloem unloading359, yet still remains the subject of much debate in the 
field of plant physiology. Recently SuSy has been cloned from cyanobacteria such as 
Anabaena and Synechocystis species, being the first prokaryotic SuSy’s elucidated. These 
SuSy’s exhibit a preference for adenosine diphosphate (ADP) and have a non-
homologous N-terminal region of the amino acid sequence.360 
 
Since SuSy has the possibility to directly generate the expensive nucleotide sugar UDP-
glc from the cheap and sustainable carbon source sucrose, it has been used in 
bioconversion experiments or enzymatic synthesis for the production of nucleotide 
sugars361 and glycoconjugates123,130,362. When coupling SuSy with a (uridine) 
glycosyltransferase (UGT), UDP is recycled which makes the overall process 
economically attractive. However, the use of SuSy in (in vivo) glycosylation systems has 
been hampered by its low affinity for sucrose, low stability or difficult expression of this 
large (eukaryotic) protein (805 residues). Moreover, expression of several SuSy’s in E. 
coli showed a 10-fold increase of the Km in comparison to the native enzyme purified 
from the plant.125,134 Native SuSy is phosphorylated on a conserved serine (Ser11) 
residue near the N-terminus which has a significant impact on the kinetic 
parameters.134,363 This feature is disadvantageous since E. coli is unable of 
phosphorylating SuSy. Cyanobacterial SuSy has no phosphorylation site and a high 
affinity constant for sucrose of 303 mM.360  
 
Despite the recent structure elucidation of SuSy from A. thaliana by Garavito and 
coworkers364, SuSy has never been the subject of extensive protein engineering to 
improve its kinetic parameters, nor the target for introduction of an alternative sucrose 
metabolism in micro-organisms. To this end, the main goal of this chapter is selecting a 
SuSy for subsequent engineering to obtain a stable, active enzyme with an improved 
affinity for sucrose, which can be used as an efficient in vivo catalyst. The pinnacle of this 
engineering strategy would be a SuSy that enables growth on sucrose when expressed in 
E. coli and is coupled with a UGT, thus giving rise to an effective in vivo glycosylation 
host.  
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To achieve this challenging goal, a novel SuSy enzyme will be selected as a starting point 
for both rational and random mutagenesis. The obtained mutants or mutant library will 
be screened for altered kinetic parameters using a developed high-throughput in vitro 
and in vivo screening system. The overall strategy is depicted in Figure 6.1, whereby the 
most active SuSy (exhibiting the lowest Km) will be coexpressed with a UGT in an 
engineered E. coli W production host. In this perspective, VvGT2 (from Chapter 4) will 
be used as UGT of choice due to its in vivo versatility towards various phenolic acids. The 
production of vanilloyl-β-D-glucose was chosen as a proof of concept, since this 
compound has remarkable antioxidant properties365 and a promising therapeutic 
potential366. 
 
 
 
 
Figure 6.1: Overview of the strategy for the development of an in vivo glycosylation 
platform based on an engineered sucrose synthase and coexpression of an uridine 
glycosyltransferase (UGT) of choice. First, a novel SuSy will be selected based on reported 
activities, which will serve as a template for both random and rational mutagenesis. The 
obtained mutants are subsequently screened for altered kinetic parameters using a 
developed in vitro and in vivo screening system. Finally, the SuSy exhibiting the highest 
affinity for sucrose is coexpressed with a UGT in an engineered host to produce a 
glucosylated acceptor molecule. 
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6.3 Materials and methods 
6.3.1 Bacterial strains and plasmids 
All plasmids and strains used in this study are listed in Appendices A1 and A2, 
respectively. A codon optimized susy gene (accession number P49039) from Solanum 
tuberosum was synthesized by GeneArt® (Life Technologies, Massachusetts) and was 
used as a template for the amplification of susy using primers Fw_SuSy_EcoRI and 
Rv_SuSy_SacI, listed in Appendix A6. The amplified fragment was cut with EcoRI-HF and 
SacI-HF and ligated into the pCX-Kan-P22258 vector resulting in the plasmid pCX-Kan-
P22-SuSy (pSuSy). This plasmid was used as a template for both random and rational 
mutagenesis using primers from Appendix A6. All resulting fragments (truncated genes, 
S11E and S11D mutants, and randomly mutated genes) were subsequently religated in 
the pCX-Kan-P22 backbone following the Gibson assembly method237. Error prone PCR 
(ePCR) was performed according to the protocol of Savilahti and coworkers.367 The 
obtained pCX-Kan-P22-SuSy-S11E was used as template for the amplification of susy-
S11E sequence, whereas pBaSP/VvGT2 (Chapter 4) was used for amplification of the 
backbone. Gibson assembly of the SuSy-S11E insert at the BaSP position resulted in the 
production plasmid pCX-Kan-L5-P22-VvGT2-L6-P22-SuSy-S11E-L7 (pSuSy-
S11E/VvGT2). E. coli W ∆cscAR was used as general expression host for pSuSy mutants, 
while E. coli W ∆cscAR ∆pgm ∆agp ∆ushA was used as production host for pSuSy-
S11E/VvGT2.  
6.3.2 Materials and Molecular Agents  
T4-ligase, all restriction enzymes and Q5 polymerase were purchased from New 
England Biolabs (Ipswich, Massachusetts). All chemicals used were purchased from 
Sigma Aldrich (Germany) unless otherwise stated. Oligonucleotides were purchased 
from IDT (Leuven, Belgium). 
6.3.3 Structural modelling 
SuSy homology models were created on the I-TASSER server.368 All figures were created 
with PyMOL.369 Protein and ligands (sucrose, UDP, fructose) were converted when 
needed to pdb files and were further prepared using AutoDock Tools by converting 
them to pdbqt files.370 Docking was performed using Autodock Vina371 and affinities 
(kcal/mol) of the ligands to the receptor were calculated automatically. An estimation of 
the route(s) to the active site was calculated by using CAVER.372 
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6.3.4 Culture media and culture conditions 
General growth media (LB and minimal medium) are described in Chapter 4. MacConkey 
agar base was purchased from Difco and was used to create sucrose based MacConkey 
agar according to the manufacturer’s instructions. Minimal medium agar plates with 
sucrose (50 g/L) where created according to Aerts (2012)373, but with addition of 1 mL 
L-1 of mineral solution as described in Chapter 4. Cells for permeabilization experiments 
were grown in tubes containing 5 mL LB with kanamycin (50 µg/mL) and served as a 2 
% inoculum for 2 L shake flasks containing 500 mL LB medium and kanamycin . The 
cultures were grown at 37 °C at 200 rpm until the end of the exponential phase was 
reached. Cells were sterilely harvested by centrifugation for 20 min at 5000 × g and 
washed with 50 mM MOPS buffer (pH 7). Cell pellet was stored at -80 °C for 
permeabilization experiments. Conversion medium consisted of 50 mM MOPS buffer 
(pH 7) containing 200 mM sucrose, 0.5 mM UDP-glc, 1 mM MgCl2 and 1 g/L vanillic acid. 
6.3.5 Preparation of crude extracts and enzyme assays 
Preparation of crude enzyme extracts has been described in Chapter 3. Determination of 
the enzyme activity was based on the protocol described by Salerno and coworkers374, 
but fructose accumulation was continuously measured by adding hexokinase, 
phosphoglucose isomerase, glucose 6-phosphate dehydrogenase, ATP and NAD+ directly 
to the reaction mixture. UDP-glucose was continuously measured (340 nm) using a 
newly developed assay by adding 1.2 U UDP-glucose pyrophosphorylase, 1.2 U 
phosphoglucomutase, 1.2 U glucose 6-phosphate dehydrogenase, 1 mM pyrophosphate 
(PPi), 2 mM NAD+ and 0.2 mM glucose 1,6-bisphosphate.  
6.3.6 Bioconversion experiments 
Cells stored at -80 °C were thawed and dissolved in cold 50 mM MOPS buffer (pH 7) to a 
concentration of 500 g/L. Aliquots of 1 mL cell paste were used for cell permeabilization 
by sonication for 4 min at suboptimal conditions (Branson sonifier, 50 % duty cycle, 
output 3). Conversion experiments were initiated by adding 10 mL of conversion 
medium to the permeabilized cells.  
6.3.7 Product analysis and quantification 
Vanilloyl-β-D-glucose was primarily analyzed on TLC and afterwards quantified in detail 
using the same method described in Chapter 4 for glucogallin measurements. Purified 
vanilloyl-β-D-glucose from Chapter 4 was used as a standard. 
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6.3.8 Kinetic analysis 
The kinetic constants were derived from initial rate analysis by varying the 
concentration of individual substrate. Using the continuous fructose assay, sucrose was 
varied from 0 to 1 M in the presence of 2 mM UDP. Kinetic parameters were calculated 
from an S-V plot by non-linear regression analysis using the Michaelis-Menten kinetic 
equations in R (‘nlstools’ package).  
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6.4 Results and discussion 
6.4.1 Selection of a suitable sucrose synthase 
Since a large number of sucrose synthases have been described to date and a lot of 
isoforms exist, choosing a suitable SuSy as a starting point for engineering is challenging. 
The goal of this chapter is to identify or design a SuSy with favorable kinetic parameters 
(high affinity for sucrose) when expressed in E. coli, which can coupled to a UGT, thus 
resulting in an efficient in vivo glucosylation platform. However, heterologous 
expression of SuSy in E. coli often results in an increased Km when compared to the 
native enzyme due to the impossibility of phosphorylation.134 An exception is the 
cyanobacterial SuSy of Anabaena which does not possess this conserved serine 
residue.135 Although many SuSy’s have been kinetically characterized, the obtained data 
are often inconsistent due to the fact that Km estimation methods, protein expression 
and purification, and assay conditions significantly vary. Table 6.1 attempts to give an 
overview of frequently reported SuSy’s and compares these affinity constants for 
different isoforms and expression methods.  
 
Table 6.1: Overview of the affinity constants for sucrose of native SuSy’s (Km,scr) and 
recombinant SuSy’s (Km,scr,rec) expressed in E. coli. All Km values were determined at 
saturation with UDP. A distinction is made between different isoforms when applicable. 
ND: not determined. 
origin isoform Km,scr (mM) Km,Scr,rec (mM) reference 
Solanum tuberosum 1 35 80.3 375,376 
Solanum tuberosum 2 ND 105 ± 10 This study 
Vigna radiata 2 17 161 134 
Arabidopsis thaliana 1 ND 53 ± 6 355 
Arabidopsis thaliana 3 ND 48 ± 3 355 
Glycine max 1 31.3 ± 7.1 55.4 377,378 
Pisum sativum 1 33 ± 5 32.1 ± 2.1 379,380 
Pisum sativum 2 ND 42.7 ± 2.2 379 
Pisum sativum 3 ND 67.5 ± 1.6 379 
Zea mays 1 52 to 40 ND 381-383 
Zea mays 2 63 ND 381 
Anabaena sp.  2 303 270 135,360 
  
Although their affinity constants are rather high, the SuSy’s from S. tuberosum were 
selected since they have been proven to be very stable at 37 °C and show no activity loss 
during repeated freeze-thawing125, making them suitable for industrial applications and 
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the goals of this chapter. Furthermore, they are well documented125,375,376, exhibit a high 
affinity375 for the cosubstrate UDP (Km = 0.2 mM) when expressed in E. coli and they 
already have been deployed as efficient catalysts for the large scale production of ADP-
glucose384 and various oligosaccharides131,385. Isoform 1 (SuSy1) has been 
comprehensively studied, but isoform 2 (SuSy2, hereafter named SuSy) from S. 
tuberosum was not yet characterized in detail. The native sequence of susy was screened 
for rare codon clusters, which can drastically impede ribosomal translation and thus 
have a negative impact on protein expression.386 As shown in Appendix A14, the number 
of  rare codon clusters increased from 16 to 58 % when the expression host switched 
from S. tuberosum to E. coli. Based on this information the susy sequence was codon 
optimized and cloned in the constitutive expression vector pCX-Kan-P2259, resulting in 
the plasmid pCX-Kan-P22-SuSy that was used throughout this chapter as a template for 
mutagenesis. Expression of SuSy in E. coli BL21(DE3) showed activity and had a Km of 
105 ± 10 mM based on the crude enzyme extract (Table 6.1). As a preliminary test, this 
strain was inoculated on minimal medium with 20, 200 and 500 g/L sucrose as only 
carbon source, but none of the cultures displayed growth after 72 h. 
6.4.2 Developing a SuSy screening system 
Obtaining an enzyme with desired properties solely by rational design is a very difficult 
challenge. Hence, a lot of enzyme engineering strategies rely on evolutionary processes 
in which a selective pressure is applied to a population of mutants, and those expressing 
a particular or desired function are preferentially propagated.387 Due to the relative ease 
with which a mutant library can be generated nowadays, high-throughput screening 
efforts are needed. On the other hand, the mutagenesis process is typically applied in an 
iterative fashion until a satisfactory level of functional performance has been attained.387 
The probability that a first round of mutagenesis yields a SuSy with a 10-fold higher 
sucrose affinity is very low, which implies the need for developing an in vitro screen to 
evaluate the kinetic parameters of the obtained mutants. Therefore, a typical sceening 
system consists of two parts: an in vivo high-throughput screen to assess the possibility 
to grow on sucrose and a continuous assay for rapid determination of the kinetic 
parameters. 
 
Developing a high-throughput screen 
 
To develop a growth-based high-throughput screen, it is important to select a suitable 
screening host for SuSy mutants. A good host is sucrose negative, has a high 
transformation efficiency, expresses an active SuSy and is able to import sucrose. Three 
commonly used E. coli strains BL21(DE3), DH5α and MG1655 were screened together 
with the created E. coli W mutant ΔcscAR from Chapter 4 for these desired properties 
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(Table 6.2). All strains showed no growth on minimal medium with sucrose as only 
carbon source and had a high transformation efficiency, which is important to maintain 
the diversity generated by random mutagenesis. The occurrence of a sucrose 
transporter in many E. coli strains is still not fully elucidated, but it is suggested that lacY 
and lamB respectively code for a lactose permease and a maltose porin, which have a co-
affinity for sucrose.388 E. coli W, which grows particularly fast on sucrose, expresses a 
sucrose permease (CscB) which belongs like LacY to the oligosaccharide/H+ symporter 
subfamily of the major facilitator superfamily.389 It was shown that a cscB deletion 
mutant was unable to grow on sucrose, proving that no other transporter in E. coli W is 
capable of transporting sucrose.269 On the other hand, MG1655 that constitutively 
overexpresses a sucrose phosphorylase (BaSP) is able to grow on sucrose while a DH5α 
transformant is not.269,390 This suggests that LacY probably plays a significant role in 
sucrose transport, as the lacZYA operon is absent in E. coli DH5α. 
 
Table 6.2: Overview of desired properties in some frequently used E. coli genotypes 
concerning the expression of (mutant) SuSy’s. Transf. eff.: transformation efficiency. 
E. coli strain 
Growth on 
sucrose 
Transf. eff. a 
(CFU/µg 
DNA) 
Sucrose 
transporter 
Reference 
BL21 (DE3) No 1 x 109 LacY? 271 
DH5α No 2.54 x109 - 269 
K12 MG1655 No 1 x 109 LacY? 390 
W ΔcscAR No 1.56 x109 CscB This study 
a transformation by electroporation 
 
Since E. coli W ΔcscAR displays all the necessary characteristics, it was chosen as the 
expression host for SuSy screening. Furthermore, E. coli W ΔcscAR is deprived of its 
sucrose regulator which encodes the CscR protein that represses expression of the 
sucrose utilization genes at low sucrose concentrations.268 In addition, E. coli W 
expresses a unique fructokinase CscK, absent in the other investigated E. coli strains, 
that effectively channels intracellular fructose towards the glycolysis.269 This feature is 
of particular interest since cleavage of sucrose by SuSy or a sucrose phosphorylase 
releases fructose in the cell, which is normally converted by the manno(fructo)kinase 
Mak. This enzyme is shown to be promiscuous and exhibits a rather low activity270,391, 
thus hampering the screen for an active SuSy in the other hosts.  
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Assay development 
 
Various enzymatic assays have been developed for SuSy in both the synthesis and 
cleavage reaction. Since a quick screen for improved kinetics of SuSy is required, there 
will be only focused on continuously coupled assays which greatly reduce the assay time 
and cost. Figure 6.2 gives an overview of three possible continuous assays. An 
adaptation of the discontinuous fructose assay described by Salerno and coworkers374 
was identified as the best of these three, since the coupled enzymes are cheap, widely 
available and form a stabile mixture. Therefore, this assay was used for the 
determination of the kinetic constants of SuSy. 
6-PGL
G6P
NAD+
NADH
F6P
G6P 
dehydrogenase
Phosphoglucose 
isomeraseHexose kinase
UDP
sucrose
fructose
UDP-glc
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UDP-glucose 
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Phosphogluco- 
mutase NAD+
NADH
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NAD+ NADH
ATP ADP
UDP-glucose 6-dehydrogenase
 
Figure 6.2. Possible continuous assays for the cleavage reaction of SuSy. Coupling 
enzymes are shown in green and NADH (absorbance at 340 nm) is depicted in blue. PPi: 
pyrophosphate, glc1P: glucose 1-phosphate, glc6P: glucose 6-phosphate, 6-PGL: 6-
phosphogluconolactone. 
Conversely, the UDP-glucose 6-dehydrogenase assay has been used by some research 
groups392,393, but the current availability, price and overall stability of the enzyme make 
it however very expensive. Also, the possibility of coupling UDP-glucose 
pyrophosphorylase to the SuSy reaction was explored.156 Though the new assay 
performed well in measuring SuSy activity, combination of Mg and pyrophosphate (PPi) 
resulted in the precipitation of an insoluble MgPPi complex (Kd = 55.3 µM)394 which 
interfered with the absorbance measurements.  
 
6.4.3 Engineering the affinity for sucrose 
Finalization of the screening system permits the start of engineering a SuSy with an 
increased affinity for sucrose. First, the general structure of SuSy will be discussed 
whereafter some structure based engineering strategies will be evaluated.  
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General structure considerations 
 
Although SuSy has been the subject of extensive (physiological) characterization for the 
past 50 years, any attempts towards protein engineering are scarce.134,378 Only in 2011, 
the structure of SuSy1 from A. thaliana was elucidated by Garavito and coworkers364 and 
showed that the structure was a flat, donut-like tetramer with two types of subunit 
interfaces. Each monomer has a tri-lobed structure with 4 distinct domains shown in 
Figure 6.3: a cellular targeting domain (CTD, residues 11-127), an ENOD10 peptide 
binding domain (EPBD, residues 157-276), and 2 glycosyltransferase B domains (GT-BN, 
residues 277-526; GT-BC, residues 527-754).364 An interesting characteristic is the 
presence of a unique Nα1 helix which is 10 Å longer than any other homologous helix in 
GT-B structures reported. 
 
The SuSy structure of Arabidopsis (AtSuSy) is 78 % identical to isoform 2 of Solanum and 
a monomeric homology model was created using I-TASSER368, which was used to 
identify interesting regions for mutagenesis. Plotting of the overall electrostatic 
potential φ(r)395,396 by solving the Poisson-Boltzmann equation revealed that SuSy has a 
negatively charged surface (Figure 6.4). This is in accordance to the theoretical 
isoelectric point of 5.93 and the slightly more acidic pI of 5.5 as determined 
experimentally125. Figure 6.4 also displays the presence of a positively charged (blue) 
zone which probably acts as an entrance for the negatively charged UDP or UDP-glucose. 
The route towards the active site of SuSy has never been investigated and the 3D 
structure of AtSuSy is presumably in the “closed” and thus active conformation364, a 
typical feature of glycosyltransferases34,397. The substrates are captured in between the 
cleft of GT-BN (light green) and GT-BC (light yellow) as shown in Figure 6.4. The CAVER 
tool372 was used to search for possible routes towards the active center and are depicted 
in white, which correspond to the positively charged cleft.  
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Figure 6.3: Ribbon representation of the tetrameric SuSy from A. thaliana (PDB 3S27) 
displaying the subunit interface interactions (A:B and A:D). The cellular targeting domain 
(CTD) is colored in marine and the ENOD40 peptide binding domain (EPBD) is cyan. The 
GTB domains are depicted in wheat together with the C-terminus in orange. Figure 
adapted from Zheng et al. (2011).364 
 
    
 
Figure 6.4: Structural overview of the electrostatic potential (left) and closed 
conformation with routes to the active site (right) of SuSy from S. tuberosum (PDB 3S29). 
The electrostatic surface potential shows a positively charged zone (blue) which 
corresponds to the cleft between the GTBN (green) and GTBC (yellow) domains. Two 
possible routes near the active site were visualized using CAVER372 (white).  
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Truncation mutants of SuSy 
A first attempt to gain insight in the function and necessity of the N-terminal domains 
(CTD and EPBD) of SuSy, is to make truncations. These domains cover 34 % of SuSy 
without any contribution to the active site of the GTB. A previous study created an N-
terminal truncation (A2 to R13) of soybean SuSy and concluded that the activity and Km 
were not significantly different compared to the wild type.378 In addition, precise 
truncation of proteins can result in a higher specific activity398 or the identification of 
the minimal active protein399. Figure 6.5 shows the location of various selected 
truncations whereby SuSy-T111 codes for SuSy with amino acids 2 to 110 deleted. The 
selection of deleted residues was based on the starting position of a new helix or 
limitation of  the hydrophobic effect.  
 
EPBDCTD C-terminus
T111
P139
G156
T243
D262
I273
 
 
Figure 6.5: Location of the selected truncations in SuSy of S. tuberosum in the N-terminal 
region, consisting of a cellular targeting domain (CTD) and an ENOD40 peptide binding 
domain (EPBD). Arrows indicate the position where the truncation was made, whereby 
T111 is SuSy with amino acids 2 to 110 deleted. 
 
Analysis of the crude protein extracts revealed that all activity in both cleavage and 
synthesis direction was lost. These findings illustrate the importance of the cellular 
targeting domain (CTD) and ENOD40 peptide binding domain (EPBD). Possible 
explanations for the inactivity of these mutants are the loss of its tetrameric 
conformation, deletion of highly conserved residues and destabilization of the structure. 
As shown in Figure 6.3, the A:B interface originates almost entirely from interactions 
between adjacent EPBDs, while the A:D interface is formed between EPBD and the C-
terminus. It has been shown that a C-terminal truncation results in the direct loss of 
activity378 and that a dimeric SuSy is not active400. Furthermore, the highly conserved 
residue Q77 makes a polar contact with E491 from the GTB domain thus ensuring 
proper folding and holding both domains together. Deletion of this residue probably 
results in a destabilized structure. 
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Mimicking phosphorylation  
 
 
The S11 residue is highly conserved in plants and is phosphorylated, which results in a 
lowering of the Km.125,134 The N-terminus of cyanobacterial SuSy’s is completely different 
as depicted in Figure 6.6 and has no comparable residue. Two mutations (S11D and 
S11E) were introduced to mimic a constitutive phosphorylation, resulting in the pCX-
Kan-P22-SuSy-S11D/E plasmids. The plasmids were transformed in the developed E. 
coli W ΔcscAR host and the crude extracts showed an apparent increase in sucrose 
affinity from 105 mM to 54.8 ± 1.2 mM for S11D and 35.7 ± 1.1 mM for the S11E mutant, 
respectively. The S11E mutation is more beneficial since its phosphomimetic potential 
(charge and residue length) is higher. These findings are inconsistent with the data 
obtained by Elling and coworkers375, which showed no significant increase in affinity 
between isoform 1 of SuSy from S. tuberosum and the corresponding S11D mutant.  
 
 
Figure 6.6: Alignment of the SuSy amino acid sequences from Table 6.1 at the N-terminus. 
The serine (S11) residue is conserved in plants and is not present in Anabaena, while K39 
and L42 are conserved within all described SuSy’s. 
 
Random mutagenesis 
 
 
Rational design of SuSy is very challenging and resulted till now in an S11E mutant with 
a 3-fold higher affinity for sucrose. Since other educated guesses to improve the kinetic 
constants of this enzyme are difficult to make, some effort will be put in (semi) random 
mutagenesis. The activity of SuSy S11E was not significantly different from the native 
SuSy, so that the corresponding sequence was used as a template for mutagenesis. Error 
prone PCR (ePCR) using a mutagenic buffer based on the method of Rasila et al.367 was 
used to generate mutant libraries of the complete SuSy-S11E gene or large subdomains 
thereof. The latter regions of interest were the Nα1 helix (stretching from G301 to 
Q324), an outer loop (from L338 to Q349) and a combination thereof (from G301 to 
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Q349). The complementary backbones were amplified using a high fidelity polymerase 
and the degenerated inserts were ligated using the Gibson assembly method237. The 
created mutant libraries were transformed in E. coli W ΔcscAR and 80 % of the 
transformation mixture was plated on sucrose minimal medium agar, whereas 10 % was 
plated out on sucrose based MacConkey agar and the remaining 10 % on LB agar with 
kanamycin. No colonies were detected on minimal medium after extended incubation. In 
addition, no mutants were found on MacConkey agar that could coferment sucrose. The 
colonies on LB+Kan plates were grown on liquid medium and the crude extracts were 
tested for activity. The positives were rapidly screened for an improved affinity for 
sucrose and are listed in Table 6.3. A second round of ePCR on the Nα1 helix resulted in 
loss of activity or activity starting from 100 mM sucrose, thus illustrating the challenge 
of lowering the Km value by both rational and random mutagenesis. 
 
Table 6.3. Results of the random mutagenesis. 
Mutation Result 
Complete gene All active. Km higher than WT. 
Nα1 helix G301 to Q324 Active mutants with Km as WT. 
Outer loop L338 to Q349 Mutants only active from 100 mM sucrose 
Combined V303 to Q349 Mutants only active from 100 mM sucrose 
6.4.4 Coupling SuSy to UGT 
Although this affinity constant was greatly reduced with the S11E mutation, it proved to 
be too high to enable growth on sucrose when expressed in E. coli. As the intracellular 
concentration of UDP is almost 10-fold higher than the Km for UDP of this enzyme125,401, 
sucrose concentration in the cell is likely to be the limiting factor. When taken into 
account the Km of other sucrose degrading enzymes like invertases and phosphorylases 
(SP)373 which do permit growth when expressed, an estimation of the affinity range 
needed is between 0.5 and 5 mM. This is supported by the fact that SP enzymes with a 
Km above 5 mM were unable to grow on sucrose when expressed in E. coli.390 Since the 
affinity constant of SuSy-S11E is over 7-fold higher than this threshold, further 
engineering is required when a strain needs to be obtained with production coupled to 
growth as described in Chapters 4 and 5. 
 
Nevertheless, this engineered SuSy has become more suitable and efficient for 
biocatalysis, especially when coupled with a UGT. To this end, SuSy-S11E was 
coexpressed with the glucosyltransferase VvGT2, resulting in the constitutive expression 
plasmid pSuSy/VvGT2, which was transformed in the sGLC4 host (E. coli W ∆cscAR 
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∆pgm ∆agp ∆ushA) from Chapter 4. The strain was grown on LB after which the cells 
were harvested, washed and stored at -80 °C. The cell pellet was resolved in 50 mM 
MOPS (pH 7), permeabilized and used at a concentration of 50 g/L for conversion 
experiments. Vanillic acid was used as acceptor, since the resulting glucose ester 
vanilloyl-β-D-glucose has promising therapeutic potential366. A first bioconversion was 
carried out in 50 mM MOPS buffer (pH 7) containing 200 mM sucrose, 2 mM UDP, 1 mM 
MgCl2 and 1 g/L vanillic acid, but after 8 h of incubation at 37 °C, no glucoside could be 
detected. Analysis of SuSy in the permeabilized extracts showed an activity of 61 ± 12 
U/L, thus proving that SuSy was not the bottleneck. Repeating the experiment in the 
presence of 0.5 mM of UDP-glc instead of 2 mM UDP showed a rapid formation of 
glucoside as shown in Figure 6.7. 
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Figure 6.7: Bioconversion of 1 g/L of vanillic acid into vanilloyl-β-D-glucose by coupling 
SuSy-S11E and VvGT2 in presence of 200 mM sucrose and 0.5 mM UDP-glucose at pH 7 
and 37 °C. 
 
This indicates that UDP inhibits VvGT2 as an end product, a phenomenon frequently 
encountered with O-glucosyltransferases124,130. The vanillic acid was almost completely 
converted in 2 h, resulting in 8.13 regeneration cycles of UDP-glc. Remarkably, the 
product degraded over time and resulted in a maximal conversion of 69.1 ± 9.7 %. An 
average production rate of 0.41 ± 0.11 g/L/h of glucoside could be reached, which is to 
our knowledge in the same line as the most efficient in vitro process reported regarding 
the glucosylation of specialized metabolites130. This system could efficiently convert the 
dihydrochalcon phloretin in its corresponding C-glucoside nothofagin at an estimated 
rate of 0.34 g/L/h. Despite the potential of this in vitro process, it should be mentioned 
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that this was carried out on a 1.5 mL scale and that scale-up will be far from cost-
effective due to the need for extensive enzyme purification. Moreover, the process 
required repeated enzyme feed to avoid slowdown of the production rate, thus making 
this system even more expensive. In contrast, our process alleviates the need for 
extensive enzyme purification and is easily scalable, thus illustrating an improved in vivo 
method for the glucosylation of small molecules. 
6.5 Conclusions 
In this chapter, a structural analysis is made of the Sucrose Synthase (SuSy) from 
Solanum tuberosum to generate both rational and random mutants with an increased 
affinity towards sucrose. To efficiently screen and characterize these mutants, a 
screening system was developed which consisted of a growth-based high-throughput 
screen and an adapted continuous assay. The newly designed E. coli W ΔcscAR proved to 
be the most suitable screening host for SuSy due to its high transformation efficiency 
and presence of the sucrose transporter CscB. N-terminal truncation mutants (up to 
I237) showed no activity, thus illustrating the importance of these domains. The native 
affinity constant (Km) for sucrose could be reduced 3-fold to 35.7 ± 1.1 mM by 
introducing an S11E mutation, which mimics phosphorylation of the serine residue. 
Random mutagenesis efforts starting from this SuSy-S11E mutant yielded only mutants 
with the same Km or enlarged values. Coexpression of the improved SuSy-S11E with the 
glucosyltransferase VvGT2 in an engineered E. coli W host (sGLC4) resulted in a strain 
that could efficiently glucosylate vanillic acid after permeabilization. The glucoside 
vanilloyl-β-D-glucose was produced at a rate of 0.41 ± 0.11 g/L/h with 8.13 
regeneration cycles of UDP-glucose, which illustrates the potential of this new system 
for the glucosylation of specialized metabolites. 
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7 Chapter 7 
Conclusions and perspectives 
 
 
Glycosylation is an important modification in nature which can significantly improve the 
physicochemical and biological properties of small molecules like specialized 
(secondary) plant metabolites or antibiotics. The majority of glycosylation reactions are 
mediated by glycosyltransferases (GTs), which transfer the sugar residue from an 
activated sugar donor (like UDP-sugars) to various acceptors such as specialized 
(secondary) metabolites or oligosaccharides. The addition of a sugar residue to these 
molecules can greatly alter their solubility, stability or bioactivity, which are desirable 
properties when they are applied as nutraceuticals, therapeutics or cosmetics. Since the 
majority of specialized metabolites occurs as glycosides, extraction from natural 
resources remains the most widely used method to deal with the ever increasing 
demand for glycosylated compounds. However, this is often a low-yielding and laborious 
task using toxic solvents and generating much waste.  
 
Fuelled by these challenges, many ‘green’ alternatives have been developed for the 
production of glycosides as illustrated in Chapter 2. These can be divided in in vitro 
(using enzymes) and in vivo (using whole cells) systems, each having their specific 
advantages and challenges. Since in vitro processes are difficult to scale up and need 
purified enzymes and expensive cofactors, the key factors towards their economic 
viability are engineering the enzymatic (thermo)stability and increasing the number of 
regeneration cycles (RC) of nucleotide sugars. Furthermore, the search for tailor-made 
enzymes with novel or improved functions is greatly stimulated by the expanding fields 
of enzyme engineering402 and metagenomics218. Sequence based metagenomics can aid 
in the discovery of more stabile or active alternatives for existing enzymes, while 
function based screens can unravel completely novel enzyme activities.  
 
On the other hand,  in vivo processes have been proven to be very useful for the cheap 
and large scale production of various oligosaccharides and glycosylated specialized 
metabolites. Notwithstanding the promising conversion yields obtained in hosts like E. 
coli and S. cerevisiae, the corresponding production rates and titers of many glycosides 
are often very low. This is primarily caused by metabolic engineering strategies which 
mostly achieve indirect formation of UDP-sugars via the bottleneck enzyme Pgm. To this 
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end, alternative routes could be introduced in the form of sucrose synthase or sucrose 
phosphorylase, thus resulting in the direct formation of activated precursors from the 
bio-economically attractive and more sustainable substrate sucrose. In addition, the 
released fructose can function as a substrate for growth, which opens the possibility to 
simultaneously produce and grow. A final and recently emerging perspective for in vivo 
glycosylation is the complete de novo synthesis of glycosides, whereby the aglycon is 
equally formed by the host. In this way, glycosylation becomes a ‘decoration’ module in 
the total biotechnological synthesis of natural or new to nature glycosides. 
 
In the light of efficient UDP-sugar formation and the search for more flexible enzymes, a 
promiscuous uridylyltransferase from B. bifidum was identified in Chapter 3. Three 
putative gene candidates (galT1, galT2 and ugpA) were cloned in a newly engineered E. 
coli strain. Expression in this host enabled to screen and characterize the enzymes only 
by their crude extracts since major interference reactions were deleted, thus alleviating 
the need for enzyme purification. A newly developed chemo-enzymatic assay based on 
phosphate detection in the micromolar range enabled to identify UgpA as the 
promiscuous uridylyltransferase with UTP-monosaccharide-1-phosphate 
uridylyltransferase activity (EC 2.7.7.64). This enzyme catalyzed both the formation of 
UDP-glucose and UDP-galactose from glucose 1-phosphate (glc1P) and galactose 1-
phosphate (gal1P), respectively. Remarkably, UgpA showed a 7-fold higher activity 
compared to the homologous E. coli uridylyltransferase GalU. Hence, UgpA proved to be 
a versatile catalyst for in vitro UDP-sugar generation. To what extent other sugar 1-
phosphates may be converted by UgpA could be the subject of future research, hereby 
optionally using the developed screening host. 
 
To address the aforementioned inadequate UDP-sugar formation in most in vivo 
platforms and to harness the power of the newly discovered UgpA, a novel glucosylation 
platform was designed in Chapter 4. Through metabolic engineering of Escherichia coli 
W, a robust plug and play strain was developed that couples production of glucosides 
directly to growth, hereby only using sucrose as a cheap carbon source. To this end, the 
existing sucrose metabolism (encoded by cscARKB) was modified by knocking out cscAR 
combined with introduction of the sucrose phosphorylase from Bifidobacterium 
adolescentis (BaSP), which directly generates glc1P as an activated precursor for UDP-
glucose. To ensure proper glucoside production, three consequent modules were 
elaborated: (1) the creation of a split E. coli W metabolism, resulting in the reduced or 
eliminated use of glc1P for growth, preserving it for UDP-glc formation; (2) enhancing 
and securing UDP-glucose formation; and (3) the expression of the versatile 
glucosyltransferase VvGT2 from Vitis vinifera for the glucosylation of various phenolic 
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acids. This VvGT2 specifically enabled the strain to produce the therapeutic compound 
β-glucogallin (1-O-galloyl-β-D-glucose) starting from gallic acid and sucrose while 
actively growing. Specific productivities were obtained up to 100 mg β-glucogallin/g 
CDW/h, which was 20-fold higher compared to the wild type strain harboring VvGT2. 
This effect was largely caused by the deletion of ushA, which prevented degradation of 
the UDP-sugar pool. Due to the promiscuous character of VvGT2, 14 other glucose esters 
of various hydroxycinnamic and hydroxybenzoic acids were produced in a stereospecific 
way with high conversion yields up to 100 %, including three newly reported glucose 
esters. To our knowledge, this fast growing (and simultaneously producing) E. coli 
mutant is the first versatile host described for the glucosylation of phenolic acids in a 
fermentative way solely relying on sucrose.  
 
However, as discussed in Chapter 4, the envisioned split metabolism (characterized by a 
50 % decrease in biomass yield) was not fully achieved. In this context, investigating the 
effect of a double phosphatase (encoded by yihX and yidA) knockout or an ycjU knockout 
in sGLC5 could be very useful. Alternatively, 13C metabolic flux analysis can provide 
fundamental information403 on the intracellular fluxes in the central metabolism of the E. 
coli W mutants, which can result in an educated guess for engineering a truly split 
metabolism. In this way, product yields and concomitantly specific productivities will be 
even further increased, which gives rises to a more robust strain.  
 
Expression of other GTs in this platform would result in a true plug and play strain that 
glucosylates any desired small molecule, thus demonstrating the versatility towards 
different acceptors. However, this could require additional engineering efforts regarding 
transport, degradation, scalability and toxicity of each tested acceptor and 
corresponding glucoside. This was clearly demonstrated when more than 1 g/L of 
vanillic acid was added, which proved toxic and caused inhibition of growth, whereas 
the glucoside could be accumulated over 2 g/L without any effects (data not shown). 
Some ways to overcome this are the controlled (exponential) feed of the acceptor or the 
use of a continuous fermentation. Besides alteration of the process conditions, strain 
improvements can be realized on molecular level as well. At this moment, the genes 
encoding BaSP, VvGT2 and UgpA are constitutively expressed under the same promoter 
P22, possibly resulting in an imbalanced pathway with accumulation of key 
intermediates. In order to minimize the metabolic burden and to maximize the flux 
through the pathway, resulting in a fine-tuned and increased production, a combination 
of different promoters with different strengths and ribosome binding sites preceding the 
constitutively overexpressed genes can be tested. A schematic representation of the 
combinatorial pathway optimization for selecting improved β-glucogallin producer 
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strains is shown in Figure 7.1. The resulting mutant library can be rapidly screened by a 
newly developed assay whereby rhodanine reacts with residual gallic acid, resulting in a 
bright red complex (540 nm)404. 
 
 
 
Figure 7.1: Schematic representation of a combinatorial pathway optimization. A mutant 
library can be easily obtained by combining the fixed pathway parts (BaSP, UgpA, VvGT2) 
with a promoter or RBS library. The selection of the best producer strains for β-
glucogallin is done using a high-throughput screen based on the coloration of residual 
gallic acid (rhodanine assay). 
 
In Chapter 5 the generic nature of the created glucosylation host was demonstrated by 
expanding it towards a galactosylation and rhamnosylation platform. To this end, UDP-
glucose was converted into UDP-galactose or UDP-rhamnose by simply expressing a 
UDP-glucose epimerase (galE) or a UDP-rhamnose synthase (MUM4), respectively. As a 
proof of concept, the bio-active flavonol quercetin was selected for galactosylation and 
rhamnosylation, yielding hyperoside (quercetin 3-O-galactoside) and quercitrin 
(quercetin 3-O-rhamnoside), respectively. To achieve this, the flavonol 3-O-
galactosyltransferase (F3GT) from Petunia hybrida and the flavonol 3-O-
rhamnosyltransferase from Arabidopsis thaliana (RhaGT) were overexpressed in the 
engineered E. coli W mutants. The created strains were able to produce 940 mg/L of 
hyperoside and 1176 mg/L of quercitrin at specific production rates of 68.7 mg/g 
CDW/h and 47.8 mg/g CDW/h, respectively, which are the highest reported to date. 
Interestingly, both GTs showed in vivo activity towards other dietary flavonols, whereby 
over 400 mg/L of kaempferol 3-O-rhamnoside could be formed extracellularly. Finally, 
the flexibility of the galactosylation platform to produce specialty oligosaccharides from 
lactose was also assessed. However, to prevent metabolization of this acceptor, the lac 
operon, containing an β-galactosidase (lacZ) and lactose permase (lacY) was knocked 
out and lactose transport was restored by knocking a constitutively expressed lacY back 
in at the same locus. Replacing F3GT with the lipo-oligosaccharide galactosyltransferase 
(LgtC) from Neisseria meningitidis, enabled our mutant strain to efficiently produce 2.8 
g/L of globotriose (α-galactosyl-1,4-lactose) at a rate of 117 mg/g CDW/h.  
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Due to the pivotal role of UDP-glc, various other UDP-sugars can be formed in vivo such 
as UDP-glucuronate, UDP-xylose, UDP-arabinose, UDP-apiose and UDP-galacturonate. 
Figure 7.2 gives an overview of the UDP-sugars produced in this dissertation (coloured 
in green) and the most common derivatives thereof. When implementing a 
dehydrogenase like Ugd, effects of NAD+ consumption should be taken into account to 
co-engineer an optimal redox balance.  
 
 
 
 
Figure 7.2: Overview of the interconverting reactions starting from the central molecule 
UDP-glucose for the generation of the most common UDP-sugars found in nature. UDP-
sugars depicted in green were successfully produced in this dissertation. EC numbers and 
the abbreviated gene products are shown next to each reaction. 
In combination with the modularity of the developed glycosylation strains, which 
permits rapid introduction of any GT or UDP-sugar pathway, virtually any glycoside can 
be produced. Together with the novel metabolic engineering strategy which established 
coupling of growth and production, over 50-fold increase in productivity can be 
achieved compared to existing processes. To fully exploit this strategy, the 
fermentations carried out in this dissertation should be expanded into a fed-batch set-
up. In this way, high cell densities can be obtained which equally result in exponentially 
increasing product titers. Interesting target molecules for future research with industrial 
applications are the antioxidative bisglycoside rutin (quercetin 3-O-rutinoside), the 
anticarcinogenic baicalin (baicalein 7-O-glucuronide) or the cardioprotective piceid 
(resveratrol 3-O-glucoside). 
 
Finally in Chapter 6, we explored the potential of the promising enzyme sucrose 
synthase (SuSy), which is able to directly generate UDP-glucose from sucrose. Since 
combination of SuSy with a GT gives rise to a rapid and energy efficient recycling of UDP, 
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exploiting this principle in actively growing cells is industrially very attractive. However, 
due to its unfavorable kinetics (low affinity for sucrose), SuSy has been rarely used for 
the in vivo formation of UDP-glucose. To create a more suitable SuSy, a new screening 
system was developed to rapidly evaluate and characterize SuSy mutants. This system 
consists of a growth-based high-throughput screen and a continuous assay to quickly 
identify altered kinetic parameters. The SuSy of Solanum tuberosum was used as a 
starting point and displayed an affinity constant (Km) of 105 ± 10 mM. This value could 
be significantly reduced to 35.7 ± 1.1 mM by introducing an S11E mutation, which 
mimics phosphorylation of the serine residue. Other attempts (random mutagenesis and 
N-terminal truncations) to lower this constant remained unfruitful and expression of 
SuSy-S11E in E. coli W ΔcscAR did not confer growth on sucrose to this strain. However, 
coexpression of this SuSy mutant with the glucosyltransferase VvGT2 in the engineered 
host created in chapter 4 resulted in an in vivo (bioconversion) host. The permeabilized 
cells were able to efficiently glucosylate vanillic acid at a rate of 0.41 ± 0.11 g/L/h with 
68 % conversion and an RCmax of 8. This system alleviates the need to purify the proteins 
involved and is easily scalable. Production rates, RCmax and titers can be further 
increased by (stepwise) addition of more acceptor, which will result in a new 
economically viable and versatile glycosylation host. 
 
This methodology could be further improved by engineering a SuSy that permits growth 
on sucrose, thus effectively creating a split metabolism with production (glycosylation) 
coupled to growth. In this way, the cells do not need to be cultured before, since growth 
and production will be coupled. An estimation of the Km to be achieved for growth will 
be in the range of 1 mM, which is 20 to 300-fold higher than the naturally occurring 
SuSy’s. However, engineering the affinity constant of SuSy will be very challenging, 
especially since no attempts have been made to date to approach this enzyme in a 
systematic and structural way. Indeed, the only available 3D structure from A. thaliana 
gives no information about the combined position of UDP and sucrose ligands, but only 
shows UDP combined with a possible glucosyl intermediate.364 To this end, a homology 
model was created of Susy from S. tuberosum, which was subsequently used to dock the 
ligands sucrose and UDP. Figure 7.3 shows the most representative docking with a 
binding affinity of 7 kcal/mol whereby the residues located in the active site are colored 
in orange. Other possible conformations were useful in the identification of other 
catalytic residues or residues that influence the affinity for sucrose or UDP. However, 
these results are estimations since the structure is only available in its closed 
conformation, yet give an interesting insight in the molecular organization of SuSy. 
Sucrose is stabilized by the pyrophosphate moiety of UDP and the conserved residues 
H436 and E673. The glycines (G300 and G301) are conserved in all GTB type 
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glycosyltransferases and possibly have the same ‘hinge’ function during closing of the 
domains in their active forms as described in sucrose 6-phosphate synthase405. 
Furthermore, G301 forms the beginning of the interesting Nα1 helix, which pushes into 
the active centre and probably has a major influence on the affinity constant for sucrose. 
Alanine scanning or site saturation of the residues surrounding the docked sucrose 
ligand could provide valuable information on their contribution to the activity, 
specificity and affinity of SuSy. 
 
 
Figure 7.3: Docking of sucrose in the modeled SuSy of S. tuberosum with UDP (green) 
ligand. Residues that participate in bonding interactions are shown in orange. Polar 
interactions are displayed as yellow dashes. 
Remarkably, all research concerning SuSy has been focused on eukaryotic enzymes, with 
two cyanobacterial homologs (Anabaena sp. and Thermosynechococcus elongatus) as 
only exceptions. However, since many proteobacterial genomes have been sequenced in 
the past years, certain gene clusters exhibiting strong homology with SuSy have been 
identified, but not yet characterized.406 To this end, we cloned a putative SuSy gene 
originating from Nitrosomonas europaea and confirmed its function as genuine sucrose 
synthase for the first time. This SuSy preferred ADP over UDP and displayed a Km value 
towards sucrose of only 25 ± 5 mM, which is even lower as the engineered SuSy of S. 
tuberosum. These proteobacterial SuSy’s could unlock new possibilities when used as 
industrial catalysts. 
 
Up to now, the created glycosylation strains were sucrose based, hereby exploiting 
sucrose phosphorylase to generate glc1P. Theoretically, various other disaccharides may 
be ‘split up’ by various carbohydrate active enzymes to yield a part for growth and a part 
for the formation of the required UDP-sugar. In this perspective, Table 7.1 gives an 
overview of disaccharides commonly used in growth media and which activated 
intermediates they form when split by a synthase, phosphorylase or hydrolase. For 
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example, UDP-galactose can be generated in different ways, other than by 
overexpressing the interconverting enzyme GalE. However, its direct formation by 
lactose synthase (EC 2.4.1.22) is not feasible since the  equilibrium is  completely  shifted  
towards  synthesis  of  lactose.  Alternatively, lactose phosphorylase may be used to 
generate gal1P, but due to the high Km value (228 mM) and low activity141, strains 
expressing this enzyme show slow growth on lactose. Finally, lactose may be hydrolyzed 
by the naturally occurring β-galactosidase LacZ in E. coli, which yields intracellular 
galactose and glucose. The latter is used as a substrate for growth, while galactose is 
converted to UDP-galactose by combined action of GalKM (galactose kinase/mutarotase) 
and the promiscuous UgpA. 
 
 
Table 7.1: Overview of other metabolic strategies for coupling production to growth, 
represented as a function of the disaccharide substrates and the carbohydrate active 
enzyme class. EC numbers of the enzymes involved are also shown. N.D.= not described. 
 Synthase Phosphorylase Hydrolase 
 
      Sucrose 
 
UDP-glucose 
EC 2.4.1.13 
fructose 
glucose 1-phosphate 
EC 2.4.1.7 
fructose 
glucose 
EC 3.2.1.26 
fructose 
 
      Lactose 
 
UDP-galactose 
EC 2.4.1.22 
glucose 
galactose 1-phosphate 
EC 2.4.1.20 
glucose 
galactose 
EC 3.2.1.23 
glucose 
 
      Trehalose 
 
UDP-glucose 
EC 2.4.1.245 
glucose 
glucose 1-phosphate 
EC 2.4.1.231 
glucose 
glucose 
EC 3.2.1.28 
glucose 
 
       Maltose  
 
 
N.D. 
 
β-glucose 1-phosphate 
EC 2.4.1.8 
glucose 
glucose 
EC 3.2.1.20 
glucose 
 
To evaluate the potential of this newly designed galactosylation pathway starting from 
lactose (depicted in Figure 7.4), two E. coli mutants were created. E. coli W ∆cscAR ∆pgm 
∆agp ∆ushA ∆galETKM was used as base strain for the expression plasmids 
pGalKM/LgtC/UgpA and pGalKM/F3gt/UgpA, resulting in a globotriose and hyperoside 
producer respectively. Both strains grew on lactose as only carbon source, albeit 
relatively slow, but showed no production of the respective galactosides. In the case of 
globotriose, this could be attributed due to competition between the substrate and 
acceptor, which are both lactose. In the case of hyperoside, a glucose/galactose and 
glycerol/galactose medium were tested, but without success. A probable explanation 
lies in the fact that the intermediate gal1P accumulates in the cell, which is toxic at very 
low concentrations (galactosemia). A possible solution for the reduction of intracellular 
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gal1P is fine-tuning of the production pathway, by altering the promoter strengths of 
galK and ugpA, for example. An unconfirmed hypothesis about the toxicity of gal1P is 
that it competitively inhibits the essential enzyme phosphoglucosamine mutase (GlmM), 
thus preventing peptidoglycan synthesis and growth. Another solution in this context 
could be the search for an alternative GlmM that is not inhibited407. 
UDP
UDP
Lactose
Globotriose
Quercetin
Hyperoside
lgtC
f3gt
ugpA
E. coli W
Lactose
UDP-galactoseβ-galactose
Glucose
α-galactose
galactose 1-
phosphate
lacZ
galM galK
Biomassa
ushAgalETagp
lacY
 
Figure 7.4: Alternative strategy for the galactosylation of small molecules starting from 
lactose. The endogenous β-galactosidase (LacZ) is used to generate intracellular 
galactose, which is converted to UDP-galactose by the combined action of GalKM and the 
promiscuous UgpA. Deletion of galET, agp and ushA again give rise to a split metabolism 
whereby glucose is used as a carbon source. 
 
In conclusion, all routes towards a novel in vivo glycosylation platform were explored 
whereby a sucrose based approach was identified as the most promising. Metabolic 
engineering of E. coli W resulted in a versatile plug and play strain for the efficient 
glucosylation, galactosylation and rhamnosylation of small molecules. This new 
approach enabled the engineered host to grow and produce glycosides simultaneously, 
hereby using only sucrose as a cheap and sustainable carbon source. As a result, we 
obtained the highest product rates and titers reported to date, which outcompetes the 
majority of existing glycosylation processes. The ease of scaling up the created 
glycosylation strains truly paves the way for an economically viable production of 
various glycosides, thus meeting the envisioned objectives of this PhD thesis. Merging 
these novel insights and engineering approaches with existing microbial cell factories 
for production of aglycons will unlock a new era for sustainable de novo glycoside 
formation. 
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A1. Plasmids created and used 
Plasmid vectors Description 
pCX-Kan-P22 a Constitutive expression vector with P22 promoter, Ampr, Kanr 
pCX-Kan-P22-BaSP a 
pCX-Kan-P22 vector carrying BaSP (sucrose phosphorylase) 
from B. adolescentis 
pCX-Kan-P22-GalU pCX-Kan-P22 vector carrying galU from E. coli 
pCX-Kan-P22-UgpA pCX-Kan-P22 vector carrying ugpA from B. bifidum 
pCX-Kan-P22-GalK pCX-Kan-P22 vector carrying galK from E. coli 
pCX-Kan-P22-VvGT2 pCX-Kan-P22 vector carrying vvGT2 from Vitis vinifera 
pKan-L5-P22-LgtC-L6 
pUC57-Kan vector carrying C-25 truncated lgtC from N. 
meningitidis flanked by homologous linkers L5 and L6 and P22 
pKan-L5-P22-F3GT-L6 
pUC57-Kan vector carrying codon optimized f3gt from Petunia 
hybrida flanked by homologous linkers L5 and L6 and P22 
pKan-L5-P22-RhaGT-L6 
pUC57-Kan vector carrying codon optimized AtUGT78D1 from A. 
thaliana flanked by homologous linkers L5 and L6 and P22 
pCX-Kan-P22-SuSy 
pCX-Kan-P22 vector carrying codon optimized susy isoform 2 
from Solanum tuberosum 
pCX-Kan-P22-SuSy-S11D pCX-Kan-P22-SuSy vector with Ser11 changed to aspartic acid 
pCX-Kan-P22-SuSy-S11E pCX-Kan-P22-SuSy vector with Ser11 changed to glutamic acid 
p10-Trc a Inducible expression vector, Cmr, low copy number (± 10) 
p10-Trc-galT1 p10-Trc carrying galT1 from B. bifidum 
p10-Trc-galT2 p10-Trc carrying galT2 from B. bifidum 
p10-Trc-His-galT1 p10-Trc carrying galT1 from B. bifidum with His6 tag 
p10-Trc-His-galT2 p10-Trc carrying galT2 from B. bifidum with His6 tag 
pUC-Ln-RFP-Ln+1 a 
pUC57 vector carrying RFP sequence flanked by 200 bp 
homologous linkers, Ampr 
pUC-L4-P22-BaSP-L5 
pUC57 vector constitutively expressing BaSP flanked by 
homologous linkers L4 and L5 
pUC-L4-P22-GalE-L5 
pUC57 vector constitutively expressing galE from E. coli flanked 
by homologous linkers L4 and L5 
pUC-L4-P22-GalE2-L5 
pUC57 vector constitutively expressing galE2 from B. bifidum 
flanked by homologous linkers L4 and L5 
pUC-L4-P22-GalK-L5 
pUC57 vector constitutively expressing galK flanked by 
homologous linkers L4 and L5 
pUC-L4-P22-GalKM-L5 
pUC57 vector constitutively expressing galKM from E. coli 
flanked by homologous linkers L4 and L5 
pUC-L5-P22-VvGT2-L6 
pUC57 vector constitutively expressing vvGT2 flanked by 
homologous linkers L5 and L6 
pUC-L6-P22-GalU-L7 
pUC57 vector constitutively expressing galU flanked by 
homologous linkers L6 and L7 
pUC-L6-P22-UgpA-L7 
pUC57 vector constitutively expressing ugpA flanked by 
homologous linkers L6 and L7 
pUC-L4-P22-MUM4-L5 
pUC57 vector constitutively expressing codon optimized MUM4 
from A. thaliana flanked by homologous linkers L4 and L5 
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pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6 
pCX-Kan vector constitutively expressing BaSP and vvGT2 
flanked by homologous linkers 
pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-GalU-L7 
pCX-Kan vector constitutively expressing BaSP, vvGT2 and galU 
flanked by homologous linkers 
pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing BaSP, vvGT2 and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-BaSP-L5-P22-LgtC-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing BaSP, lgtC and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalE-L5-P22-LgtC-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galE, lgtC and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalE2-L5-P22-LgtC-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galE2, lgtC and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-BaSP-L5-P22-F3GT-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing BaSP, f3gt and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalE-L5-P22-F3GT-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galE, f3gt and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalE2-L5-P22-F3GT-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galE2, f3gt and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-MUM4-L5-P22-
RhaGT-L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing MUM4, AtUGT78D1 and 
ugpA flanked by homologous linkers 
pCX-Kan-L4-P22-SuSy-S11E-L5-P22-
VvGT2-L6 
pCX-Kan vector constitutively expressing susy S11E and vvGT2 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalK-L5-P22-LgtC-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galK, lgtC and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalK-L5-P22-F3GT-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galK, f3gt and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalKM-L5-P22-LgtC-
L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galKM, lgtC and ugpA 
flanked by homologous linkers 
pCX-Kan-L4-P22-GalKM-L5-P22-
F3GT-L6-P22-UgpA-L7 
pCX-Kan vector constitutively expressing galKM, f3gt and ugpA 
flanked by homologous linkers 
pKD46 b λ Red recombinase expression, Ampr 
pCP20 b FLP recombinase expression, Ampr, Cmr 
pKD3 b Cm cassette template, Cmr, Ampr 
pKD4 b Kan cassette template, Kanr, Ampr 
 
a plasmids were in house 
b plasmids obtained from Datsenko and Wanner (2000) 
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A2. Strains 
Strain (CODE) Description 
E. coli DH5α a General cloning host 
E. coli DH5α Competent Cells a Subcloning Efficiency Competent Cells 
E. coli MG1655 a Escherichia coli λ-, F-, rph-1 
E. coli BL21 (DE3) a Escherichia coli  F– λ(DE3 [lacI lacUV5-T7]) 
E. coli W Escherichia coli W LMG 11080 
B. bifidum 
Bifidobacterium bifidum (Tissier 1900) LMG 
11041 
E. coli MG1655 ΔgalETKM ΔgalU ΔushA Δugd 
Δagp(sMEMO_WT) 
E. coli MG1655 with galETKM, galU, ushA, ugd, 
and agp -deleted 
sMEMO_UgpA sMEMO_WT carrying pCX-Kan-P22-UgpA 
sMEMO_GalU sMEMO_WT carrying pCX-Kan-P22-GalU 
sMEMO_GalT1 sMEMO_WT  carrying p10-Trc-GalT1 
sMEMO_GalT2 sMEMO_WT  carrying p10-Trc-GalT2 
sMEMO_His_GalT1 E. coli BL21 (DE3) carrying p10-Trc-His-GalT1 
sMEMO_His_GalT2 E. coli BL21 (DE3) carrying p10-Trc-His-GalT2 
E. coli W ∆cscAR (sGLC1) E. coli W with cscAR-deleted 
E. coli W ∆cscAR ∆melA::L4-P22-BaSP-L5 
E. coli W with cscAR and melA deleted and L4-
P22-BaSP-L5  integrated in genome 
E. coli W ∆cscAR ∆glgC::L4-P22-BaSP-L5 
E. coli W with cscAR and glgC deleted and L4-
P22-BaSP-L5  integrated in genome 
E. coli W ∆cscAR ∆pgm (sGLC2) E. coli W with cscAR, and pgm-deleted 
E. coli W ∆cscAR ∆pgm ∆agp (sGLC3) E. coli W with cscAR, pgm, and agp-deleted 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA (sGLC4) 
E. coli W with cscAR, pgm, agp, and ushA-
deleted 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC (sGLC5) 
E. coli W with cscAR, pgm, agp, ushA and glgC-
deleted 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC ∆yihX::cat 
(sGLC6) 
E. coli W with cscAR, pgm, agp, ushA , glgC and 
yihX –deleted with Cm cassette at yihX position 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC ∆yidA::cat 
(sGLC7) 
E. coli W with cscAR, pgm, agp, ushA , glgC and 
yidA –deleted with Cm cassette at yidA position 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔgalETKM (sGLYC4) 
E. coli W with cscAR, pgm, agp, ushA and 
galETKM-deleted 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
(sGLYC1) 
E. coli W with cscAR, pgm, agp, ushA and lacZYA 
deleted and P22-lacY integrated in genome 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalTKM (sGLYC3) 
E. coli W with cscAR, pgm, agp, ushA, lacZYA 
and galTKM deleted and P22-lacY integrated in 
genome 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔmelA::L4-P22-BaSP-L5 
E. coli W with cscAR, pgm, agp, ushA, lacZYA 
and melA deleted and P22-lacY and L4-P22-
BaSP-L5 integrated in genome 
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E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔmelA::L4-P22-BaSP-L5 ΔgalETKM (sGLYC2) 
E. coli W with cscAR, pgm, agp, ushA, lacZYA, 
melA and galETKM deleted and P22-lacY and 
L4-P22-BaSP-L5  integrated in genome 
E. coli W + pVvGT2 E. coli W carrying pCX-Kan-P22-VvGT2 
E. coli W + pLgtC E. coli W carrying pKan-L5-P22-LgtC-L6 
E. coli W + pF3GT E. coli W carrying pKan-L5-P22-F3GT-L6 
E. coli W + pRhaGT E. coli W carrying pKan-L5-P22-RhaGT-L6 
E. coli W ∆cscAR + pBaSP sGLC1 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR + pSuSy sGLC1 carrying pCX-Kan-P22-SuSy 
E. coli W ∆cscAR + pSuSy-S11D sGLC1 carrying pCX-Kan-P22-SuSy-S11D 
E. coli W ∆cscAR + pSuSy-S11E sGLC1 carrying pCX-Kan-P22-SuSy-S11E 
E. coli W ∆cscAR ∆pgm + pBaSP sGLC2 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR ∆pgm ∆agp + pBaSP sGLC3 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA + pBaSP sGLC4 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC + pBaSP sGLC5 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC ∆yihX::cat + 
pBaSP 
sGLC6 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC ∆yidA::cat + 
pBaSP 
sGLC7 carrying pCX-Kan-P22-BaSP 
E. coli W ∆cscAR + pBaSP/VvGT2 
sGLC1 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6 
E. coli W ∆cscAR ∆pgm ∆agp + pBaSP/VvGT2 
sGLC3 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA + pBaSP/VvGT2 
sGLC4 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6 
E. coli W ∆cscAR + pBaSP/VvGT2/GalU 
sGLC1 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-GalU-L7 
E. coli W ∆cscAR ∆pgm ∆agp + pBaSP/VvGT2/GalU 
sGLC3 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-GalU-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA + 
pBaSP/VvGT2/GalU 
sGLC4 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-GalU-L7 
E. coli W ∆cscAR + pBaSP/VvGT2/UgpA 
sGLC1 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp + pBaSP/VvGT2/UgpA 
sGLC3 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA + 
pBaSP/VvGT2/UgpA 
sGLC4 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC + 
pBaSP/VvGT2 
sGLC5 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC + 
pBaSP/VvGT2/GalU 
sGLC5 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-GalU-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC + 
pBaSP/VvGT2/UgpA 
sGLC5 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
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E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC ∆yihX::cat + 
pBaSP/VvGT2/UgpA 
sGLC6 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆glgC ∆yidA::cat + 
pBaSP/VvGT2/UgpA 
sGLC7 carrying pCX-Kan-L4-P22-BaSP-L5-P22-
VvGT2-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY + 
pBaSP/LgtC/UgpA 
sGLYC1 carrying pCX-Kan-L4-P22-BaSP-L5-
P22-LgtC-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalTKM + pBaSP/LgtC/UgpA 
sGLYC3 carrying pCX-Kan-L4-P22-BaSP-L5-
P22-LgtC-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP + pGalE/LgtC/UgpA 
sGLYC2 carrying pCX-Kan-L4-P22-GalE-L5-
P22-LgtC-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP + pGalE2/LgtC/UgpA 
sGLYC2 carrying pCX-Kan-L4-P22-GalE2-L5-
P22-LgtC-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP + pGalE/F3GT/UgpA  
sGLYC2 carrying pCX-Kan-L4-P22-GalE-L5-
P22-F3GT-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP + pGalE2/F3GT/UgpA 
sGLYC2 carrying pCX-Kan-L4-P22-GalE2-L5-
P22-F3GT-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP + pRhaGT + pMUM4  
sGLYC2 carrying pCX-Kan-L5-P22-RhaGT-L6 
and pUC-L4-P22-MUM4-L5 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ΔlacZYA::P22-lacY 
ΔgalETKM ΔmelA::P22-BaSP + pMUM4/RhaGT/UgpA 
sGLYC2 carrying pCX-Kan-L4-P22-MUM4-L5-
P22-RhaGT-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆galETKM + 
pGalK/LgtC/UgpA 
sGLYC4 carrying pCX-Kan-L4-P22-GalK-L5-
P22-LgtC-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆galETKM + 
pGalK/F3GT/UgpA 
sGLYC4 carrying pCX-Kan-L4-P22-GalK-L5-
P22-F3GT-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆galETKM + 
pGalKM/LgtC/UgpA 
sGLYC4 carrying pCX-Kan-L4-P22-GalKM-L5-
P22-LgtC-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA ∆galETKM + 
pGalKM/F3GT/UgpA 
sGLYC4 carrying pCX-Kan-L4-P22-GalKM-L5-
P22-F3GT-L6-P22-UgpA-L7 
E. coli W ∆cscAR ∆pgm ∆agp ∆ushA + pSuSy/VvGT2 
sGLC4 carrying pCX-Kan-L4-P22-SuSy-S11E-
L5-P22-VvGT2-L6 
 
a strains were in house 
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A3. Accession numbers of cloned genes 
Gene Acc. number Remarks 
galU NC_000913 Amplified from gDNA 
ugpA KC261357 Amplified from gDNA. Deposited at GenBank. 
galT1 KC261358 Amplified from gDNA. Deposited at GenBank. 
galT2 KC261359 Amplified from gDNA. Deposited at GenBank. 
BaSP NC_008618 Sequence has a N-terminal hexahistidine tag 
vvGT2 JN164680 Sequence was provided by N. Terrier (INRA) 
lgtC U65788 Sequence was C-terminal truncated (25 AA) and ordered 
f3gt AF165148 Sequence was codon optimized and ordered 
MUM4 NC_003070 Sequence was codon optimized and ordered 
AtUGT78D1 NC_003070 Sequence was codon optimized and ordered 
galK NC_000913 Amplified from gDNA. 
galM NC_000913 Amplified from gDNA. 
galE NC_000913 Amplified from gDNA. 
galE2 KJ543703 Amplified from gDNA. Deposited at GenBank. 
susy P49039 Sequence was codon optimized and ordered 
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A4. Reaction overview 
Enzyme Reaction EC code 
Agp Glucose 1-phosphate + H2O   Glucose + Phosphate 3.1.3.10 
BaSP Sucrose + phosphate  Fructose + Glucose 1-phosphate 2.4.1.7 
CscA Sucrose + H2O   Glucose + Fructose 3.2.1.26 
CscB Sucrose[extracellular] + H+   Sucrose[intracellular] + H+ - 
CscK Fructose + ATP   Fructose 6-phosphate + H2O + ADP 2.7.1.4 
F3GT Flavonol + UDP-galactose  Flavonol-3-O-galactoside + UDP 2.4.1.234 
GalE UDP-glucose  UDP-galactose 5.1.3.2 
GalE2 UDP-glucose  UDP-galactose 5.1.3.2 
GalK Galactose + ATP   Galactose 1-phosphate + ADP 2.7.1.6 
GalM α-D-galactose  β-D-galactose 5.1.3.B1 
GalT(1) Galactose 1-phosphate + UDP-glc  UDP-gal + glucose 1-phosphate 2.7.7.12 
GalT2 galNAc1P + UDP-glcNAc  glcNAc1P + UDP-galNAc 2.7.7.12 
GalU UTP + Glucose 1-phosphate  UDP-glucose + pyrophosphate  2.7.7.9 
GlgC ATP + Glucose 1-phosphate  ADP-glucose + pyrophosphate  2.7.7.27 
Glk Glucose[intracellular] + ATP   Glucose 6-phosphate + ADP 2.7.1.2 
LgtC Lactose[moiety] + UDP-galactose  Globotriose[moiety] + UDP 2.4.1.44 
Mak Fructose[intracellular] + ATP   Fructose 6-phosphate + ADP 2.7.1.4 
MelA Globotriose + H2O  Lactose + Galactose 3.2.1.22 
MUM4 UDP-glucose + NADPH + H+  UDP-rhamnose + NADP+ + H2O - 
Ndk Nucleoside diphosphate + ATP  Nucleoside triphosphate + ADP 2.7.4.6 
Pgi Glucose 6-phosphate  Fructose 6-phosphate 5.3.1.9 
Pgm Glucose 1-phosphate  Glucose 6-phosphate 5.4.2.2 
RhaGT Flavonol + UDP-rhamnose  Flavonol-3-O-rhamnoside + UDP 2.4.1.- 
SuSy Sucrose + UDP   UDP-glucose + Fructose 2.4.1.13 
Ugd UDP-glucose + 2 NAD+ + H2O   UDP-glucuronate + 2 NADH + 3 H+ 1.1.1.22 
UgpA UTP + sugar 1-phosphate   pyrophosphate + UDP-sugar 2.7.7.64 
UshA UDP-glucose + H2O  UMP + glucose 1-phosphate + 2 H+ 3.6.1.45 
 UMP + H2O  uridine + phosphate 3.1.3.5 
VvGT2 UDP-glucose + gallic acid   UDP + 1-galloyl-β-D-glucose 2.4.1.136 
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A5. Primers for knockouts and knockins 
Primers a Oligonucleotide sequences (5’-3’) b 
Fw_galETKM_KO_MG1
655 
CTGGTGATTTGAACAATATGAGATAAAGCCCTCATGACGAGGGCGTAACAgtgtaggctg
gagctgcttc 
Fw_galETKM_KO_W 
GTGATTTGAGCAATATAAGGATAAAGCCCTCATTACGAGGGCTTCAGGTGgtgtaggc
tggagctgcttc 
Rv_galETKM_KO 
CTTTGTTATGCTATGGTTATTTCATACCATAAGCCTAATGGAGCGAATTATGcatatga
atatcctccttag 
Fw_galU_KO GCGATACAGAAATATGAACACGTTCAAAACACGAACAGTCCAGGAGAATTTAAgtgta
ggctggagctgcttc 
Rv_galU_KO ACGGCGTCGATTGCTCAACGCCGTTTCGTGGATAACACCGATACGGATGcatatgaatatc
ctccttag 
Fw_ushA_KO 
TCGCGTCATACTATTTTTCAACACGTTGAAATCAGGTCAGGGAGAGAAGTgtgtaggctg
gagctgcttc 
Rv_ushA_KO 
CCCGCCGCGATTAAGCATTGTGCCGGATGCAAACATCCGGCACTTTCGGAcatatgaatat
cctccttag 
Fw_ugd_KO 
TGTAAGTAACAAAAGACAATCAGGGCGTAAATAGCCCTGATAACAAGATGgtgtaggct
ggagctgcttc 
Rv_ugd_KO 
GATGCTAAAAACATCATGATTCACAGTTAAGTTAATTCTGAGAGCATGAAcatatgaat
atcctccttag 
Fw_agp_KO 
CATATTTCTGTCACACTCTTTAGTGATTGATAACAAAAGAGGTGCCAGGAgtgtaggctg
gagctgcttc 
Rv_agp_KO_MG1655 
TAAAAACGTTTAACCAGCGACTCCCCCGCTTCTCGCGGGGGAGTTTTCTGcatatgaatat
cctccttag 
Rv_agp_KO_W TAAAAACGTTTAACCAGCGACTCCCCCACTTCTCGCGGGGGAGTTTTCTGcatatgaatat
cctccttag 
Fw_cscAR_KO AAAAGTTAACGTTAACAATTCACCAAATTTGCTTAACCAGGATGATTAAAgtgtaggct
ggagctgcttc 
Rv_cscAR_KO GCTTGGGTATGGCTTCATTAAAGGATGTCGCACGCCTGGCGGGAGTGTCGcatatgaata
tcctccttag 
Fw_pgm_KO TGAGAAGGTTCGCGGAACTATCTAAAACGTTGCAGACAAAGGACAAAGCAgtgtaggct
ggagctgcttc 
Rv_pgm_KO CAAAGTAAAAAAGGGCGATCTTGCGACCGCCCTTTTTTTATTAAATGTGTcatatgaata
tcctccttag 
Fw_glgC_KO AGACCGCCGGTTTTAAGCAGCGGGAACATCTCTGAACATACATGTAAAACCTGCAgtg
taggctggagctgcttc 
Rv_glgC_KO GTCTGGCAGGGACCTGCACACGGATTGTGTGTGTTCCAGAGATGATAAAAAAGGAGT
TAGTCcatatgaatatcctccttag 
Fw_lacZYA_KO 
GCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTTCGCCTACC
TGTGACGGAAG 
Rv_lacZYA_KO 
GCTGAACTTGTAGGCCTGATAAGCGCAGCGTATCAGGCAATTTTTATAATCTTCATT
TAAATGGCGCGC 
Fw_galTKM_KO_W 
GGCACTGGCAGTCACGCCATCCACAGGGATATCCCGATTAAGGAACGACCgtgtaggctg
gagctgcttc 
Rv_galTKM_KO_W 
GTGATTTGAGCAATATAAGGATAAAGCCCTCATTACGAGGGCTTCAGGTGcatatgaata
tcctccttag 
Fw_yihX_KO 
CCATCCTTTCCCGCTACAGTTAATTTCTTGTGGCGCGAAAGGAGGCAAAAgtgtaggctg
gagctgcttc 
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Rv_yihX_KO 
CCAGGCCCATAGTGGACGGGTACGGTGCCTGGCTTTGTCCTGAATGGTTTcatatgaatat
cctccttag 
Fw_yidA_KO 
AATAATCAGTAAGCGGGCAAACGCGTTTATGCTGTTTGCCCGTCCACTGAgtgtaggctg
gagctgcttc 
Rv_yidA_KO 
GAGCGGAATCGCGTTAGCATGGGTCAGGAACTAATCTACCTGGGGAACTCcatatgaata
tcctccttag 
Fw_lacY_KI CAGGTTTCCCGACTGGAAAG 
Rv_lacY_KI TGTGCGTCGTTGGGCTGATG 
Fw_L4_start_BaSP_KI GGCAGGAGTATCGTCCGTAG 
Rv_L5_tail_BaSP_KI CTGAAGGCGCTCCTCATAC 
Fw_glgC::BaSP_L GACCATGTTCGTCACCGGCCAGTAACATCGCCTTGATAGGCCAGGTTGTG 
Rv_glgC::BaSP_L ACAGTTGAAACTACGGACGATACTCCTGCCGAAATGCTACGGAAGTTAGG 
Fw_glgC::BaSP_R 
GTATTCAGCCAGTATGAGGAGCGCCTTCAGGACTAACTCCTTTTTTATCATCTCTGGA
AC 
Rv_glgC::BaSP_R CGATGTTACTGGCCGGTGAC 
Fw_melA::BaSP_L GGATATTCCCTTCTGGTCGCTGGTTCCAAGCGTGATATGACCCTGATTG 
Rv_melA::BaSP_L ACAGTTGAAACTACGGACGATACTCCTGCCCTCCTGGCTTGCTTGAATAAC 
Fw_melA::BaSP_R GTATTCAGCCAGTATGAGGAGCGCCTTCAGAACGCGACTAAACGCTACTG 
Rv_melA::BaSP_R TTGGAACCAGCGACCAGAAG 
Fw_glgC_KO_BaSP_KI AAGCCCGCTGGCCATTTCTG 
Rv_glgC_KO_BaSP_KI CGCCGCGTTAATCCATCTGC 
Fw_melA_KO_BaSP_KI TGCTTCACGCAGGATCTGAG 
Rv_melA_KO_BaSP_KI ACAGACAGCCCAACGACATC 
 
a Notations KO: knockout, KI: knockin, MG1655: primer specific for E. coli MG1655 
genome, W: primer specific for E. coli W genome. 
b Priming sites for the kanamycin resistance marker are denoted in lower case, flanking 
regions in upper case. 
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A6. Primers for plasmid constructions and SuSy mutagenesis 
Primers Oligonucleotide sequences (5’-3’) a 
Fw_galU_EcoRI CCGGCGAATTCGGAGGAAACAAAGATGGCTGCCATTAATACGAAAG 
Rv_galU_SacI CGCCGAGCTCTTACTTCTTAATGCCCATCTC 
Fw_ugpA_EcoRI CCGGCGAATTCGGAGGAAACAAAGATGTTTGCCGAAGATCTGAAACG 
Rv_ugpA_SacI CGCCGAGCTCTCACACCCAATCACCGGGCTCGATG 
Fw_galT1_NdeI AGGTCGCGCATATGGCAGAAATCACCAACTACAC 
Rv_galT1_PmeI 
TATGTTTAAACGCTAGCCTCGAGGCGGCCGCGAGCTCTAAAGGGCCGGCCTAAACG
AATTCTCAGTCGGAGATGTCGATCTG 
Fw_galT2_NdeI AGGTCGCGCATATGACCACGGAAGAGAAGAAGG 
Rv_galT2_PmeI 
TATGTTTAAACGCTAGCCTCGAGGCGGCCGCGAGCTCTAAAGGGCCGGCCTAAACG
AATTCCTAATGCTGAGTATGGAATCCGAGGCCTTCC 
Fw_galT1_his 
ATGGGCGGCTCACACCACCACCACCACCACGGTATGGCGTCTATGGCAGAAATCAC
CAACTAC 
Fw_galT2_his 
ATGGGCGGCTCACACCACCACCACCACCACGGTATGGCGTCTATGACCACGGAAGA
GAAGAAG 
Rv_galT1_his CAATGATGATGATGATGATGGTCGACTCAGTCGGAGATGTCGATCTGTC 
Rv_galT2_his CAATGATGATGATGATGATGGTCGACCTAATGCTGAGTATGGAATC 
Fw_backbone_p10 
AGACGCCATACCGTGGTGGTGGTGGTGGTGTGAGCCGCCCATATGTTATTCCTCCT
TATTTAATC 
Rv_backbone_p10 GTCGACCATCATCATCATCATCATTG 
Fw_L4_backbone ATTTATAAATGAAGCGGCCGCCCGGGATAGACTTCAGGCAGACCACGCTTGAC 
Rv_L5_Backbone TAACCATGGGCTAGCATTGC 
Fw_L5_backbone ATTTATAAATGAAGCGGCCGCCCGGGATCTGAAGGCGCTCCTCATACTG 
Rv_L6_Backbone TAACCATGGGCTAGCGGCCAGCAAAG 
Fw_L6_backbone ATTTATAAATGAAGCGGCCGCCCGGGATGTTCCGATGGCGTGCATCAG 
Rv_L7_Backbone TAACCATGGGCTAGCAATGC 
Univ_Fw_primer_P22
_insert 
ATCCCGGGCGGCCGCTTCATTTATAAATTTC 
Rv_insert_BaSP AGTCGGAACGGCAATGCTAGCCCATGGTTATCAGGCGACGACAGGCGGATTG 
Rv_insert_VvGT2 
GTCCCTTTGCTGGCCGCTAGCCCATGGTTATTAAATTTTCTTTGACTTGCAAACCA
GCTCCATAC 
Rv_insert_galU GGTTAAGGCCGTTTGGCATTGCTAGCCCATGGTTATTACTTCTTAATGCCCATCTC 
Rv_insert_UgpA 
GGTTAAGGCCGTTTGGCATTGCTAGCCCATGGTTATCACACCCAATCACCGGGCTC
GATG 
Fw_pCX_backbone GAAGGCGGCGGTGGAATCGAAATC 
Rv_pCX_backbone CGTGAGTTTTCGTTCCACTGAGCGTCAGAC 
Fw_L4_BaSP 
TCACGAGATTTCGATTCCACCGCCGCCTTCAGACGAATTACTTATCTGGCAGGAGT
ATC 
Rv_BasP_L5 GTCTGACGCTCAGTGGAACGAAAACTCACGCTGAAGGCGCTCCTCATACTG 
Fw_ori_pCX CGTTCCACTGAGCGTCAGAC 
Rv_L5_stitch GCCGTTGCACTAATACAGGGTAATTC 
Fw_L5_stitch GAGGGAATTACCCTGTATTAG 
Rv_L6_end TTTCTACGGGGTCTGACGCTCAGTGGAACGGTTCCGATGGCGTGCATCAG 
Rv_L6_stitch GTAAAGCGGGCGCACCCTCTGAGAATTAAC 
Fw_L6_stitch GTTAATTCTCAGAGGGTGCGCCCGCTTTAC 
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Rv_L7_end TTTCTACGGGGTCTGACGCTCAGTGGAACGCATCTTCTTCGAGTGGTCCCAGAAC 
Fw_P22_galE CCGTCGACCTCGAATTCGGAGGAAACAAAGATGAGAGTTCTGGTTACCGGTGGTAG 
Rv_galE_T4 GAACGGCAATGCTAGCCCATGGTTATTAATCGGGATATCCCTGTGGATGG 
Fw_P22_galE2 CCGTCGACCTCGAATTCGGAGGAAACAAAGATGACAGTTCTCGTTACCGGTGGGTG 
Rv_galE2_T4 GAACGGCAATGCTAGCCCATGGTTATCAGCCGACCTGCTTCCAGGTG 
Rv_bb_general CTTTGTTTCCTCCGAATTCGAGGTC 
Fw_L4_stitch CGATGGTCAAGCGTGGTCTG 
Rv_L4_stitch AGACTTCAGGCAGACCACGC 
Fw_L5-stitch_CLIVA CGCGGA*CATGAT*TTTGATTG 
Rv_L6-stitch_CLIVA CGCTGC*GGCAAT*CTTATGG 
Fw_L6-stitch_CLIVA ATTGCC*GCAGCG*CTTTATTG 
Rv_L5-stitch_CLIVA ATCATG*TCCGCG*CCAGTTTC 
Rv_SuSy_T6 CCGTTTGGCATTGCTAGCCCATGGTTATTATTCAACTGCCAGCGGAACC 
Rv_L6_P22 ATTTATAAATGAAGCGGCCGCCCGGGATGTTCCGATGGCGTGCATCAG 
Rv_L7_ori TTTCTACGGGGTCTGACGCTCAGTGGAACGCATCTTCTTCGAGTGGTCCCAGAAC 
Rv_L4_P22 ATTTATAAATGAAGCGGCCGCCCGGGATAGACTTCAGGCAGACCACGCTTGAC 
Rv_galK_T4 GGAACGGCAATGCTAGCCCATGGTTATCAGCACTGTCCTGCTCCTTG 
Fw_P22_galKM 
CCGTCGACCTCGAATTCGGAGGAAACAAAGATGAGTCTGAAAGAAAAAACACAAT
CTC 
Rv_galKM_T4 GGAACGGCAATGCTAGCCCATGGTTACTACTCAGCAATAAACTGATATTCC 
Fw_pCXkanBackbone CATCTTTGTTTCCTCCGAATTCG 
Rv_pCXKanBackbone TAAGAGCTCCCAACGCGTTGGATG 
Fw_SuSy_EcoRI GGTACCGAATTCGGAGGAAACAAAGATGGCAGAACGTGTTCTGAC 
Rv_SuSy_SacI GCCCAGGAGCTCTTATTATTCAACTGCC 
Rv_backbone_S11E ATGAACACGGGTCAGAACACG 
Fw_backbone_S11E GTAAACTGGCACAGCTGGTTCC 
Fw_insert_S11E GGAAACAAAGATGGCAGAACGTGTTCTGACCCGTGTTCATGAACTGCGTGAACG 
Rv_insert_S11E CTTATTATTCAACTGCCAGCGGAACCAGCTGTGCCAGTTTACG 
Rv_Susy_end 
TTGCATGCCTGCATCCAACGCGTTGGGAGCTCTTATTATTCAACTGCCAGCGGAAC
C 
Fw_SuSyThr111 
GATCCGTCGACCTCGAATTCGGAGGAAACAAAGATGACCGTTCCGGAATTTCTGCA
GTTTAAAG 
Fw_Susy_Pr139 GATCCGTCGACCTCGAATTCGGAGGAAACAAAGATGCCGTTTACCGCAAGCTTTCC 
Fw_Susy_Gly157 
GATCCGTCGACCTCGAATTCGGAGGAAACAAAGATGGGTGTGGAATTTCTGAATC
GTCATC 
Fw_Susy_Thr243 
GATCCGTCGACCTCGAATTCGGAGGAAACAAAGATGACCGCAGAACGTGTGCTGGA
AATG 
Fw_Susy_Asp262 
GATCCGTCGACCTCGAATTCGGAGGAAACAAAGATGGATAGCTGTACCCTGGAAA
AATTTCTG 
Fw_Susy_Ile273 
GATCCGTCGACCTCGAATTCGGAGGAAACAAAGATGATTCCGATGGTGTTCAATGT
TG 
Fw_SuSy_begin CTTGGGATCCGTCGACCTCGAATTC 
Fw_dgBackboneA GGCACTGGAACGTGAAATGC 
Rv_dgBackboneA CATTTTCTTGGGCAAAATAACCATGCGGACTC 
 
Fw_dgloopA 
 
CCGCATGGTTATTTTGCCCAAGAAAATGNNNNNNNNNNNNNNNNNNNNNNNN
NNNNGGTTGTTTATATTCTGGATCAGGTTCCG 
Rv_dgloopA GTTTCAGCATTTCACGTTCCAGTGCCGGAACCTGATCCAGAATATAAACAACC 
Fw_ins_helixNa 
TTCTGAGTCCGCATGGTTATTTTGCCCAAGAAAATGTTCTGGGTTATCCGGATACC
GGTGGTC 
Appendices 
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Rv_ins_helixNa 
TGGTGCCAACTGCATCCGGCAGCAGACGGGTAACAATCAGAATACGCGGTTTAATG
TCCAG 
Rv_bb_helixNa CCAGAACATTTTCTTGGGC 
Fw_bb_helixNa TGATTGTTACCCGTCTGCTG 
Fw_ins_loopA 
GCACCGGATAGCTGTACCCTGGAAAAATTTCTGGGTCGTATTCCGATGGTGTTCAA
TGTTGTTATTCTG 
Rv_ins_loopA 
CGGTACGAAACGGCACACGCAGAATATGGCTATGTTCGGTGCCAAAAACTTTTTCC
AGACGC 
Fw_bb_loopA CCGAACATAGCCATATTCTGCGTGTG 
Rv_bb_loopA AATACGACCCAGAAATTTTTCCAGGG 
 
a Restriction sites are underlined. His6 tags are underlined and in bold. 
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A7. Cloning strategy for plasmids of the glucosylation platform 
pUC57-Ln-RFP-Ln+1
Ln
Ln+1
Terminator n
RFP
Fw_Ln_backbone
Rv_Ln+1_backbone
Ampr
pCX-Kan-P22-gene
P22
gene
Fw_primer_P22_insert
Rv_insert_gene
Kanr
Terminator
pUC-L4-P22-BaSP-L5
L4
L5
Term. 4
BaSP
Fw_L4_BaSP
Rv_L5_stitch
Ampr
P22
gene =
BaSP
VvGT2
GalU
UgpA
pUC-L5-P22-VvGT2-L6
L5
L6
Term. 5
VvGT2
Fw_L5_stitch
Rv_L6_stitch
Ampr
P22
pUC-L6-P22-GalU-L7
L6
L7
Term. 6
GalU or 
UgpA
Fw_L6_stitch
Rv_L7_stitch
Ampr
P22
Gibson Assembly
pCX-Kan-P22-gene
P22
gene
Fw
_p
CX
_b
ac
k
b
on
e
Kanr
Terminator
R
v
_p
C
X
_b
a
ck
b
o
n
e
G
ib
s
o
n
 A
s
s
e
m
b
ly
pCX-Kan-L4-P22-
BaSP-L5
L4
L5
Term. 4
BaSP
Rv_L5_stitch
P22
Kanr
Rv_ori_pCX
Gibson Assemblies
‘final stitching’
L5 L6Term. 5VvGT2P22
L6 L7Term. 5GalUP22
L6 L7Term. 5UgpAP22
PCR
pCX-Kan-L4-P22-
BaSP-L5-P22-
VvGT2-L6
L4
L5
Term. 4
BaSP
P22
Kanr
L6
Term. 5
VvGT2
P22
L4
L5
Term. 4
BaSP
P22
Kanr
L6
Term. 5
VvGT2
P22
L7
Term. 6
GalU or 
UgpA P22
pCX-Kan-L4-P22-
BaSP-L5-P22-
VvGT2-L6-P22-
UgpA-L7
Rv_L6_end
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A8. Cloning strategy for constitutive lacY knockin 
 
Promoter
lacI
Term. Prom.
lacZ lacY lacA
Terminator
lac operon
Operator
Cm resistance
pKD3
gDNA E. coli WA
B Fw_lacZYA_KO Rv_lacZYA_KO
Promoter
lacI
Terminator Terminator
Cm resistance gDNA E. coli W
Promoter
lacI
Term.
lacY
Terminator
gDNA s1
P22 (truncated)
Kan resistance
FRT FRTFw_lacY_KI Rv_lacY_KI
Promoter
lacI
Term.
lacY
Terminator
gDNA E. coli W
P22 (truncated)
Kan resistance
FRT FRT
+ pKD46
+ pKD46
+ pCP20
Promoter
lacI
Term.
lacY
Terminator
gDNA E. coli W
P22 (truncated)
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A9. Cloning strategy for plasmids of the galactosylation platform 
 
 
L4
L5
Term. 4
BaSP
P22
Kan
r
L6
Term. 5
VvGT2
P22
L7
Term. 6
UgpA
P22
pCX-Kan-L4-P22-BaSP-
L5-P22-VvGT2-L6-P22-
UgpA-L7
pCX-Kan-L5-P22-
lgtc_C25-L6
L5
L6
Term. 5
lgtC_C25
Fw_L5_stitch
P22 L5
Term. 5
f3gt
P22
Kan
r Kan
r
pCX-Kan-L5-P22-
f3gt-L6
Rv_L6_stitch
Rv_L5_stitch/
Rv_L5_stitch_CLIVA
Fw_L6_stitch/
Fw_L6_stitch_CLIVA
L6
Rv_L6_stitch
_CLIVA
Fw_L5_stitch_CLIVA
Gibson Assembly CLIVAssembly 
L4
L5
Term. 4
BaSP
P22
Kan
r
L6
Term. 5
lgtC_C25
P22
L7
Term. 6
UgpA
P22
pCX-Kan-L4-P22-BaSP-
L5-P22-lgtC_C25-L6-
P22-UgpA-L7
L4
L5
Term. 4
BaSP
P22
Kan
r
L6
Term. 5
f3gt
P22
L7
Term. 6
UgpA
P22
pCX-Kan-L4-P22-BaSP-
L5-P22-f3gt-L6-P22-
UgpA-L7
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galEgDNA E. coli W
Promoter
galE2 gDNA B. bifidum
Promoter
Fw_P22_galE Rv_galE_T4 Fw_P22_galE2 Rv_galE2_T4
pUC-
L4-P22-gene-L5
Ampr
L4L5
Term.4 P22
gene
Fw_T4 Rv_bb_general
Gibson 
Assembly
Gibson 
Assembly
pUC-
L4-P22-galE2-L5
Ampr
L4L5
Term.4 P22
galE2
pUC-
L4-P22-galE-L5
Ampr
L4L5
Term.4 P22
galE
Rv_L5_stitch
Fw_L4_stitch Rv_L5_stitch
Fw_L4_stitch
L4
L5
Term. 4
BaSP
P22
Kanr
L6
Term. 5
lgtC_C25
P22
L7
Term. 6
ugpA
P22
pCX-Kan-L4-P22-BaSP-
L5-P22-lgtC_C25-L6-
P22-UgpA-L7
Fw_L5_stitch
Rv_L4_stitch
Gibson Assembly
L4
L5
Term. 4
galE
P22
Kanr
L6
Term. 5
lgtC_C25
P22
L7
Term. 6
ugpA
P22
pCX-Kan-L4-P22-galE-
L5-P22-lgtC_C25-L6-
P22-ugpA-L7
L4
L5
Term. 4
galE2
P22
Kanr
L6
Term. 5
lgtC_C25
P22
L7
Term. 6
ugpA
P22
pCX-Kan-L4-P22-galE2-
L5-P22-lgtC_C25-L6-
P22-ugpA-L7
Gibson Assembly
 
 
 
Appendices 
141 
 
A10. Cloning strategy for KO/KI of ΔmelA::BaSP and ΔglgC::BaSP 
Promoter
melA melB
Promoter
glgCglgA glgXBgDNA E. coli W
pUC-
L4-P22-BaSP-L5
Ampr
L4L5
Term.4 P22
BaSP
Fw_L4_start
_BaSP_KI
Rv_L5_tail
_BaSP_KI
Fw_melA
::BaSP_L
Rv_melA
::BaSP_R
Rv_melA
::BaSP_L
Rv_melA
::BaSP_R
Fw_melA
::BaSP_L
Rv_melA
::BaSP_L
Rv_glgC
::BaSP_R
Rv_glgC
::BaSP_R
melA_L melA_R glgC_L glgC_R
Gibson 
Assembly
Gibson 
Assembly
L4L5
Term.4 P22
BaSP
melA_LmelA_R
L4L5
Term.4 P22
BaSP
glgC_LglgC_R
Circular
DNA
Circular
DNA
Fw_melA_KO
_BaSP_KI
Rv_melA_KO
_BaSP_KI
Fw_glgC_KO
_BaSP_KI
Rv_glgC_KO
_BaSP_KI
P22
BaSP
Term. 4
L5L4 melA_RmelA_L
P22
BaSP
Term. 4
L5L4 glgC_RglgC_L
melA melB
Promoter
glgCglgA glgXBgDNA E. coli W
+ pKD46
P22
BaSP
Term. 4
L5L4 melB
P22
BaSP
Term. 4
L5L4glgA glgXB
melR
Promoter
melR
melR gDNA E. coli W
gDNA E. coli W  
Figure A10. BaSP knockin strategy at two different loci, resulting in two new strains. First, BaSP and its 
surrounding linker sequences, were amplified from the plasmid pUC-L4-P22-BaSP-L5 using PCR. Adjacent 
DNA regions of the integration spots, genes melA and glgC, were also amplified from the genome. The primers 
were designed with the reverse primer of the left border and the forward primer of the right border having 
an overhanging sequence homologous to respectively linker L4 and L5. Also the forward primer of the left 
border has an overhang sequence homologous to the right end of the right border. For both the melA and glgC 
gene replacement, these 3 pieces were put together using Gibson Assembly. Subsequently, these circular DNA 
molecules were used as a template to pick up the knockin-knockout constructs containing prolonged 
homologous regions for recombination. 
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A11. Cloning strategy for plasmid of the rhamnosylation platform 
 
L5L6
Term.5 P22
RhaGT
pUC-L4-P22-
MUM4-L5
L4L5
Term.4 P22
MUM4
Rv_L5_stitch
Fw_L4_stitch Rv_L6_stitch
Fw_L5_stitch
L4
L5
Term. 4
BaSP
P22
Kanr
L6
Term. 5
LgtC
P22
L7
Term. 6
UgpA
P22
pCX-Kan-L4-P22-BaSP-
L5-P22-LgtC-L6-P22-
UgpA-L7
Fw_L6_stitch
Rv_L4_stitch
L4
L5
Term. 4
MUM4
P22
Kanr
L6
Term. 5
RhaGT
P22
L7
Term. 6
UgpA
P22
3 pieces Gibson 
Assembly
Ampr
pCX-Kan-L5-
P22-RhaGT-L6
Kanr
pCX-Kan-L4-P22-
MUM4-L5-P22-RhaGT-
L6-P22-UgpA-L7
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A12. NMR spectra of novel glucose esters 
1-O-cyclohexanoyl-β-D-glucose 
 
 
1H-NMR (DMSO-d6, 400 MHz)  
δ 1.13 – 1.41 (5H, m, H2’a, H3’a, H4’a, H5’a, H6’a),  
1.56 – 1.60 (1H, m, H4’b) 
1.66 – 1.69 (2H, m, H3’b, H5’b) 
1.79 – 1.91 (2H, m, H2’b, H6’b) 
2.24 – 2.36 (1H, m, H1’) 
3.06 – 3.13 (2H, m, H2, H4) 
3.16 – 3.24 (2H, m, H3, H5) 
3.40 – 3.46 (1H, m, H6a) 
3.61 – 3.66 (1H, m, H6b) 
4.53 (1H, dxd, J1 = 5.9 Hz, J2 = 5.9 Hz, C6-OH) 
4.98 (1H, d, J = 5.4 Hz, OH) 
5.07 (1H, d, J = 5.0 Hz, OH) 
5.21 (1H, d, J = 5.5 Hz, OH) 
5.31 (1H, d, J = 8.1 Hz, H1) ppm 
 
13C-NMR (DMSO-d6, 100.6 MHz) 
δ 24.6 – 24.7 (C3’, C5’) 
25.3 (C4’) 
28.3 – 28.5 (C2’, C6’) 
42.1 (C1’) 
60.5 (C6) 
69.5 (C4) 
72.5 (C2) 
76.4 (C5) 
77.9 (C3) 
94.1 (C1) 
173.9 (C7’) ppm 
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1-O-isophthaloyl-β-D-glucose 
 
 
 
1H-NMR (Acetone-d6, 400 MHz)  
δ 2.82 (OH) 
3.51 – 3.58 (4H, m, H2, H3, H4, H5) 
3.69 – 3.73 (1H, m, H6a) 
3.83 – 3.86 (1H, m, H6b) 
5.80 (1H, d, Jequatoriaal = 2.9 Hz, Jaxiaal = 8.0 Hz, H1)* 
7.72 (1H, dxd, J1 = 7.8 Hz, J2 = 7.8 Hz, H5’) 
8.30 – 8.33 (2H, m, H4’, H6’) 
8.70 (1H, s, H2’) ppm 
* over 80 % of the compound had glucose in an equatorial position.  
 
13C-NMR (Acetone-d6, 100.6 MHz) 
δ 62.3 (C6) 
71.0 (C4) 
73.8 (C2) 
77.7 (C5) 
78.6 (C3) 
96.3 (C1) 
130.0 (C5’) 
131.2 (C1’ or C3’) 
131.5 (C2’) 
132.0 (C1’ or C3’) 
134.8 (C4’) 
135.2 (C6’) 
164.9 (C7’) 
166.7 (C8’) ppm 
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1-O-terephthaloyl-β-D-glucose 
 
 
 
1H-NMR (DMSO-d6, 400 MHz)  
δ 3.16 – 3.21 (1H, m, H4) 
3.30 – 3.32 (3H, m, H2, H3, H5) 
3.47 (1H, m, H6a) 
3.64 – 3.69 (1H, m, H6b) 
5.61 (1H, d, Jequatoriaal = 3.5 Hz, Jaxiaal = 7.8 Hz, H1)* 
8.07 – 8.13 (4H, m, H2’, H3’, H5’, H6’) ppm 
* over 90 % of the compound had glucose in an equatorial position. 
 
13C-NMR (DMSO-d6, 100.6 MHz) 
δ 60.7 (C6) 
69.6 (C4) 
72.6 (C2) 
76.4 (C5) 
78.1 (C3) 
95.4 (C1) 
129.7 (C2’, C6’ or C3’, C5’) 
129.9 (C2’, C6’ or C3’, C5’) 
132.6 (C4’) 
136.0 (C1’) 
164.3 (C7’) 
167.0 (C8’) ppm 
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A13. Growth and glucose ester formation  
 
 
 
Figure A13. Overview of the growth (triangles) and conversion of a phenolic acid 
(squares) into the corresponding glucose ester (diamonds) over time. The engineered 
mutant sGLC5 + pBaSP/VvGT2/UgpA is compared with the WT + pVvGT2 for the 
formation of caffeic, terephthalic and p-aminobenzoic acid (PABA). 
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A14. Rare codon clusters of SuSy isoform 2 in different hosts 
SuSy native sequence – codon usage of S. tuberosum 
 
SuSy native sequence – codon usage of E. coli 
 
SuSy codon optimized – codon usage of E. coli 
 
Figure A14. Frequency plots on the distribution of rare and common codons in the 
sequence of SuSy from Solanum tuberosum. A comparison is shown between the native 
sequence translated in S. tuberosum (top) and E. coli (middle) versus a codon optimized 
sequence for E. coli translated in E. coli (bottom).  
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Summary 
 
 
Glycosylation is one of the most important and widespread modifications in nature. 
Adding a sugar residue to (lipophilic) small molecules greatly alters or enhances their 
solubility, stability or bioactivity, which are desirable properties when they are applied 
as nutraceuticals, therapeutics or cosmetics. The majority of specialized (secondary) 
metabolites exists in its glycosylated form, with well-known examples like steviosides 
(used as sweeteners), the skin lightener arbutine, the chemotherapeutic daunorubicin or 
the antiviral compound quercitrin. Glycosides can be extracted from natural sources 
such as plants, or can be chemically synthesized. However, this is often a low-yielding 
and laborious task using toxic solvents. In nature, glycosylation is mainly catalyzed by 
glycosyltransferases (GTs), which efficiently and selectively transfer a sugar residue 
from an activated sugar donor (such as UDP-sugars) to a myriad of acceptor molecules. 
Despite the potential of GTs, their use in in vitro (enzymatic) synthesis is often 
hampered by the exuberant price of nucleotide sugars (UDP-glucose: 150 €/g; UDP-
galactose: 1500 €/g) and difficulties regarding scale-up. Fuelled by these challenges and 
a high demand for glycosides, various in vivo (whole cell) systems have been developed 
whereby the host cell produces its own UDP-sugars and enzymes in situ starting from 
cheap substrates. Although very promising, economically viable processes remain scarce 
due to low product yields, titers and rates. 
 
Therefore, the main objective of this PhD research is to create a novel in vivo 
glycosylation platform which is easily scalable and couples production to growth. To this 
end, the model organism Escherichia coli W was metabolically engineered to obtain a 
generic yet versatile host that effectively glycosylates various small molecules, hereby 
using only sucrose (250 €/ton) as cheap carbon source.  
 
To ensure adequate UDP-sugar formation in the E. coli host, a robust and flexible 
uridylyltransferase needs to be expressed. The native enzyme (GalU) ‘activates’ glucose 
1-phosphate (glc1P) into the corresponding UDP-glucose, but is unable to catalyze the 
formation of other UDP-sugars. To this end, a promiscuous uridylyltransferase was 
searched for in Bifidobacterium bifidum and three gene candidates (ugpA, galT1 and 
galT2) were selected and expressed in a newly engineered E. coli strain. Expression in 
this host enabled to screen and characterize the enzymes only by their crude extracts 
since major interference reactions were deleted, thus alleviating the need for enzyme 
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purification. The extracts were firstly screened for hexose-1-phosphate 
uridylyltransferase activity due to the development of a novel chemo-enzymatic assay 
based on phosphate detection in the micromolar range. UgpA was identified as the 
promiscuous uridylyltransferase with activity towards both glc1P and galactose 1-
phosphate (gal1P). Interestingly, UgpA showed a 7-fold higher activity compared to the 
native GalU. On the other hand, GalT1 and GalT2 exhibited UDP-glucose-hexose-1-
phosphate uridylyltransferase activity, with the latter being 375-fold less active, thus 
revealing that GalT1 plays a more significant role than previously thought regarding 
galactose metabolism in B. bifidum. 
 
To harness the power of the newly discovered UgpA, it was used to build a glucosylation 
platform in the form of a metabolically engineered E. coli W strain. Although this strain 
is sucrose positive by the presence of a sucrose hydrolase (CscA), its metabolism was 
altered by introducing a sucrose phosphorylase from Bifidobacterium adolescentis 
(BaSP). This novel strategy is advantageous since the precursor glc1P is directly formed 
together with fructose, which serves as a carbon source. By introducing specific gene 
(pgm, agp, ushA and glgC) deletions, the formed glc1P is exclusively channeled towards 
UDP-glucose. Expression of a glucosyltransferase from Vitis vinifera (VvGT2) enabled the 
strain to efficiently produce β-glucogallin (1-O-galloyl-β-D-glucose) starting from gallic 
acid and sucrose. By implementing this novel metabolic engineering approach, growth 
and production occurred simultaneously. Indeed, specific productivities could be 
reached up to 100 mg β-glucogallin/g CDW/h, which was 20-fold higher than compared 
to the wild type strain. This effect was largely caused by the deletion of ushA, which 
prevents the degradation of the UDP-sugar pool. Due to the promiscuous character of 
VvGT2, 14 other glucose esters of various hydroxycinnamic and hydroxybenzoic acids 
were produced in a stereoselective way with high conversion yields up to 100 %, 
including 3 newly reported glucose esters. To our knowledge, this fast growing (and 
coupled production) E. coli mutant is the first versatile host described for the 
glucosylation of phenolic acids in a fermentative way using only sucrose as a cheap and 
sustainable carbon source. 
 
In view of the pivotal role of UDP-glc as ideal starting point for the production of a large 
variety of UDP-sugars, the glucosylation strain was expanded towards formation of UDP-
galactose (UDP-gal) and UDP-rhamnose (UDP-rha) by overexpressing a UDP-glucose 
epimerase (GalE) and UDP-rhamnose synthase (MUM4), respectively. Due to its 
beneficial effects on human health, the flavonol quercetin was chosen as target for the 
production of hyperoside (quercetin 3-O-galactoside) and quercitrin (quercetin 3-O-
rhamnoside). The production of these bio-active flavonol glycosides was achieved by co-
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expression with a galactosyltransferase from Petunia hybrida (F3GT) or a 
rhamnosyltransferase from A. thaliana (RhaGT). The created strains were able to 
produce 900 mg/L of hyperoside and 1176 mg/L of quercitrin at specific production 
rates of 68.7 mg/g CDW/h and 47.8 mg/g CDW/h, respectively, which are the highest 
reported to date. Furthermore, the glycosylation potential towards other flavonols was 
also evaluated, with the formation of over 400 mg/L of kaempferol 3-O-rhamnoside as 
most successful example. In addition, the galactosylation strain proved equally flexible 
for the production of therapeutic and extremely expensive oligosaccharide globotriose 
(α-galactosyl-1,4-lactose). To this end, the lipo-oligosaccharide galactosyltransferase 
from Neisseria meningitidis (LgtC) was expressed. However, to prevent metabolization of 
the acceptor lactose, the lac operon, containing an β-galactosidase (lacZ) and lactose 
permase (lacY) was knocked out and lactose transport was restored by knocking a 
constitutively expressed lacY back in at the same locus. By optimization of the added 
lactose concentrations, a specific production rate of 117 mg globotriose/g CDW/h was 
obtained, yielding a final titer of 2.8 g/L. 
 
Finally, the potential of sucrose synthase (SuSy) for the one-step generation of UDP-
glucose from sucrose was explored. Since combination of SuSy with a GT gives rise to a 
rapid and energy efficient recycling of UDP, exploiting this principle in actively growing 
cells is industrially very attractive. However, due to its unfavorable kinetics (low affinity 
for sucrose), SuSy has been rarely used for the in vivo formation of UDP-glucose. To 
create a more suitable SuSy, a new screening system was developed to rapidly evaluate 
and characterize SuSy mutants. SuSy from Solanum tuberosum was used as a starting 
point and displayed an affinity constant (Km) of 105 mM. This value could be 
significantly reduced to 35.7 mM by introducing an S11E mutation, which mimics 
phosphorylation of the serine residue. Coexpression of this SuSy mutant with the 
glucosyltransferase VvGT2 in the engineered strain created in chapter 4 resulted in an in 
vivo (bioconversion) host. The permeabilized cells were able to efficiently glucosylate 
vanillic acid at a rate of 0.41 g/L/h with 68 % conversion and an RCmax of 8. This system 
alleviates the need to purify the proteins involved and is easily scalable. 
 
To conclude, the most important outcome of this PhD thesis is the creation of versatile 
glycosylation platform using a completely novel metabolic strategy which couples 
growth and production. In this way, in vivo glucosylation, galactosylation and 
rhamnosylation of various molecules could be achieved, hereby outcompeting the 
majority of glycosylation processes described to date. Therefore, this unique 
fermentative approach using only sucrose as sustainable carbon source paved the way 
for economically viable production of glycosides. 
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Samenvatting 
 
 
Glycosylatie, de additie van een suikergroep aan een andere molecule, is één van de 
belangrijkste en meest voorkomende modificaties in de natuur. Dit proces beïnvloedt of 
verandert de oplosbaarheid, stabiliteit of bio-activiteit van vele verbindingen, wat erg 
aantrekkelijke eigenschappen zijn wanneer deze moleculen worden gebruikt in de 
farmaceutische of voedingsindustrie. Bekende voorbeelden zijn steviosiden, die gebruikt 
worden als laag-calorische zoetstof, daunorubicine, een gevestigd chemotherapeuticum, 
of quercitrine, een veelbelovend antiviraal middel. De meerderheid van secundaire 
metabolieten komt voor in zijn geglycosyleerde vorm, waardoor tot op heden de meeste 
glycosiden geëxtraheerd worden uit natuurlijke bronnen zoals plantenmateriaal. Deze 
extractieprocessen zijn echter vaak zeer arbeidsintensief en gaan gepaard met lage 
opbrengsten. Anderzijds wordt chemische synthese van geglycosyleerde verbindingen 
sterk bemoeilijkt door de vele reactieve groepen, waardoor vele beschermings- en 
ontschermingsstappen nodig zijn die veel afval genereren. Als duurzaam alternatief 
wordt daarom tegenwoordig gebruikt gemaakt van glycosyltransferasen (GT’s), die het 
merendeel van glycosyleringsreacties in de natuur katalyseren. Deze enzymen brengen 
zeer efficiënt en selectief een suikergroep over van een geactiveerde suikerdonor 
(bijvoorbeeld UDP-suikers) naar een groot aantal acceptormoleculen. Ondanks het 
potentieel van deze GT’s wordt hun gebruik in enzymatische synthese (in vitro) vaak 
belemmerd door de exuberante prijs van de benodigde UDP-suikers (kostprijs UDP-
glucose = 150 €/g; UDP-galactose = 1500 €/g). Door de steeds groter wordende vraag 
naar glycosiden zijn recent diverse cellulaire (in vivo) systemen ontwikkeld, waarbij een 
microbiële cel zelf zijn UDP-suikers en enzymen produceert vertrekkende van goedkope 
substraten. Hoewel deze nieuwe processen veelbelovend zijn, blijft hun uitvoering op 
grote schaal verre van economisch rendabel ten gevolge van lage productiviteiten, 
opbrengsten en titers. 
 
Daarom is de belangrijkste doelstelling van dit onderzoek om een geheel nieuw in vivo 
glycosyleringsplatform te creëren dat eenvoudig opschaalbaar is en eveneens productie 
koppelt met groei. Hiertoe werd het modelorganisme Escherichia coli W metabolisch 
gemodificeerd zodat een generieke en veelzijdige gastheer werd bekomen die 
verschillende kleine moleculen kan glycosyleren, en hierbij bovendien enkel gebruik 
maakt van sucrose (250 € / ton) als goedkope koolstofbron. 
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Om adequate vorming van UDP-suikers in de E. coli gastheer te verzekeren, dient een 
flexibel uridylyltransferase tot expressie te worden gebracht. Het natieve E. coli-enzym 
GalU “activeert” glucose 1-fosfaat (glc1P) tot het overeenkomstig UDP-glucose, maar kan 
de vorming van andere UDP-suikers niet katalyseren. Daarom werd een promiscue 
uridylyltransferase gezocht in Bifidobacterium bifidum waarna drie kandidaat genen 
(ugpA, galT1 en galT2) werden geselecteerd en tot expressie werden gebracht in een 
gemodificeerde E. coli mutant. Expressie in deze mutant maakte het mogelijk om de 
onderzochte enzymen enkel op basis van hun ruwe celextracten te screenen en 
karakteriseren doordat de belangrijkste afbraakreacties waren verwijderd en het 
bijgevolg niet nodig was om de enzymen op te zuiveren. De extracten werden eerst 
gescreend op hexose-1-fosfaat uridylyltransferase activiteit door middel van een nieuwe 
chemo-enzymatische assay, dewelke gebaseerd was op fosfaatdetectie op micromolair 
niveau. UgpA werd geïdentificeerd als promiscue uridylyltransferase dat zowel glc1P en 
galactose 1-fosfaat (gal1P) als substraat kon gebruiken. Bovendien vertoonde UgpA een 
7-maal hogere activiteit vergeleken met het natieve GalU. GalT1 en GalT2 daarentegen 
vertoonden een UDP-glucose-hexose-1-fosfaat uridylyltransferase activiteit. GalT2 bleek 
375 keer minder actief dan GalT1, waardoor dit enzym een veel belangrijker rol speelde 
in het complexe galactosemetabolisme van B. bifidum dan tot nu toe gedacht.  
 
Het geïdentificeerde UgpA werd gebruikt om eerst een glucosyleringsplatform te 
bouwen in een metabolisch gemanipuleerde E. coli W stam. Hoewel dit organisme van 
nature in staat is om sucrose te gebruiken door de aanwezigheid van een sucrose 
hydrolase (CscA), werd het metabolisme veranderd door introductie van het sucrose 
fosforylase uit Bifidobacterium adolescentis (BaSP). Deze nieuwe strategie zorgt ervoor 
dat de precursor glc1P direct gevormd wordt samen met fructose, die als koolstofbron 
fungeert. Door gericht specifieke genen (pgm, agp, ushA en glgC) uit te schakelen, werd 
het gevormde glc1P voorbehouden voor de vorming van UDP-glucose. Expressie van een 
glucosyltransferase uit Vitis vinifera (VvGT2) stelde de stam in staat om efficiënt β-
glucogalline (1-O-galloyl-β-D-glucose) te produceren uitgaande van galluszuur en 
sucrose. Implementatie van deze nieuwe metabolic engineering strategie zorgde ervoor 
dat groei en productie gelijktijdig plaatsvonden en aan elkaar gekoppeld waren. Op deze 
manier kon een specifieke productiviteit worden bereikt boven de 100 mg β-
glucogalline/g CDW/h, wat 20 maal hoger was dan deze in de wild type stam. Dit effect 
werd grotendeels veroorzaakt door het uitschakelen van ushA, wat afbraak van de 
intracellulaire UDP-suikers verhindert. Door het promiscue karakter van VvGT2 konden 
14 andere glucose esters van verschillende hydroxykaneelzuren en 
hydroxybenzoëzuren worden gevormd op een stereoselectieve wijze met hoge 
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conversies tot 100 %. Deze snel groeiende (en simultaan producerende) E. coli stam is 
de eerste veelzijdige mutant voor de glucosylering van fenolische zuren op een 
fermentatieve manier, waarbij enkel sucrose wordt verbruikt als een goedkope en 
duurzame koolstofbron.  
 
In de natuur speelt UDP-glucose een centrale rol als startpunt voor de vorming van vele 
andere UDP-suikers. Hierdoor kon het ontworpen glucosyleringsplatform makkelijk 
worden uitgebreid tot het vormen van UDP-galactose en UDP-rhamnose door 
overexpressie van respectievelijk een UDP-glucose epimerase (GalE) en een UDP-
rhamnose synthase (MUM4). Het flavonol quercetine werd omwille van zijn interessante 
gezondheidseffecten gekozen als startverbinding voor de productie van hyperoside 
(quercetine 3-O-galactoside) en quercitrine (quercetine 3-O-rhamnoside). De productie 
van deze bio-actieve flavonolglycosiden gebeurde door co-expressie met een 
galactosyltransferase van Petunia hybrida (F3GT) of een rhamnosyltransferase van 
Arabidopsis thaliana (RhaGT). De gecreëerde mutanten konden 900 mg/L hyperoside en 
1176 mg/L quercitrine produceren met een specifieke productiviteit van 68,7 mg/g 
CDW/h en 47,8 mg/g CDW/h, respectievelijk, dewelke de hoogste zijn tot nu toe 
beschreven. Bovendien werd het glycosyleringspotentieel tegenover andere flavonolen 
eveneens geëvalueerd, waarbij de vorming van meer dan 400 mg/L kaempferol 3-O-
rhamnoside het meest succesvol bleek. Voorts kon het ontworpen 
galactosyleringsplatform worden aangepast voor de productie van het therapeutische 
oligosacharide globotriose (α-galactosyl-1,4-lactose). Daartoe werd het lipo-
oligosacharide galactosyltransferase van Neisseria meningitidis (LgtC) tot overexpressie 
gebracht en werd lactose toegevoegd als acceptormolecule. Hiertoe werd het lac operon 
uitgeschakeld (om degradatie van lactose te vermijden) en vervangen door een 
constitutieve knock-in van het lactose permease lacY. Door optimalisatie van de 
toegevoegde lactose concentratie kon een specifieke productiesnelheid van 117 mg 
globotriose/g CDW/h worden bekomen met een finale titer van 2,8 g/L. 
 
Tenslotte werd ook de combinatie van een GT met sucrose synthase (SuSy) geëvalueerd. 
SuSy is immers in staat om in één stap UDP-glucose te vormen uit sucrose en vormt zo 
een aantrekkelijk alternatief voor het hierboven beschreven sucrose fosforylase-
gebaseerde glycosylatie platform. Wegens de ongunstige kinetische eigenschappen van 
SuSy (lage affiniteit voor sucrose) is dit enzym echter zelden gebruikt voor in vivo 
vorming van UDP-glucose. Hiertoe werden verschillende SuSy mutanten (random en 
rationeel) gecreëerd die met behulp van een nieuw screeningssysteem snel konden 
worden gekarakteriseerd. Het SuSy van Solanum tuberosum werd gebruikt als startpunt 
voor mutagenese en had een initiële affiniteitsconstante van 105 mM. Deze waarde kon 
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significant verlaagd worden tot 36 mM door introductie van een S11E mutatie, dewelke 
fosforylatie van het serine residu nabootst. Co-expressie van deze verbeterde SuSy 
mutant met het glucosyltransferase VvGT2 in de gemodificeerde E. coli W stam, 
resulteerde in een nieuw in vivo (bioconversie) glucosylatieplatform. De 
gepermeabiliseerde cellen konden efficiënt vanillezuur glucosyleren met een 
productiesnelheid van 0,41 g/L/h en een RCmax van 8. Dit systeem omzeilt de noodzaak 
om de betrokken enzymen op te zuiveren en is gemakkelijk opschaalbaar.  
 
De belangrijkste uitkomst van dit proefschrift is de creatie van een veelzijdig 
glycosyleringsplatform met behulp van een geheel nieuwe metabolic engineering 
strategie die groei en productie aan elkaar koppelt. Zo werd de in vivo glucosylering, 
galactosylering en rhamnosylering van verschillende moleculen bekomen, die efficiënter 
en economisch rendabeler is dan alle bestaande processen tot nu beschreven. Deze 
unieke fermentatieve benadering, die enkel sucrose als duurzame koolstofbron gebruikt, 
heeft de weg vrijgemaakt voor een grootschalige en duurzame productie van glycosiden. 
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